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Current drug discovery techniques tend to identify potential new drug entities 
with more complex structures which may pose significant formulation challenges.  In 
particular, an increasingly large number of new drug compounds have extremely poor 
solubility in water, impacting the bioavailability of the drug.  Solubility enhancement 
techniques, such as amorphous solid dispersions (ASDs), can be used in oral dosage 
forms to increase the apparent solubility of the drug in the gastrointestinal tract thus 
increasing the bioavailability of the drug.  However, the drug solution generated from the 
dissolution of an ASD formulation is supersaturated. In other words, the solution 
concentration is higher than the crystalline solubility.  These solutions are therefore 
thermodynamically unstable and can crystallize.  Recent evidence suggests that some 
systems can undergo another phase transformation prior to crystallization, namely liquid-
liquid phase separation (LLPS).  LLPS creates a discrete drug-rich phase dispersed in the 
continuous aqueous drug-lean phase and is expected to impact the bioavailability of the 
drug though effects on diffusion and crystallization behavior.  Currently there is a lack of 
understanding of the mechanisms underlying the complex phase behavior of these 






amorphous solid dispersions. The work presented within this thesis is focused on 
developing the techniques necessary for studying complex phase behavior through the 
investigation of a model drug system.  The relationship between amorphous solubility 
and supersaturation was examined and correlated to the dissolution of amorphous solid 
dispersions. The ability to predict, evaluate, measure, and understand supersaturated drug 
solutions and the associated phase transitions, specifically LLPS and crystallization, is 





CHAPTER 1. INTRODUCTION 
1.1 Pharmaceutical Significance and Objective 
Innovation and advances in drug discovery lead to exciting new molecular entities 
(NMEs) every day.  These chemically complex NMEs are increasingly difficult to 
formulate and frequently have suboptimal solubility and permeability.  To aid in the early 
development process, the Biopharmaceutics Classification System (BCS) was developed 
to highlight the major factors impacting oral bioavailability.  The system categorizes 
molecules into one of four classes based on aqueous solubility (necessary for proper 
dissolution within the gastrointestinal (GI) tract) and permeability (necessary for proper 
uptake from the GI tract into the blood circulation).1  In recent years, there has been a 
dramatic increase in NMEs with poor solubility, designated as BCS Class II and Class IV 
molecules (Class II - good permeability or Class IV - poor permeability).  Class II and IV 
drugs make up roughly 40% of current drugs available on the market while nearly 90% of 
NMEs in development are categorized as either Class II or Class IV.2  Thus, overcoming 
the poor solubility hurdle is becoming an increasingly pressing issue. 
The need to increase the solubility of new drugs to achieve adequate oral 
bioavailability has led to the development of many novel solubility enhancement 
techniques for formulation such as salts, co-crystals, lipid formulations, complexation, 





approaches have their own benefits and limitations, but amorphous solid dispersions are 
increasingly being viewed as the approach of choice for increasing the bioavailability of 
poorly soluble drugs.4, 5   
Amorphous formulations offer some additional advantages such as retaining the 
original chemical entity, minimizing the addition of other molecules within the 
formulation, and the potential to administer lower doses4.  These formulations also 
present a number of obstacles including issues with physical stability (crystallization) of 
the solid dosage form, manufacturability, and the formation of an unstable supersaturated 
solution following dissolution.6  While a large body of research addresses the solid state 
physical stability and manufacturing of amorphous solids dispersions, mechanistic and 
kinetic understanding of the phase behavior of the supersaturated solutions created from 
the dissolution of amorphous solid dispersions is lacking.   
There is mounting evidence that there are multiple phase transitions that can occur 
within highly supersaturated solutions of poorly water soluble hydrophobic drugs.  Very 
highly supersaturated solutions are thermodynamically unstable and thus will undergo 
phase transitions to reduce their free energy.  Liquid-liquid phase separation (LLPS), 
crystallization, and amorphous precipitation have all been observed when evaluating 
various drug systems.7-10  Such phase behaviors have been evaluated in other contexts 
(e.g. industrial crystallization) and are intrinsically linked. Recognizing the issues 
involved in creating thermodynamically unstable solutions from the dissolution of ASDs 
will allow for a broader range of amorphous formulations of NMEs.  The objective of this 
research was to analyze and characterize the complex phase behavior of supersaturated 





1.2 The Crystalline vs. Amorphous State 
Oral dosage forms are the preferred dosage form throughout most of world based on 
ease of administration and bulk manufacturing advantages.  These can take many 
different forms such as capsules, liquids, liquid-filled capsules, orally dissolving strips, 
but the most common and cost-effective form is a tablet.  The ability to provide a stable, 
consistent, regulatory compliant, and effective drug product is vital to pharmaceutical 
industry and oral solid dosage forms currently offer the best solution for the majority of 
compounds.11   
Solids can exist in multiple different states.  The first, and most well recognized, is 
the crystalline solid which has a defined long-range order and molecular packing.  
However, solids can also be amorphous in nature.  These amorphous solids have no long-
range order, but possess the physical characteristics of a solid (such as a defined volume 
and little-to-no flow).  The ability to understand and utilize different solid forms is 
necessary to optimize solid oral dosage forms.  The following section outlines the major 
properties of crystalline and amorphous solids and summarizes the thermodynamic 
differences. 
 
1.2.1 Crystalline Systems 
Crystalline solids are the backbone of solid dosage forms and are usually 
considered the starting point for formulation development.  They possess very specific 
physical and chemical properties which can be utilized and manipulated in order to 
achieve the desired formulation effect.  Understanding the properties of crystalline solids 





The four basic forms of matter, solid, liquid, gas, and plasma, all have unique 
properties which define them.  Solids are simply defined as structurally rigid and resistant 
to change of shape or volume.  Within the solid classification, solids can further be 
differentiated into crystalline or amorphous solids (which will be discussed momentarily).  
Crystalline solids exhibit a molecular ordering or long-range order which has a specific 
periodicity of the molecules.  Essentially, the molecules of a given substance in a 
crystalline solid arrange themselves in a regular, repeating fashion so that they have 
favorable interactions with other molecules within the crystalline solid.  These 
intermolecular interactions are either in the form of hydrogen bonds or other non-
covalent bonds (such as van der Waals forces or electrostatic interactions).  The 
formation of this regular periodicity through the creation of these bonds significantly 
lowers the internal free energy of the crystal.  Therefore, crystalline solids have a 
multitude of distinguishable properties which we can observe and subsequently try to 
manipulate. 
The chemical structure of a molecule directly dictates this periodic arrangement, 
specifically the polarity, symmetry, and functional groups of the molecule greatly impact 
the ability of the molecules to pack in an efficient manner.  The ability of a molecule to 
arrange itself in an ordered fashion leads to a specific molecular packing and crystal 
density and gives rise to the concepts of the unit cell, point and space groups, crystal 
shape, habit, and morphology.  The unit cell of a crystal lattice is the smallest unique 
arrangement of molecules (illustrated in Figure 1-1) while the point and space groups are 
built off of how these unit cells are arranged together.  The macroscopic crystal features 





point and space group symmetry along with the growth rates of particular facets of these 
microscopic crystal features.  Furthermore the chemical structure and subsequent 
intermolecular interactions and packing determine key physical properties including the 
melting temperature, heat capacity, and solubility.  The unit cell is the building block for 
the crystal structure and understanding how a given compound interacts in the crystal is 
key for understanding its physicochemical properties. 
The lowered free energy of the crystal, achieved through stabilizing molecules in a 
uniform arrangement, sets crystalline materials apart from their liquid, gas, and even 
amorphous solid counterparts in terms of their properties.  Typically, at room temperature, 
crystalline solids are the most thermodynamically stable phase and are thus the preferred 
form for formulations since phase transformations are not thermodynamically favored.  
However, the same lower internal free energy that leads to better solid state and chemical 
stability can also yield issues with dissolution and solubility because the most 
thermodynamically stable form is also the least soluble.  This topic will be discussed in 
detail later. 
In contrast to the internal free energy, the surface energy of a crystalline solid is 
higher.  The lattice bond structure required for crystalline solids creates an interface 
which will have unfavorable molecular interactions with the surrounding phase. The high 
surface energy of crystalline solids provides a barrier to crystallization and the 
thermodynamics of the crystallization process are complex.  Figure 1-2 graphical displays 
the competing processes of surface free energy and internal (volume) free energy and the 





mechanisms have been explored extensively and play crucial roles in dictating the 
properties of resultant crystalline solids.12, 13  
In addition, a single compound can exist in several different crystal forms, each 
with their own properties, which can be either advantageous or detrimental to the 
formulation process depending on their properties.  Polymorphs arise when the molecule 
can pack into different arrangements in the crystal lattice leading to different unit cells, 
internal free energy and other properties. The thermodynamic relationship between 
polymorphs, which underlies the differences in properties, can be characterized by phase 
diagrams as shown in Figure 1-3.   
Polymorphs can be classified as either enantiotropic or monotropic.  In 
enantiotropic systems, the most stable polymorph varies with temperature below the 
melting point (Crystal A and B in Figure 1-3) leading to a transition temperature.  
Polymorphs are considered monotropic when there is one polymorph that is the most 
stable through the entire temperature range up to the melting point (Crystals A and 
C/Crystals B and C in Figure 1-3).14   
Alternatively, a compound can have many other crystalline solid forms such as 
hydrates (water is incorporated into the crystal lattice), solvates (solvent is incorporated 
into the crystal lattice), salts (ionized, with a counterion present in the lattice), and co-
crystals (two different neutral compounds in the same crystal lattice).  These forms will 
not be discussed further since they are outside of the scope of this research.15  
All of these crystalline forms have distinct properties dictated by the way in which 
the molecules arrange and interact with each other within the crystal lattice.  These 





solid-form stability, melting temperature, and solubility.  The solubility, or ability for one 
substance to dissolve and form a homogeneous mixture within another substance, is 
vaguely defined throughout literature and can sometimes be confusing with terms such as 
“apparent” solubility, “intrinsic” solubility, and “equilibrium” solubility in widespread 
use.1, 3, 5, 6  The following terms and definitions will be used herein: 
 Solubility – this refers to crystalline solubility of the most thermodynamically 
stable form of a substance and is achieved by reaching an equilibrium between the 
crystalline material and the solution phase; it is dependent on the solution phase 
and temperature, both of which must be specified.  This is also sometimes defined 
as intrinsic solubility or equilibrium solubility.   
 Amorphous Solubility – the amorphous solubility is the maximum concentration 
achievable through the dissolution of the amorphous form of a drug with the 
formation of a temporary equilibrium between the solvent and the amorphous 
material.  Any equilibrium achieved is only temporary because the system is 
supersaturated with respect to the crystalline solubility and at some point 
crystallization will occur; thus this is a metastable equilibrium. This will be 
discussed further in the following sections. 
 
1.2.2 Amorphous Systems 
Amorphous solids are thermodynamically metastable compared to the crystalline 
complement.  They have short–range intermolecular interactions such as hydrogen 





found in crystalline solids.  Amorphous solids below the glass transition temperature 
have a rigid physical structure but lack the basic molecular packing which could define a 
point/space group, habit, or shape.   
Amorphous materials can be delineated as super-cooled liquids and glasses which 
are separated by the glass transition temperature (Tg).  Above the Tg, the material is a 
supercooled liquid which has a high molecular mobility and a heat capacity that is 
continuous with the heat capacity of the equilibrium liquid, however supercooled liquids 
occur below the melting temperature of the compound and are thus metastable relative to 
the crystal.  Glasses are amorphous solids below the Tg, have a lower molecular mobility 
as well as a lower heat capacity as compared to the supercooled liquid.  These trends are 
summarized in Figure 1-5. 
Amorphous solids have a higher free energy than the crystalline form and 
consequently are metastable relative to the crystalline form.  These properties can be 
taken advantage of for oral drug delivery, as the higher energy can lead to increased 
dissolution/solubility and subsequently higher bioavailability.  However, amorphous 
solids are more chemically reactive16 and tend to crystallize into the more stable form 
which creates issues with solid oral dosage formulation stability.  The use of additives to 
inhibit crystallization from both the solid dosage form and the aqueous dissolution 
medium (i.e. GI tract) is common.2, 3, 5  Zografi et al. elegantly described the two major 
competing forces which impact the crystallization of amorphous solids; the large 
thermodynamic driving force for nucleation which favors crystallization and the low 
molecular mobility which provides a kinetic barrier to crystallization.  Figure 1-6 





increased with the decrease in temperature below the melting point.  In contrast, the 
molecular mobility decreases as the system approaches the glass transition, which hinders 
the molecular rearrangement needed to form ordered crystals.  A maximum rate between 
the melting temperature and the glass transition temperature is reached where the 
thermodynamics of nucleation and the kinetics of molecular mobility are optimal for 
crystallization from the amorphous material.4 
Amorphous solids have been shown to provide greater bioavailability than many if 
not all other types of solubility enhancement.2, 3, 5, 17, 18  As a result, understanding the 
thermodynamic and physical properties associated with all aspects of an amorphous 
dosage form is critical to formulating efficacious products.  The amorphous solubility, as 
defined earlier, is the term given to the solution concentration that can be achieved 
through the dissolution of the amorphous form of a substance.  Because of the higher 
energy state and more disordered structure of an amorphous solid, there are fewer bonds 
between molecules to be broken and this leads to more facile dissolution as compared to 
the crystalline form. Within a solution, this creates a concentration that is higher than the 
crystalline solubility, leading to supersaturation and ultimately is a metastable system.  
There are many different processes that can occur during the dissolution of an oral dosage 
form and Figure 1-7 outlines these competing processes. 
The thermodynamics and kinetics of the various phase transformationswill 
determine the overall stability of the system.  This will be discussed in detail in the 
thermodynamic section below but the important detail that is rarely considered is that the 
amorphous solubility is a second boundary within the phase diagram, above which a 






1.2.3 Amorphous Solid Dispersions 
Although amorphous solids have been shown to provide improvements in the 
apparent solubility they are not sufficiently stable to use without excipients that can 
prevent crystallization in the solid formulation.  Polymers are thus frequently blended 
with the amorphous drug to create an amorphous solid dispersion (ASD), providing a 
formulation approach whereby the amorphous form of a drug can be stabilized and the 
resultant solubility benefits utilized to improve bioavailability.19, 20  The polymers act to 
preserve the amorphous form of the drug.  There are many ways to create amorphous 
solid dispersions, and ideally a homogeneous molecular level dispersion results from the 
manufacturing process since this will provide maximum stability against crystallization.  
Melt extrusion, spray drying, and co-precipitation have been used to effectively make 
solid dispersions with good stability against crystallization.21, 22   
A schematic of an amorphous molecular level dispersion is shown in Fig. 1-7. Here 
it can be seen that the drug molecules are uniformly dispersed in the polymer matrix. 
Because of the molecular level mixing in the drug dispersion, the polymer is in intimate 
contact with the drug and therefore has a major impact on the crystallization behavior. 
Mechanistically, the stabilizing effect of polymer has been attributed to a number of 
factors. The polymer molecules increase the viscosity of the solid, decreasing molecular 
mobility and hindering crystallization.  The polymer molecules can also act as a physical 
barrier between drug molecules, reducing the tendency for the self-assembly needed for 
crystallization.  Additionally, the polymer can interact with the drug through hydrogen 
bonding or van der Waals forces, effectively reducing the ability of the drug molecules to 






highly dependent on the extent of miscibility between the drug and polymer.23, 24  ASDs 
are considered the main approach for formulating amorphous solids and are currently the 
subject of intense research effort.   
 
1.3 Thermodynamics and Kinetics 
The phase transitions within crystalline and amorphous systems depend on both 
thermodynamics and kinetic factors.  Thermodynamics account for whether or not a 
phase change or transition can occur based on the excess energy within the system.  The 
kinetics, dictate whether or not a change or transition will be observed over a given time 
frame.  The following section will highlight the contributions of both and provide a 
foundation for understanding the driving forces behind the phenomena under 
investigation in this research. 
 
1.3.1 Free Energy Diagram 
Phase transitions result in changes in the thermodynamics of the system and 
proceed from a higher energy to a lower energy state.  Gibbs derived the elegant Gibbs 
free energy (∆𝐺) equation which shows the interplay between two important parameters: 
∆𝐺 = ∆𝐻 − 𝑇∆𝑆 
Equation 1-1 
The equation shows the balance between two terms; the change in enthalpy (∆𝐻) 
and change in entropy multiplied by temperature (𝑇∆𝑆) .  The enthalpic component 
represents the energy change of the system, such as when intermolecular bonds are 






through the changes in the extent of disorder in the system.  Again using the breaking of a 
bond as a reference, the entropy of the molecule will increase due to the increased 
freedom of movement due to the lack of a bond (rotational, translational, or 
configurational freedom) and the entropy term is directly related to the temperature of the 
system.  The overall free energy of a system as shown by Equation 1-1 is a balance 
between the changes in enthalpy and entropy.  Due to the contribution of temperature to 
the entropy term, there will come a point where the entropy of the system will dominate 
the overall free energy of the system.  As we decrease the temperature, we see that the 
enthalpic term will become more prevalent and the underlying energy associated with 
bond formation and interfaces play a large role in dictating the overall free energy of the 
system.15   
Figure 1-9 illustrates the excess enthalpy (or volume) as a function of temperature 
for an amorphous material relative to the crystal.  Thermodynamically, the temperature at 
which the entropy contribution of the system overtakes the enthalpy contribution is 
known as the fusion point (or melting point, Tm).  This change between enthalpy and 
entropy dominance is accompanied by a phase transition from the crystal to the liquid.  
Amorphous systems arise when the system temperature is lowered below the fusion point, 
usually through rapid cooling, without an accompanying structural change into the crystal.  
The supercooled liquid has the structural characteristics of a liquid but with a much 
greater viscosity and is thermodynamically metastable relative to the lower free energy 
crystal.  A second transition which is kinetic in origin occurs where the molecular 






and another change in the enthalpy/temperature relationship.4 This temperature is known 
as the glass transition temperature (Tg).  
The stability of a phase is dictated by the balance of the enthalpy (energy) and 
entropy (order) of the substance.  If the system is thermodynamically metastable or 
unstable, then there are one or more phases that exist with a lower free energy under the 
same conditions of temperature and pressure, and the phase transition will be dictated by 
kinetic factors.  Within amorphous systems, properties such as dissolution and diffusion 
of molecules which impact crystallization are kinetically controlled. 
For multicomponent systems, which can be as simple as the amorphous or 
crystalline system in contact with the solvent, it is critical to understand the 
thermodynamics of mixing two phases.   
 
1.3.2 Mixing Energy and Solubility 
When considering the solubilization of a crystal versus the corresponding 
amorphous solid, the different thermodynamic properties of the two forms needs to be 
considered.  Figure 1-10 is a diagram that depicts the processes needed to solubilize a 
crystalline solid.  The first step in solubilization is the breaking of the crystal lattice 
bonds.  One way of describing this thermodynamically is through a heat and cool cycle. 
Energy must be supplied to heat the crystalline solid to the melting point and additional 
energy must be added to break the bonds within the lattice to form a liquid; this is the 
enthalpy of fusion (∆𝐻𝑓).  Once the bonds are broken, the solid is now a liquid and must 
be cooled down, with release of energy, and then the pure liquid form of the compound is 






∆𝐺𝑠𝑜𝑙𝑛 = ∆𝐻𝑠𝑜𝑙𝑛 − 𝑇∆𝑆𝑠𝑜𝑙𝑛 
Equation 1-2 
As can be seen from Figure 1-10, the ∆𝐻𝑠𝑜𝑙𝑛  term consists of two individual 
enthalpy terms, the heat of fusion, ∆𝐻𝑓, necessary to break the lattice bonds, and the heat 
of mixing, ∆𝐻𝑚𝑖𝑥 , which reflects the balance between the new interactions formed 
between the solute and solvent molecules and these interactions in each of the pure 
components.  Assuming the molecules are similar in size and polarity, we can assume an 
ideal solution; i.e. the bonds broken in each individual liquid phase are equal to the bonds 
formed in the new homogeneous phase and thus there is no energy change, ∆𝐻𝑚𝑖𝑥 = 0.  
Therefore, ∆𝐻𝑓 = ∆𝐻𝑠𝑜𝑙𝑛 . In other words, for an ideal solution, the solubility is only 
dictated by the properties of the crystal. Since the heat of fusion is easily determined from 
melting data, estimates of the crystal contribution to solubility can readily be made, as 
will be discussed in more detail below. 
The entropy of the solution is more complex.  Again, assuming an ideal solution, 
the entropy of solution can be calculated25 as follows: 
∆𝑆𝑠𝑜𝑙𝑛 =  ∆𝑆𝑚𝑖𝑥 =  −𝑅( 𝑥𝐴 ln 𝑥𝐴 + 𝑥𝐵 ln 𝑥𝐵) 
Equation 1-3 
The entropy of mixing thus depends on the mole fraction of each component 
(𝑥𝐴, 𝑥𝐵)  multiplied by the gas constant (R).  In an ideal solution, the two different 
molecules are similar in both chemistry and size, and the entropy of mixing can be 
readily estimated.  While polymers and water are an example of non-ideal mixing, the 






Further derivation with the approximations described in 26 enables us to describe the 
free energy change for forming a solution as: 
∆𝐺𝑠𝑜𝑙𝑛 = −𝑅𝑇 ln 𝑥𝑠𝑜𝑙𝑢𝑡𝑒 = ∆𝐻𝑓 − 𝑇∆𝑆𝑓 
Equation 1-4 
With the assumption of ideality, the entropy of fusion ∆𝑆𝑓 can be derived from the 
melting temperature and enthalpy of fusion, ∆𝐻𝑓/𝑇𝑀.  Because the entropy and enthalpy 
values are dependent on temperature, and the systems being evaluated are usually at 
much lower temperatures, the heat capacity difference (Δ𝑐𝑝) between the liquid and the 
crystal is needed to determine the entropy and enthalpy at the temperature of interest. 
Simplifying and rearranging the equation to express it in terms of the mole fraction 





















Equation 1-5 is a fairly accurate representation of the energy needed to incorporate 
a molecule into an ideal solution from a crystalline solid.  However, the use of this 
equation to predict solubility involves the assumption that the solute and solvent 
molecules are very similar in structure and interactions.  The drugs of interest for this 
research are hydrophobic, complex molecules which violate this assumption.  Therefore, 
the activity coefficient (𝛾) term is added in order to account for differences in interactions 
between each pure phase and the mixed phase.  The activity coefficient describes the 






dimensionless factor directly related to the chemical potential of the molecule.  Adding in 
the activity coefficient term leads to equation 1-6: 
  


















)] − ln 𝛾 
Equation 1-6 
Understanding all of these factors that contribute to the behavior of a drug in 
solution reveals the intrinsic relationship between the solubility (represented here as the 
solute mole fraction) and physical properties of the molecule.  Experimentally 
determining the crystalline solubility and comparing this value to the estimated ideal 
solubility enables the magnitude of the activity coefficient to be determined. Thus it is 
possible to understand the underlying cause of poor solubility of a given crystalline 
compound, namely if the main contribution is from a large lattice energy, or due to the 
hydrophobicity of the molecule which leads to a large activity coefficient. For most 
compounds, a combination of both of these factors leads to poor aqueous solubility.  For 
compounds where the lattice contribution has a substantially negative impact on 
solubility, using an amorphous formulation is theoretically beneficial as a solubility 
enhancement strategy. 
 
1.3.3 The Amorphous Solubility Advantage 
The previous section outlined the relationship between the free energy of a 
solution and the solubility of a crystalline solid as well as its relationship to the activity of 






To estimate this, it is necessary to approximate the free energy difference between the 









While, equation 1-7 is a good approximation of the free energy difference 
between crystalline and amorphous forms, accounting for the changes in enthalpy and 
entropy with respect to temperature, one major assumption should be noted:  The 
derivation by Hoffman assumes that the temperature range of the system will be between 
𝑇𝑚  and 𝑇𝑔 .  However, relevant temperature ranges for conducting pharmaceutically 
relevant research usually fall below the 𝑇𝑔 of a drug.  Additionally, it is assumed that the 
heat capacity has a linear relationship with temperature and the difference in heat 
capacity between the solid and liquid states is constant; this has been shown to be a 
reasonable assumption over small temperature ranges.5 The ratio of the mole fraction 
solubility of the amorphous form (𝜎𝑎) and the crystalline form (𝜎𝑐) can also be related to 
the free energy difference as follows: 























If the crystal solubility, the melting temperature and the enthalpy of fusion are 
known, then equation 1-9 provides a means to estimate the amorphous solubility. 
Equation 1-9 has been found to provide reasonable estimates of the amorphous solubility 
for a number of compounds28, and is expected to work well for compounds with Tg 
values close to the experimental temperature and with a very low capacity to absorb 
water.  However, most amorphous solids absorb significant amounts of water (on a molar 
basis) and a correction to the solubility estimate is needed to take into account the water 
mixed with the amorphous solid.  Murdande outlined an additional term to account for 
the water in the amorphous solid. This correction factor can be estimated from the 
moisture sorption profile of the amorphous form of the drug. Thus [−𝐼(𝑎2)]  is the 
activity of the amorphous solid saturated with water and equation 1-9 is modified to5: 










Murdande went on to show that adding the water sorption correction is important 
for estimating the amorphous solubility in some organic molecules.5, 17, 18  One major 
problem with the experimental assessment of amorphous solubility is that crystallization 
tends to occur before equilibrium with the amorphous solid is reached.6 Adding polymers 
may delay crystallization so that a better experimental value can be obtained.28, 29  
However, it is consistently observed that dissolution of amorphous solid dispersions 








In practice, supersaturation (𝑆) is usually expressed as the ratio of the solution 






Supersaturation can be defined on a more rigorous thermodynamic basis using the 
chemical potential of a molecule in an equilibrium state (𝜇𝑒𝑞) and in a supersaturated 
state (𝜇𝑠𝑠).  The chemical potentials of two components in equilibrium are equal to one 
another.  The chemical potential of a supersaturated solution can be defined as: 
𝜇𝑠𝑠 = 𝜇𝑒𝑞 + 𝑅𝑇 ln 𝑎𝑖 
Equation 1-12 
Where a is the activity of the solute in the solution.  The activity is the product of 
the activity coefficient of a molecule and the excess molecules, 
𝑐
𝑐∗
 , or supersaturation.  
Thus, when the concentration of a solution is above the crystalline solubility, 
supersaturation is above 1, leading to an increase in solute chemical potential.  The 
increase in solute chemical potential creates a thermodynamic driving force for phase 
transitions to occur.  Figure 1-11 below summarizes the phase behavior of a system.   
The diagram depicts 3 distinct regions (I, II, and III).  Region I is a stable regin, 
being an undersaturated, homogenous solution; the concentration is not high enough for 
any phase change to occur at a given temperature.  In this region, the supersaturation ratio 
is less than 1 (i.e. the solution is undersaturated) and therefore the solution is stable and 






the crystalline solubility but below the amorphous solubility as defined earlier.  The blue 
solid line represents 𝑐∗  otherwise known as the crystalline solubility or equilibrium 
solubility.  All concentrations above this line at a given temperature have a 
supersaturation ratio greater than 1, and have a thermodynamically driving force for 
crystallization.  The dashed blue line defines a metastable crystallization zone (II-m) in 
which crystallization can occur through secondary nucleation.31  Below this line, crystals 
can grow if seeds are added, and secondary nucleation (discussed later) is also possible. 
Above this line primary nucleation can spontaneously occur. The last region, III, is above 
the amorphous solubility and is a region where liquid-liquid phase separation can occur 
(thought of as amorphous precipitation) and crystallization can also occur.  Again, the 
dashed red line defines a meta-stable zone (III-m) of LLPS where an energy barrier needs 
to be overcome (again discussed later).     
Overall, the diagram shows two major solubility curves, the crystal solubility and 
the amorphous solubility with thermodynamic driving forces existing to cause 
precipitation (defined here as the formation of a new phase) either through crystallization 
or LLPS.  Furthermore, above the amorphous solubility, the two phase transformations 
(i.e. LLPS and crystallization) will compete and the observed phase will be determined 




The thermodynamics of the system explains whether or not a phase transition is 






the new phase, which may or may not be the lowest free energy phase depends on the 
kinetics of the system. 
Within a solution, the kinetics are the rates at which the reactions between 
molecules leading to a phase transformation occur, and is impacted by factors such as 
temperature, mass transport and conformational differences. Focusing on the kinetics of 
the molecules forming or decaying from a specific phase allows us to obtain a complete 
picture of phase transformations.  The dissolution of one phase into another (most 
commonly a crystal into a liquid) along with the diffusion of molecules within a single 
phase will briefly be discussed in this section. 
 
1.3.5.1 Dissolution 
The kinetics of dissolution determine the rate at which one phase dissolves in 
another phase, and becomes one homogeneous phase.  This process is most commonly 
researched as the dissolution of solids into liquids.  The kinetic process of removing a 
molecule from one phase and incorporating it into another requires multiple processes to 
occur in succession; the bonds within the solid phase must be broken followed by the 
incorporation into the new phase.  Many factors contribute to the rate of dissolution 
including both physical and chemical properties.   
There are many models which attempt to predict the dissolution behavior of given 
systems.  Zero, first, and second order models are simplistic mathematical models that 






mechanistic and chemical parameters, such as Hixson-Crowell, Higuchi, and the Weibull 
models. 
These models have been used to predict the dissolution of crystalline and 
amorphous solids into aqueous media.  In more recent research, the dissolution of 
amorphous solid dispersions has been investigated.  Characterizing the dissolution 
profiles of ASDs is one of the most relevant topics of research regarding amorphous 
drugs based on the potential to increase drug concentrations.  Figure 1-12 shows that the 
dissolution of the pure amorphous solid can yield higher solution concentrations than the 
crystalline counterpart. As can be seen from the figure, the dissolution profiles differ 
drastically depending on the solid state properties.   
Polymers are widely used in ASDs in order to prevent crystallization in both the 
solid matrix and within solution once dissolved.  The use of polymers for inhibition of 
crystallization has led to the “spring and parachute” concept of dissolution profiles.  
Figure 1-13 demonstrates the difference between this type of dissolution profile and the 
dissolution of the stable crystalline form. 
All of the research thus far into the dissolution of amorphous solids and more 
importantly ASDs has sought to model, predict, observe, and analyze the solution 
concentration of the drug.  The logic is that the higher the sustained drug concentration, 
the more solubilized drug can be absorbed by the body (either passively or actively).  
However, beyond considering the crystallization of the drug, none of the research 
typically conducted seeks to incorporate the consequences of creating such highly 
supersaturated drug solutions into the phase behavior of these systems.  The following 






second liquid phase (LLPS) within these systems.  Achieving a more complete 
characterization of highly supersaturated systems should be incorporated into the current 
understanding of dissolution behavior in order to better understand the effect on the drug 
concentration and ultimately the bioavailability of the drug. 
 
1.3.5.2 Diffusion 
The second major kinetic process is the diffusion of the molecules within a given 
phase.  While this topic is somewhat out of scope of the current research, a basic 
understanding is required to fully grasp the concepts of phase behavior within solutions. 
Diffusion is the motion of the particles within the system.  This process will be 
strongly influenced by environmental parameters such as temperature, pressure, and 
intermolecular interactions.  Simplistically we can use Fick’s first law of diffusion to 








Here, 𝐽 is the diffusion flux or amount of material that will move through a certain 
area during a certain time period. 𝐷 is the diffusion coefficient, 𝑐𝑖 is concentration, 𝜇 is 
the chemical potential, 𝑅  is the universal gas constant, 𝑇  is temperature, and 𝑥  is the 
position.  As can be seen from the equation, the diffusion of a molecule depends on the 
temperature, concentration, chemical potential, and diffusion coefficient; all of which 






the Stokes-Einstein relationship and depends on the contributions of temperature, 
viscosity, and size of the molecule. 
All of these factors can affect the diffusion rate of molecules within a system, 
ultimately leading to effects on phase transformations.  For example, if the concentration 
is increased, the flux increases and thus more molecules can move in a certain area 
leading to more collisions and a lower energy barrier to phase transitions.  The following 
sections will outline these phase transitions. 
 
1.4 Crystallization 
Crystallization is the process of creating a new crystalline solid phase and can be 
divided into two processes, nucleation and crystal growth.  For crystallization from 
solution to occur, the chemical potential of the solute in solution must be greater than that 
of the solid, i.e. the solution is supersaturated.  Once an energy barrier is overcome, the 
solute molecules will nucleate and subsequently undergo crystal growth until the system 
has reached equilibrium, i.e. the chemical potential of the solute in the solution is equal to 
that of the crystal. 
When designing formulations that create a supersaturated solution of a drug, both 
processes must be considered in order to understand the longevity of the supersaturation 
that is generated following dissolution. Different mechanisms are important for crystal 
growth and nucleation and understanding each process independently will aid in 
comprehending the crystallization process as a whole.  Solubility enhancement 






order to increase the bioavailability of the drug.  Thus, nucleation and crystal growth are 
issues that must be dealt with by formulators. 
 
1.4.1 Nucleation 
The initial event of creating a new crystalline solid phase from another phase is 
called nucleation.  Nucleation is a first-order phase transition where the rate at which 
nucleation occurs is determined by the concentration of a single entity, in this case the 
drug.12, 13, 32  Other factors such as excipients33 and pH9 can affect the nucleation rate, 
albeit indirectly through altering the effective concentration of the drug molecule.  The 
first nucleus of a given species within a given species is referred as primary nucleation.  
Any nuclei that result from a system with nuclei already present are referred to as 
occurring by secondary nucleation.  Furthermore, nucleation can occur through one of 
two major mechanisms; 
1) Homogeneous Nucleation – nuclei that occur within the interior of a single, 
homogeneous phase with no external seeding or catalysts.  While this model is 
extensively used,12, 27, 34 this type of nucleation is exceedingly rare to observe 
experimentally because of impurities in most real systems. All homogeneous 
nucleation is primary nucleation. 
2) Heterogeneous Nucleation – nuclei that form at preferential sites within a 
system such as phase boundaries, cell/beaker walls, existing crystals, or other 
entities which are not a part of the homogeneous phase.  Heterogeneous 






In general, these two types of nucleation mechanisms have different energy barriers 
with primary homogeneous nucleation having the highest energy barrier for a given 
system. Within the scope of this research, the broad term of nucleation will be used to 
describe experimentally observed processes which may encompass both homogeneous 
and heterogeneous nucleation unless otherwise stated.  This section will outline some of 
the theories of nucleation and why each theory is relevant to the overall goals of this 
research. 
 
1.4.1.1 Classical Nucleation Theory 
The first nucleation theory was derived by Gibbs and describes the homogeneous 
nucleation of droplets from a vapor.35, 36  Classical nucleation theory (CNT) is a statistical 
approach based on the sequential addition of single molecules to a cluster until a critical 
size is reached.  The critical size is determined from the balance of the unfavorable 
energy of creating a new phase (increase in free energy of the system) and the favorable 
energy resulting from intermolecular bond creation during formation of a crystal lattice 
(decrease in free energy of the system).  Considering a solid nucleus rather than a liquid 
droplet, we can model the Gibbs free energy of a new nucleus of size, 𝑛.  As stated, there 
are two major competing effects for the formation of a new nucleus.  The first is the 
unfavorable contribution from creating a new phase boundary with an area, 𝑆, described 
by the surface free energy between the nucleus and the solution, 𝛼.  A shape factor is 
added to described the geometry of the nucleus (such as 6𝑎2 for a cube with side length 






free energy contribution due to the chemical potential of a molecule in the solid being 
lower than that of a molecule in a supersaturated solution, ∆𝜇 = 𝜇𝑠𝑜𝑙𝑢𝑡𝑒 − 𝜇𝑐𝑟𝑦𝑠𝑡𝑎𝑙 > 0.  
Therefore the overall contribution of free energy of a nucleus of size n to a system is 
−𝑛∆𝜇.  The overall Gibbs free energy equation for the formation of a nucleus is: 
∆𝐺(𝑛) =  −𝑛∆𝜇 + 𝑆𝛼 
Equation 1-14 
This dependence is outlined in the Fig. 1-15; a critical nucleus size is reached once 
the energy associated with lowering the potential of the molecules due to forming a 
crystal lattice outweighs the energy associated with creating a new interface.  The critical 
nucleus size can be determined for a given system and marks the energy barrier that must 
be exceeded for nucleation to occur.  This model has been studied both theoretically and 
experimentally as well as modified to consider many different assumptions but the basic 
assumption is that nucleation is a stochastic event.  The model requires the right number 
of molecules to associate together to begin to form a crystal lattice the timeframe for 
which will depend on the kinetics of the system.  If the cluster of these molecules is large 
enough (≥ 𝑛∗) then the cluster can survive and continue to grow.  If the cluster is not 
large enough (≤ 𝑛∗) then the molecules are driven to decay and the subcritial nucleus 
dissolves.  The critical nucleus size is defined as the point at which a cluster of a given 
size can either become a viable nucleus or decay back into solution.12  
CNT led to the derivation of a crystal nucleation rate equation, by Volmer who 
proposed an equation for the rate of nucleation, (𝐽), based on the Arrehenius equation, 
𝐽 = 𝐽0exp (−
∆𝐺∗
𝑘𝐵𝑇
), where 𝑘𝐵 is the Boltsmann constant, 𝑇 is temperature, and ∆𝐺 






critical free energy change necessary to form a stable nuclei.  ∆𝐺 ∗, as can be seen in 
Figure 1-15, is to the thermodynamic barrier to nucleation with the nucleation rate also 
depending on: temperature, supersaturation (chemical potential difference, which impacts 
the magnitude of ∆𝐺 ∗), and pressure.  The most common adaption of the original Volmer 
equation is: 
𝐽 = 𝑣∗𝑍𝑛 exp (−
∆𝐺∗
𝑘𝐵𝑇
)   
Equation 1-15 
The final expression includes a term for the rate of attachment (𝑣∗) of monomers 
(𝑛) and the Zeldovich factor  (𝑍).  Many assumptions are made to derive this equation, 
most of which depend on mass balance and degrees of freedom within the system, but the 
most important one to consider is that the model assumes that solution molecules are 
exchanged directly with an ordered cluster or nucleus.   
Overall, the CNT with one energy barrier to overcome to achieve nucleation has 
been revised 13, 32, 34, 37 to include additional factors and in some instances can predict 
nucleation in specific systems, whereas in other systems, large discrepancies between 
experiments and predictions are observed.10, 34 Such discrepancies have led to a proposal 
for a different mechanism for nucleation. 
 
1.4.1.2 Two-Step Nucleation 
The assumption that molecules may directly exchange with the ordered cluster 
has been called into question based on what we know about ordered processes and other 






nucleus relies on the molecules of solution undergoing a transition in not one but two 
order parameters; concentration and structure.  For example, assume we have an 
amorphous solid, which is unstable and will have a driving force to crystallize.  The local 
concentration of the molecules will not change drastically as the molecules are seemingly 
just rearranging themselves within the solid to form an ordered crystal lattice.  However, 
in order to form a crystal from solution, molecules must first condense to increase their 
local concentration and subsequently increase their structural order.  Figure 1-16(a) 
shows this phenomenon as it pertains to solution crystallization.  CNT refers to the 
diagonal line from the top left, solution phase, to the bottom right, nucleus phase.  Two-
step nucleation theory proposes that two processes must occur in order to form a nucleus 
each with their order energy barrier; the first being to increase the concentration through 
the creation of a dense liquid phase, and the second being the rearrangement of order to 
form an ordered cluster from the dense liquid. Figure 1-16(c) is a diagram of these energy 
barriers, demonstrating two types of two-step nucleation.  The first (top) creates a dense-
liquid phase which is metastable relative to both the solution and crystal phase.  The 
instability of the dense-liquid phase forces the molecules to rapidly proceed into the 
ordered cluster state, or decay back into solution.  The second (bottom) shows a scenario 
where the dense-liquid phase is more stable than the solution phase and thus more likely 
to be observed.  The presence of a dense-liquid (or amorphous) phase may be attributed 
to high supersaturation, high immiscibility with the solvent, combined with slow 
crystallization/dissolution kinetics.38   
The presence of a dense-liquid phase has been observed to occur with proteins such 






molecules.41 The agreement of experimental data on nucleation rates with differing 
nucleation theories is highly variable.  Some data supports the CNT in certain regimes 
(such as low supersaturation or simple systems such as NaCl).  Other experimental 
nucleation rate data is considerably underestimated by the CNT and shows evidence of a 
second dense-liquid phase before crystallization.38   
Although fundamental nucleation mechanisms are still under debate, they provide a 
framework for understanding how the nucleation process can be manipulated through the 
use of additives, which is essential when using supersaturating dosage forms.   
 
1.4.2 Crystal Growth 
Once nucleation has occurred, the growth of crystals dominates the system.  In 
highly supersaturated systems, such as those created from the dissolution of amorphous 
solid dispersions, nucleation becomes the rate limiting step in crystallization, so long as 
there are not any excipients added to the system to specifically inhibit crystal growth.  
This section will provide a very broad, overview of crystal growth as it is important to the 
overall understanding of this research. 
Crystal growth rate is dictated by two main processes.  The first is the rate of 
diffusion of molecules through the solution to the crystal surface and the second is the 
rate of integration of these molecules into the crystal lattice.  The crystal growth rate 
therefore becomes the summation of the two processes.  Derivations have been made to 
theoretically calculate these rates and there are a few major parameters that need to be 
considered.  Concentration both in solution (diffusion) and around the crystal face 






𝑅𝐺 = 𝑘𝐺(𝐶∞ − 𝐶
∗)𝑔 
Equation 1-16 
Equation 1-16 is a simplified growth rate equation depicting the mass growth of a 
crystal empirically.  Diffusion and integration equations can be derived as well, but the 
overall model relies on growth rate constant(s) and the concentration of the molecule.  To 
fully understand crystal growth however, molecular growth models are necessary.  
Diffusion kinetics are well studied and understood, dependent on temperature, viscosity, 
and intermolecular interactions with the solvent and other solute molecules; all of which 
can be measured and/or determined experimentally.  Integration is more complex and 
there are two major models for crystal growth. The first is the attachment of molecules 
via "favorable sites."  These sites are essentially defects in the crystal surface which 
provide the highest possible number of interactions for the attaching solution molecule as 
compared to adhering to a clean crystal surface.  Figure 1-17 illustrates some of these 
defects which can lead to these energetically favorable sites. 
The crystal growth rate will be dependent on the density of these sites and this 
gives rise to the growth rate constant factors within derivations of growth rates.  It has 
been shown that underlying the mechanism is the surface diffusion of molecules to reach 
these favorable sites.  Spiral growth, as seen in Figure 1-18, is one such consequence of 
this mechanism.  
The growth of crystals via kinks and steps features new molecules being added to 
the crystal layer by layer.  The addition of a molecule to a kink site will create another 
kink site directly adjacent to it.  The spiral growth seen in Figure 1-18 above outlines this 






constantly preserved as the addition of another molecule creates a new kink and favorable 
reaction site in a circular pattern around the screw dislocation (Figure 1-19).42 
The second molecular model is simplistically the ideal case where a new molecule 
being incorporated in the crystal lattice directly onto a new, clean crystal surface.  While 
this is energetically unfavorable compared to the attachment sites outlined above, this 
type of growth has been demonstrated to occur and once a single molecule is 
incorporated, growth can occur similarly to the first model.  This model is known as 2D 
nucleation and growth and initially requires a higher supersaturation threshold to be 
breached, in order for the new molecule to adhere and subsequently grow.42, 43 
Figure 1-20 demonstrates 2D nucleation both schematically (a) and experimentally 
(b).  Overall, the growth mechanisms outlined here are not usually the rate-limiting step 
in crystallization, especially at high supersaturation levels.  However, as we examine the 
effect on the system through the addition polymers to inhibit different aspects of the 
system, we must consider the differences between nucleation and crystal growth as they 
are two unique, albeit interconnected, processes. 
 
1.4.3 Precipitation 
Crystallization is the end result of precipitation from a supersaturated solution.  
The previous sections outlined the mechanisms for crystallization but some systems have 
been observed to exhibit ambiguous behavior, suggesting the precipitation of metastable 
forms as a precursor to crystallization.  Precipitation experiments are usually conducted 
to investigate the time until crystallization occurs.  The use of polymers to inhibit 






resulting precipitation profiles must be carefully examined to differentiate between 
crystallization and precipitation to a non-crystalline phase.  
In addition to the work done within the Taylor lab, other studies have shown a 
change in precipitation behavior based on the presence and type of polymers within the 
system.  In one study, an extensive group of polymers was used to try and alter the 
precipitation behavior of a model compound, danazol.  The authors noted different types 
of precipitation behavior and classified each of the polymers studied based on the 
characteristics of the precipitation curve observed, where precipitation was characterized 
using turbidity measurements.44 
Figure 1-21 shows the differing precipitation profiles obtained from turbidity data 
of danazol/polymer solutions.  The data clearly showed different “types” of precipitation 
and the authors claim that they are all part of a single precipitation behavior, albeit with 
different parts exaggerated (such as the growth phase or the lag phase).  However, 
turbidity data does not give any insight into the actual phase of the precipitate whether it 
is crystalline or amorphous (LLPS).44  LLPS was not taken into consideration in these 
studies, even though LLPS is most widely observed in aqueous solutions of hydrophobic 
drugs.  
Other studies discuss the occurrence of promiscuous aggregation, observed during 
high throughput screening assays with the colloidal species characterized as submicron 
aggregates; LLPS is the most likely explanation for this behavior.44-46   Thus the ability to 
determine and differentiate both crystallization and LLPS events within a system is 






The increase in high through-put screening assays to try and assess the impact of 
polymers on the precipitation behavior of the drug combined with the use of 
indiscriminate analytical techniques that fail to properly identify the phase characteristics, 
had led to the need for more studies in this area.    
 
1.5 Liquid-Liquid Phase Separation 
There can come a point within a given system where two substances are no longer 
miscible or able to coexist as one homogeneous phase.  Thus, when a molar ratio of two 
species is reached where homogeneous mixing is no longer favorable, they can 
spontaneously separate into two distinct phases within the same system.  Most commonly 
this is observed in liquid systems and this phenomenon is called liquid-liquid phase 
separation (LLPS), oiling out,47 or liquid-liquid demixing.48   
LLPS has been observed and studied thoroughly in many different systems.  
Classically, two partially miscible solvents undergo LLPS when they exceed their 
miscibility limit e.g. octanol and water.  The chemistry of the molecules and their ability 
to form favorable interactions with the other component will impact if a system is 
partially or fully miscible.   
 The phase diagrams depicted in Figure 1.22 all demonstrate the regime where LLPS 
occurs.  Diagrams (a) and (c) illustrate experimental evidence of LLPS either through the 
coexistence of two distinct liquid phases (a), or the LLPS boundary curve and subsequent 
spinodal curve (c).  Diagrams (b) and (d) are theoretical representations of LLPS showing 
the submerged LLPS boundary (b), and intersecting meta-stable zones for LLPS and 






depend on the physicochemical properties and interactions of the drug and the aqueous 
solution.7 
As for crystallization, there is an energy barrier for nucleation of a new liquid phase 
from the homogenous solution phase that must be exceeded for LLPS to occur.  The 
behavior of mixing two liquids can be described by the Gibbs free energy of mixing, 
Equation 1-17. 
∆𝐺𝑚𝑖𝑥 = 𝑥𝐴(𝜇𝐴 − 𝜇𝐴
∗ ) + 𝑥𝐵(𝜇𝐵 − 𝜇𝐵
∗ ) 
Equation 1-17 
The Gibbs free energy of mixing, ∆𝐺𝑚𝑖𝑥, is determined by the mole fraction of each 
substance, (𝑥𝐴 and 𝑥𝐵), the chemical potential of both substances (𝜇𝐴 – 𝜇𝐵), and their 
respective reference chemical potentials (𝜇𝐴
∗  – 𝜇𝐵
∗ ).  While the chemical potential of a 
given substance within a multi-component system is not always easily extracted, the 
overall phenomenon of LLPS depends on the variation in the chemical potential with 
composition.  LLPS can occur via two different mechanisms;  
 1) LLPS occurs when the ∆Gmix is greater than 0.  The free energy associated with 
mixing the two liquids together is higher than the free energy of the two liquids 
completely separated.  Thus in this situation, the two liquids are completely 
immiscible and cannot create a single, homogeneous liquid phase.  This situation 
is regarded as theoretical as all liquids are miscible to some extent.  
 2) LLPS can also occur when the ∆Gmix is negative (i.e. mixing is 
thermodynamically favored relative to the unmixed states).  In this situation, there 






system and this can occur at two different ratios, creating a miscibility gap.  
Compositions within this gap have a higher free energy relative to the minimized 
energy points, and thus are less stable than a two phase system.  Figure 1-23 
shows this energy diagram for a partially miscible system.47 
A system which shows partial miscibility before LLPS occurs exhibits the behavior 
shown in Figure 1-23, in that the system will be miscible at certain ratios, and 
thermodynamically unstable or metastable between a set of minima referred to as the 
binodal points.  These binodal points are the limits defining when LLPS can occur within 
a given system.   
 
1.5.1 Binodal/Spinodal of LLPS 
Similar to crystallization as discussed earlier, above the binodal, the system has a 
thermodynamic driving force towards a phase transition, in this case LLPS.  However, 
there exists a metastable region where an energy barrier must be overcome for LLPS, 
between the binodal (𝑥𝐴𝐵, 𝑥𝐵𝐴) and a second barrier, known as the spinodal points (𝑥𝐴𝐵
∗ , 
𝑥𝐵𝐴
∗ ).  Beyond the spinodal points, the system is completely unstable and will 
spontaneously separate into two distinct phases without any thermodynamic barrier.  In 
summary, LLPS can occur beyond the binodal by overcoming an energy barrier and will 
occur beyond the spinodal.   
LLPS can often be easily detected visually as the separation of the system into two 
liquid phases with LLPS being widely observed for organic molecules.7, 40, 49, 50 Two 






 LLPS occurs when the solute is dissolved in a cosolvent system, phase separation 
to two liquid phases occurs and the solute is partitioned between each phase.  The 
concentration of the drug in each solvent is usually not equivalent and depends 
largely on the drug molecule’s affinity for each given solvent (i.e. its solubility).  
This type of LLPS is seen most often in the crystallization of drugs during 
manufacturing7 and is not the subject of this research.   
 LLPS also occurs when one phase consists of mainly the solvent and a second, 
liquid phase consists of mainly the drug in the form of a non-crystalline, viscous 
phase.7  High drug concentrations and high temperature conditions can lead to 
such phenomena occurring as seen in the example of vanillin and water system.51  
It was shown that the concentration of vanillin exceeded a specific supersaturated 
concentration, above which no more vanillin could exist within the water, thus the 
vanillin underwent LLPS.  For systems that were kept close to the melting 
temperature of vanillin (~80°C), LLPS is logical because vanillin should not exist 
as a solid above the melting temperature.  However, LLPS was also observed 
below the melting temperature down to about 55°C. 
 
It is logical that, for organic molecules, LLPS can occur above the melting 
temperature, however, below the melting temperature, the anticipated second phase 
created once the binodal is surpassed is the crystal since this is the thermodynamically 
stable phase.  However, there is evidence of LLPS occurring in systems far below the 






supercooled liquid, or even a glassy amorphous phase. Phase separation to an amorphous 
phase can thus occur at a high supersaturation when the free energy of creating a new 
amorphous phase is lower than the free energy of the homogeneously mixed liquid 
phases.  The occurrence of LLPS for organic molecules below the melting temperature 
has been widely documented although not extensively studied from a mechanistic 
perspective. In the context of this research, the terms LLPS, oiling out, and liquid-liquid 
demixing are all used to describe a system which now has two liquid phases, even if one 
of those phases could potentially be classified as a super-cooled liquid. 
LLPS in drug systems has been demonstrated for a variety of systems.7, 47-54  The 
ability for LLPS to occur below the melting temperature results from the competing 
effects of LLPS and crystal nucleation.  If the kinetics of LLPS are faster than the 
kinetics of crystallization, LLPS can occur in systems which exceed the binodal of the 
system, leading to the creation of two liquid phases.  Thus, these hydrophobic drugs 
when mixed with water have a LLPS boundary concentration, above which LLPS will be 
observed so long as crystallization does not occur. The drugs which have been shown to 
undergo LLPS usually show the presence of drug-rich droplets.50 
Initially, the system exists as a type of emulsion, with colloidal sized drug-rich 
droplets dispersed in the water-rich phase.53  Over time, the droplets may coalescence and 
form one continuous layer, and at any time can undergo crystallization.  It is inherently 
difficult to observe LLPS directly as the droplet size usually begins in the nanometer 
region (100-300 nm).  Dynamic light scattering (DLS) can detect and size the particles55 
but limitations due to concentration of particles and crystallization may limit the 






which can be detected through ultra-violet/visible spectroscopy but determining the 
structure of the scattering phase can be challenging.28, 55, 56 
 
1.5.2 LLPS and Drug Solubility 
The creation of the new drug phase in the form of disordered drug-rich droplets 
creates a new interface and equilibrium within the system.  For multi-phase systems 
which are partially miscible, the drug will be present in both the solvent phase and the 
drug-rich phase.  For drug systems the solvent is water, so let us consider aqueous 
systems with a drug that has undergone LLPS.  The following diagram illustrates the 
different phases that can occur and their relationship, concentration-wise, with the other 
phases. 
The aqueous phase is shown to reach a maximum concentration of drug, above 
which the system will spontaneously undergo LLPS.  If the crystallization kinetics are too 
slow to immediately compete with LLPS, then the drug-rich droplets, saturated with 
water will be observed as the discrete, scattering phase.  Theoretically, if this phase is 
observed below the melting temperature it can be assumed that it should behave much 
like a fully hydrated, super-cooled liquid amorphous phase.  Determining the relationship 
between the solubility (concentration) of the drug in the aqueous phase and the drug 
phase is one of the major goals of this research, in order to determine if this is a 
reasonable assumption. 
The utilization of ASDs as solid oral dosage forms leads to supersaturation levels 






Understanding the parameters and mechanisms for each is critical for formulating ASDs 
and can lead to important new insight of drug dissolution behavior. 
 
 
1.6 Overview of Research 
The dissolution of ASDs leads to supersaturated drug solutions, crucial for increased 
bioavailability especially for poorly soluble drug molecules.  In other words, the solution 
concentration is higher than the crystalline solubility.  These solutions are therefore 
thermodynamically metastable or unstable and can crystallize.  Recent evidence suggests 
that some systems can undergo another phase transformation, LLPS, prior to 
crystallization.  LLPS creates a discrete drug-rich phase dispersed in the continuous 
aqueous drug-lean phase and is expected to impact the bioavailability of the drug though 
effects on diffusion and crystallization behavior.  The ability to predict, evaluate, measure, 
and understand LLPS within supersaturated drug solutions is thus critical to the 
formulation and effectiveness of ASDs.  Polymeric additives have been shown to inhibit 
crystal nucleation and crystal growth, which could promote LLPS.  These observations 
have led to the following hypotheses regarding these systems: 
 The apparent amorphous solubility, which can be achieved in formulations such 
as amorphous solid dispersions, sets an upper-limit of supersaturation above 
which LLPS will occur.  The LLPS boundary concentration is inherently 
correlated to the amorphous solubility and these values can be both predicted and 
observed for a given system if crystallization can be prevented over the timeframe 






 It is further hypothesized that drug-polymer interactions within these highly 
supersaturated systems will lead to the stabilization of the liquid-liquid phase 
separated system.   
 Ultimately, it is expected that solubility, phase transformation, and dissolution 
rate information will correlate with mass transport across a membrane with the 
LLPS concentration corresponding to the upper limit in the diffusion rate.  This 
analysis should yield a new perspective on the overall solubility enhancement 
achieved through the formulation of amorphous solid dispersions of drugs which 
can undergo LLPS. 
The first chapter presented the essential background information relevant for this 
research.  Chapter two examines the supersaturation behavior of a model drug and 
polymers.  This chapter is a detailed method development to detect the presence of LLPS 
and crystallization from supersaturated drug solutions both qualitatively and 
quantitatively.  Chapter three contains a detailed characteristic analysis of the drug-rich 
droplets formed during LLPS and the impact on the free-drug concentration.  The effect 
of polymers on LLPS was investigated with regards to the amorphous solubility and 
drug-rich droplet characteristics.  In chapter four, the dissolution behavior of ASDs was 
evaluated with the same methods used in chapter two.  The results were correlated to the 
supersaturation results obtained from chapter two to determine presence and effects of 
LLPS upon ASD dissolution.  Lastly, chapter five investigated the impact of crystal seeds 






between the dissolution rate of the amorphous drug and the growth rate of the crystalline 




































Figure 1-4. Energy vs. temperature diagram of amorphous solids relative to liquids and 
solids Taken from 59, adaptation of diagram found in Ref 60. 
 
 
Figure 1-5. Visual representation of the molecular arrangement of a crystalline solid, 







Figure 1-6. Competing effects upon the crystallization of amorphous solids.4 
 
 







Figure 1-8. A schematic representation of the molecular level of an amorphous solid 
dispersion. The lines represent the polymers and the circles represent the drug molecules. 
 
 





































Figure 1-13. Dissolution-Time Profiles of ASDs of felodipine with HPMC (90% 
polymer:10% drug - black squares; 50:50 - red circles) and PVP (90:10 – blue triangles; 







Figure 1-14. Example dissolution profile of a “spring and parachute” formulation, most 







Figure 1-15. Illustration of the thermodynamic effects of formation of a crystal. 𝑛 – 
number of molecules in crystalline nucleus; ∆𝜇 − solution supersaturation (chemical 
potential difference); 𝛼 – surface free energy (6𝑛
2
3⁄  is a shape factor); ∆𝐺 – free energy. 






Figure 1-16. (a) The two ordered processes necessary for nucleation to occur through 
changes in concentration and structure. (b) A visual representation of two-step nucleation. 
(c) Free-energy reaction plot depicting the energy involved in creating crystals from 







Figure 1-17. Favorable sites of integration during crystal growth.42 
 
 








Figure 1-19. Screw dislocation and subsequent spiral crystal growth due to the layering 
around the dislocation.42 
 
 
Figure 1-20. 2D Nucleation. (a) Schematic of 2D nucleation and growth.43 (b) 







Figure 1-21. Examples of different precipitation profiles of danazol/polymer systems 







Figure 1-22. Four different types of phase diagrams depicting crystallization and liquid-








Figure 1-23. Gibbs free energy function one a system exhibiting LLPS.47 
 









Figure 1-25. LLPS (left) of an experimental drug in an aqueous system and the 
subsequent crystallization over time (middle and right) at the expense of the droplets.50 
 
 
Figure 1-26. LLPS of an experimental organic molecule shown to exhibit LLPS in the 







Figure 1-27. Simple diagram of the relationship of different phases within a 
supersaturated solution.  Zone I is the stable zone below the crystalline solubility.  Zone 
II is the "metastable" zone where crystallization can occur.  Zone III is the labile zone 
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CHAPTER 2. IMPACT OF POLYMERS ON THE PRECIPITATION BEHAVIOR OF 
HIGHLY SUPERSATURATED AQUEOUS DANAZOL SOLUTIONS 
2.1 Abstract 
The phase behavior of supersaturated solutions of a relatively hydrophobic drug, 
danazol, was studied in the absence and presence of polymeric additives.  To differentiate 
between phase separation to a non-crystalline phase and phase separation to a crystalline 
phase, an environmentally sensitive fluorescent probe was employed. Induction times for 
crystallization in the presence and absence of polymeric additives were studied using a 
combination of ultraviolet and fluorescence spectroscopy.  It was found that when 
danazol was added to aqueous media at concentrations above the amorphous solubility, 
liquid-liquid phase separation was briefly observed prior to crystallization, resulting in a 
short-lived, drug-rich non-crystalline danazol phase with an initial size of around 500 nm. 
The addition of polymers was found to greatly extend the lifetime of the supersaturated 
two phase system, delaying the onset of crystallization from a few minutes to a few hours. 
Below a certain threshold danazol concentration, found to represent the amorphous 
solubility, only crystallization was observed. Thus although the addition of polymers was 
unable to prevent danazol from precipitating once a threshold concentration was 
exceeded, they did inhibit crystallization, leading to a solution with prolonged 
supersaturation. This observation highlights the need to determine the structure of the 







Current drug discovery techniques tend to identify candidate drugs with complex 
structures which may pose significant formulations challenges.  In particular, an 
increasingly large number of new drug compounds have extremely poor solubility in 
water1, impacting the bioavailability of the drug.  Various formulation approaches can be 
employed to increase the apparent solubility and/or the dissolution rate of a drug within 
the gastrointestinal tract.  Amorphous solid dispersions (ASDs) are one such technique 
and there are numerous examples illustrating the resultant increases in apparent solubility 
and bioavailability.2-7  However, ASDs are inherently difficult to formulate because of 
the thermodynamically high energy state of the amorphous form of the drug leading to a 
high risk for transformation to the crystalline form.7   
Additives can be combined with the drug in the ASD to aid in stabilization of the 
formulation both in terms of crystallization during storage8 and during dissolution9-10 and 
these excipients enable ASDs to be a viable formulation option for some compounds.  
However, the dissolution behavior of ASDs is extremely complex and is not well 
understood.10-11  Highly supersaturated systems, such as those created from the 
dissolution of ASDs, may undergo multiple phase transformations.12-13  Thus, a more 
complete understanding of the thermodynamics and kinetics of these systems is critical to 
successfully use this approach for the delivery of poorly water soluble drugs.   
The solubility advantage achieved using an amorphous drug has been described 
previously.4,6-7,14  The maximum increase in apparent solubility that can be achieved upon 
dissolution of an amorphous solid has been termed the amorphous solubility4 and can be 






amorphous solid will lead to a supersaturated solution which will return to an 
equilibrium, saturated solution through nucleation and crystallization of the drug,5,7 
whereby the extent of supersaturation reached, as well as the timeframe for crystallization 
will vary tremendously from compound to compound and for different formulations.  
Excipients (typically polymers) are used to stabilize ASD formulations by preventing the 
nucleation and growth of the drug from the supersaturated solution phase.17-18  There is 
mounting evidence that for some systems, dissolution of a formulation consisting of a 
hydrophilic polymer containing a molecularly dispersed drug leads to the formation of a 
highly supersaturated solution which can subsequently undergo liquid-liquid phase 
separation (LLPS), prior to crystallization.16,19-20  LLPS is a widely observed 
phenomenon in organic chemistry,20-23 but the mechanisms and variables which affect 
LLPS are not well understood in the context of drug delivery.  Thus investigating LLPS 
in aqueous drug solutions is vital to understand the complicated phase transformations 
which can occur in supersaturated solutions which commonly arise following the 
dissolution of solubility enhancing formulations, such as amorphous solid dispersions. 
In this study we examined the phase behavior of supersaturated solutions of a 
relatively hydrophobic drug, danazol. Danazol has been extensively investigated in terms 
of the dissolution of the amorphous material, its precipitation behavior from 
supersaturated solutions, and in bioavailability studies.18 To differentiate between phase 
separation to a non-crystalline phase and phase separation to a crystalline phase, an 
environmentally sensitive fluorescent probe was employed. Induction times for 
crystallization in the presence and absence of polymeric additives were studied using a 






observed prior to crystallization. The addition of polymers was found to greatly extend 
the lifetime of the supersaturated two phase solution, delaying the onset of crystallization 
from a few minutes to a few hours. Below a certain threshold danazol concentration, 
found to represent the amorphous solubility, only crystallization was observed. 
 
2.3 MaterialsDanazol was purchased from Euroasia Chemicals (Euroasia Ltd, China) 
and the molecular structure is presented in Figure 2-1.  Polyvinylpyrrolidone (PVP) 
K29/32 was purchased from Sigma Aldrich (St. Louis, MO), while hydroxypropylmethyl 
cellulose (HPMC) 606 grade and hydroxypropylmethyl cellulose acetate succinate 
(HPMC-AS) MF grade were supplied by Shin Etsu (Shin-Etsu Chemical Co., Ltd., 
Tokyo, Japan). Methanol was purchased from Macron Chemicals (Phillipsburg, New 
Jersey).  The aqueous media used in all experiments was 10 mM pH 6.8 phosphate 
buffer. Pyrene at a concentration of 2 µM was added to some solutions for fluorescence 
measurements; pyrene was purchased from Sigma Aldrich (St. Louis, MO).  Polymer 




The equilibrium solubility of danazol was determined by high performance liquid 
chromatography (HPLC).  An excess amount of drug was added to 10mM pH 6.8 
phosphate buffer at 25°C and agitated for 48 hours.  The supernatant was separated from 
excess solid in solution by ultracentrifugation at 40,000 rpm in an Optima L-100 XP 






Brea, CA) for 15 minutes. The supernatant was diluted and solution concentration was 
determined using an Agilent HP 1260 HPLC system (Agilent Technologies, Santa Clara, 
CA).  The chromatographic separation was performed with a ZORBAX Eclipse Plus C18 
column (4.6mm x 100mm, 5µm). Danazol was detected by ultraviolet (UV) absorbance 
at a wavelength of 288 nm.  The mobile phase consisted of water, acetonitrile, and 
methanol (40:30:30 by volume).  The total analytical run time was 15 minutes and the 
mobile phase flow was held constant at 1.0 mL/min.  The injection volume was 50 µL.  
Standards (0.1-100 µg/mL) were prepared in methanol and all samples were analyzed in 
triplicate.  The standard curve exhibited good linearity (r2 > 0.999) over the concentration 
range.  The equilibrium solubility in solutions containing 10 µg/mL of PVP, HPMC, and 
HPMC-AS was determined using the same method. 
 
2.4.2 Amorphous Solubility Estimation 
The theoretical amorphous solubility of compound in a given medium can be 
approximated using certain physical properties and the crystal solubility in the same 
medium.  Thus the ratio of the amorphous solubility (σamorph) to that of the crystalline 







Where ∆G is the free energy difference between the amorphous and crystalline 
forms of the drug, R is the universal gas constant and T is the operating temperature.  The 






amorphous solute saturated with water.  The free energy difference can be approximated 
using the Hoffman equation where it is assumed that the enthalpy of the crystal and 




2   
Equation 2-2 
The heat of fusion (∆Hf) and melting temperature (Tm) can be readily determined 
from DSC analysis.  T is the operating temperature and ∆T is the difference between the 
melting temperature and operating temperature (Tm-T). The methods described by Baird 
et al.25 were used to determine the heat of fusion and the melting temperature of danazol.  
The amorphous solute activity term,  𝑒[−𝐼(𝑎2)] , was determined from the moisture 
sorption profile of the amorphous drug and applying the Gibbs-Duhem equation as 
described previously.26  Amorphous danazol was prepared via the quench-melt method 
by melting 15-20 mg of danazol and subsequently quench cooling the melt with liquid 
nitrogen.  The moisture sorption profile was determined at 25°C using a TA Q5000 
dynamic vapor sorption analyzer (TA Instruments, New Castle, DE).  The Q5000 was 
equipped with a humidity controlled chamber and thermobalance.  The sample was dried 
within the sample holder at 25°C and 0% humidity until the weight change was less than 
0.01% over a 5 minute interval.  The moisture sorption isotherm was collected by 
equilibrating the sample under a controlled relative humidity (RH) range from 5% RH to 
95% RH in 5% intervals.  Equilibrium was assumed to be achieved when the weight 






2.4.3 UV Extinction Measurements 
UV spectroscopy was used to determine the concentration at which LLPS occurs 
as described previously.16  The UV extinction was measured at 350 nm as a function of 
danazol concentration in order to determine when an increase in scattering occurred due 
to the formation of the drug-rich colloidal phase.  The samples analyzed consisted of 50 
mL of aqueous buffered solution (10 mM phosphate buffer, pH 6.8) stirred at 200 RPM 
and maintained at 25°C using a jacketed vessel fed by a Julabo MA water bath (Seelbach, 
Baden-Württemberg, Germany).  The aqueous solution concentration of danazol was 
controlled by using a syringe pump to add small volumes of a stock solution of danazol 
dissolved in methanol (4 mg/mL).  When no polymers were present in the buffer, danazol 
was added to the aqueous solution at a rate of 5 µg/mL/min in order to rapidly attain the 
LLPS concentration prior to crystallization occurring.  For solutions containing polymers, 
the addition rate was 1 µg/mL/min.   
 
2.4.4 Fluorescence Spectroscopy using an Environmentally Sensitive Probe 
Fluorescence spectroscopy can be used to determine the presence of the non-
crystalline drug-rich phase created upon liquid-liquid phase separation by analyzing the 
changes in the emission spectra of an environmentally sensitive fluorescent probe.12  For 
pyrene, a hydrophobic fluorescent probe molecule, the emission spectrum varies 
depending on the hydrophobicity of the local environment.27  The premise of these 
measurements is that pyrene, acting as an environmental probe, will partition into the 
more hydrophobic drug-rich phase created during the process of LLPS. The use of pyrene 






widely established. Based on this body of literature, as well as previous studies from our 
group using pyrene, a change in the ratio of two characteristic pyrene emission peaks (I1 
at 373 nm, I3 at 383 nm) was used to indicate a change in the probe environment and 
consequently the LLPS concentration.   
The aqueous systems studied consisted of buffer, 2 µM pyrene and 10 µg/mL 
polymer for experiments where polymer impact was evaluated.  Fluorescence spectra 
were collected for danazol solutions with concentrations ranging from 0-30 µg/mL. 
Solutions were prepared via the solvent shift method by adding a small aliquot of a 
methanolic solution of danazol (2 mg/mL) into the aqueous solution.  The volume of the 
final solution was approximately 10 mL and the temperature was maintained at 25°C 
using a jacketed vessel and the sample was stirred at 200 RPM.  Samples were withdrawn 
from this solution after 30 seconds and 15 minutes and analyzed using a Shimadzu RF-
5301pc Spectrofluorometer (Kyoto, Japan).  The excitation wavelength was 332 nm, and 
the emission spectrum was collected at 0.2 nm intervals from 350-420 nm.  The 
excitation slit width was 10 nm, while the emission slit width was 1.5 nm.  Triplicate 
measurements were made.  Control experiments were performed by adding crystalline 
drug (approximately 1 mg/mL) to aqueous buffer with and without polymer, and 
containing 2 µM pyrene.  In addition, the emission spectrum of pyrene in an amorphous 
film of anhydrous danazol was obtained by spincoating a solution containing a 
methanolic 40 mg/mL danazol and 0.1 mg/mL pyrene onto a quartz coverslip. The 






2.4.5 Simultaneous Ultraviolet (UV) and Fluorescence Spectroscopy 
Fluorescent spectroscopy and UV spectroscopy were performed in parallel with 
the aim of determining the induction time for crystallization in supersaturated danazol 
solutions. For UV measurements, the spectrum was obtained using a fiber optic dip probe 
with a pathlength of 1 cm coupled to a SI Photonics UV/Vis Spectrometer (Tucson, AZ)   
Standard solutions of danazol (1-100 µg/mL) were prepared in methanol resulting in a 
linear standard curve (r2 > 0.999).  Measurements were recorded at two wavelengths; the 
maximum UV absorbance wavelength of danazol of 288 nm, and at 350 nm where no 
absorption is observed. Monitoring at 350 nm enables changes in the extinction due to 
scattering to be readily observed. Fluorescence spectroscopy measurements were 
performed on the same solution as described above.  The samples analyzed consisted of 
200 mL of aqueous buffered solution (10 mM phosphate buffer pH 6.8, 2 µM pyrene), 
stirred at 200 RPM and held at 25°C using a jacketed vessel fed by a Julabo MA water 
bath.  Supersaturated solutions of danazol were created by the solvent shift method, 
adding a small aliquot of a 4 mg/mL methanolic solution of danazol.  The polymer 
concentration was 10 µg/mL. For UV measurements, spectra were obtained every 30 
seconds. 2 mL aliquots were extracted and analyzed in the fluorometer at various time 
points. 
 
2.4.6 Dynamic Light Scattering (DLS) 
The particle size and zeta potential of the colloidal droplets formed in highly 
supersaturated danazol solutions was determined with DLS.  Each sample consisted of 50 






µg/mL polymer).  The solution was stirred (200 RPM) and the temperature was held 
constant at 25°C using a jacketed beaker and water bath.  Supersaturated solutions of 
danazol were obtained as described above.  0.5 mL samples of the solution were 
withdrawn at different time points and analyzed using a Nano-Zetasizer (Nano-ZS) from 
Malvern Instruments (Westborough, MA) equipped with dispersion technology software 
(DTS).  A backscatter detector was used and the scattered light was detected at an angle 
of 173°.  Particle size data were obtained using 12mm square polystyrene disposable 
cuvettes and zeta potential data were obtained using disposable capillary cells. 
 
2.4.7 Induction Time Experiments using Second Harmonic Generation 
Second harmonic generation (SHG) was used to detect the onset of crystallinity in 
the solutions and to confirm that the initial scattering observed with UV extinction 
measurements was due to a non-crystalline phase.  Chiral crystals result in the frequency 
doubling of light when analyzed under certain conditions, while solutions and disordered 
materials do not. Therefore, the crystallization of SHG-active compounds can be detected 
by the technique of second order non-linear optical imaging of chiral compounds 
(SONICC).32-34  Supersaturated danazol samples below and above the LLPS 
concentration were examined using the SONICC instrument manufactured by 
Formulatrix (Waltham, MA).  Supersaturated solutions containing danazol concentrations 
of 10 μg/mL and 50 μg/mL were generated as described above at a 10mL scale.  100 μL 
aliquots were then dispensed into a BD Falcon 96-well plate and loaded into the SONICC 
instrument.  There was a delay of 30-60 seconds from the initial generation of 






and wells were scanned from the bottom up to the meniscus at approximately 40 μm 
increments in the Z direction, in order to capture crystallization occurring in different 
volume elements of the well. 
 
2.5 Results 
2.5.1 Danazol Solubility 
Select properties of danazol are shown in Table 2-1. The aqueous solubility of 
crystalline danazol at 25°C, 10 mM pH 6.8 phosphate buffer was determined to be 0.9 
µg/mL.  Using the values of the crystal solubility, the melting temperature, and heat of 
fusion (Table 1), the amorphous solubility is estimated to be 16 µg/mL at 25°C, and 
hence the ratio of the amorphous to crystalline solubility is 19.6.  This estimate contains 
errors introduced by the assumptions inherent in the Hoffman equation,16 and errors in 
the determination of the crystalline solubility, but is in reasonable agreement with that of 
Ozaki et al., (19.6 vs 13.7)35 who also included a moisture correction factor and both of 
these values are much lower than the estimate of Murdande et al which is 26.5.4    
Table 2-2 shows the impact of low concentrations of polymer on the aqueous 
solubility of danazol and the resultant amorphous solubility estimates. Within the error of 
the measurements, it is apparent that HPMC-AS and PVP have negligible impact on 
solubility, while HPMC increases the solubility by an appreciable amount.  
 
2.5.2 Determination of LLPS concentration using UV extinction measurements. 
It has been shown previously, that, in the absence of crystallization, the 






solution of danazol with no polymer (Figure 2-2), it is apparent that there is very low 
total extinction at a non-absorbing wavelength at concentrations below approximately 13 
µg/mL, while above this concentration, the solution scatters light and the extinction 
increases. These measurements suggest the formation of a new phase when the 
concentration of danazol exceeds ~13 µg/mL.  The formation of this new phase occurs at 
somewhat lower concentrations when low concentrations of polymers (PVP, HPMC, 
HPMC-AS) are present (Figure 2-2). The concentration where the extinction increased 
for each system was estimated by fitting the data in the regions of low and high extinction 
using linear regression analysis and determining the intersection of the two curves; results 
are presented in Table 2-3. 
 
2.5.3 Investigation of Solution Phase Behavior using Fluorescent Probe 
To confirm that the new phase detected from the UV extinction measurements is a 
non-crystalline phase, the emission spectrum of pyrene was evaluated as a function of 
danazol concentration. The emission spectrum of pyrene is highly sensitive to the 
hydrophobicity of the local environment. This is readily apparent from Figure 2-3 which 
shows the emission spectrum of pyrene dissolved in different solvents. Specifically the 
ratio of the first peak (I1 = 373nm) and the third peak (I3 = 383nm) can be used as an 
indicator of the local environment whereby this ratio will decrease with an increase in 
hydrophobicity of the environment.27 Thus the I1/I3 ratio for pyrene dissolved in water is 
1.97 while in cyclohexane, the ratio is 0.66. If a non-crystalline danzol-rich phase is 
formed, the expectation is that the hydrophobic pyrene molecule will partition into this 






All of the aqueous buffered systems studied had an I1/I3 ratio of 1.95 ± 0.03 prior 
to the addition of drug.  Thus the presence of polymers at a concentration of 10 µg/mL 
did not affect the pyrene emission spectrum.  Figure 2-4 shows the pyrene I1/I3 ratios as a 
function of danazol concentration.  In the absence of a polymer, the I1/I3 ratio remained 
constant at around 1.95 until the danazol concentration exceeded 13 µg/mL.  At higher 
danazol concentrations, the ratio steadily decreased with increasing concentration until a 
concentration of around 24 µg/mL was reached, when the ratio reached a minimum 
value. The very abrupt change in the pyrene I1/I3 ratio when the concentration of danazol 
exceeds 13 µg/mL is consistent with the formation of a new, non-crystalline phase of 
danazol into which pyrene can partition. The plateau value suggests that at around 24 
µg/mL, sufficient drug rich phase has been created so that the majority of pyrene has 
partitioned into the drug-rich phase.  The decrease in the pyrene I1/I3 ratio to 1.5 suggests 
that the probe is in an environment of similar polarity to that of methanol (Fig 2-3). The 
I1/I3 ratio for pyrene in an anhydrous amorphous film of danazol was found to be 1.4. The 
slightly higher pyrene ratio observed in the aqueous environment during the precipitation 
experiments can be attributed to the presence of some water in the drug-rich phase, which 
makes the environment slightly more hydrophilic than in the pure danazol film. 
Increasing the danazol concentration to 50 and 100 µg/mL did not further lower the I1/I3 
ratio (data not shown).  The formation of a new phase at concentrations exceeding 13 
µg/mL danazol is consistent with the UV extinction measurements described above, and 
occurs at a concentration close to the predicted amorphous solubility.   
The presence of a polymer in solution appeared to result in the phase separation of 






change in I1/I3 ratio and results are shown in Table 2-3. PVP had a minor impact (LLPS 
onset at 11 µg/mL) while HPMC and HPMCAS had a larger impact (LLPS onset at 9 
µg/mL for HPMC and 8 µg/mL for HPMC-AS).   Good agreement was observed 
between the fluorescence measurements and the UV extinction measurements.     
 
2.5.4 Initial Evaluation of Danazol Crystallization 
Based on a visual examination of the solutions, it appeared that danazol solutions, 
in the absence of polymer, crystallized fairly quickly following the occurrence of LLPS; 
particles could be seen after a few minutes. In order to confirm that crystallization was 
occurring on a fairly short time scale, the I1/I3 ratios were compared as a function of 
concentration immediately following the generation of supersaturation and after 15 
minutes. It has been previously observed that upon crystallization, the I1/I3 ratio changes 
back towards that observed for pyrene in water.12 Figure 2-5 shows a comparison of the 
I1/I3 ratios initially, and after 15 minutes for different amounts of added danazol. For 
danazol alone, after 15 minutes, the I1/I3 ratio (1.95 ± 0.03) is identical to the ratio 
observed in pure water, for all danazol concentrations, strongly suggesting that the drug 
has crystallized and thus the probe no longer experiences the more hydrophobic drug-rich 
environment. In other words, when the drug crystallizes, pyrene is excluded from the 
crystal into the aqueous solution.   
In order to confirm the pyrene emission results, a second harmonic generation 
(SHG) experiment was performed to evaluate the crystallinity of the system over time.  
Figure 2-6 shows the enhanced focus SHG images for danazol solutions below the LLPS 






exhibited SHG signal initially, with the SHG signal evolving between 5-15 minutes 
indicating that this represents the crystallization induction time.  
In contrast to the changes observed in the pyrene emission spectrum for the 
danazol alone, when any of the three polymers was present, the I1/I3 ratio remained 
constant for 15 minutes, and was much lower than the value obtained for the purely 
aqueous environment, suggesting that the polymers inhibited crystallization of danazol 
and the probe remained in the drug-rich phase. Consequently, more extended studies 
were performed to evaluate the crystallization induction times of danazol in the presence 
and absence of the polymers.    
 
2.5.5 Crystallization Induction Times as a Function of Danazol Concentration and 
Polymeric Additives. 
Experiments were conducted to measure the crystallization induction times at 
different added danazol concentrations. Three concentrations were evaluated, above (20 
µg/mL ), just above (15 µg/mL), and below (10 µg/mL) the estimated LLPS 
concentration. Based on theoretical considerations, it would be anticipated that the 
nucleation rate would increase with increasing supersaturation. However, once the LLPS 
transition occurs, the supersaturation will remain constant in the system, since 
equilibrium between the two phases will exist. At the same time once LLPS occurs, the 
solution changes from being homogeneous (single phase) to heterogeneous (two phase); 
this can also impact the nucleation kinetics. Thus it is of interest to evaluate induction 






Crystallization induction times were determined by measuring the UV response as 
a function of time at a wavelength where danazol shows good absorption, in order to 
observe decreases in absorption that would be consistent with phase separation to a 
crystalline phase with a resultant decrease in the solution concentration. Changes in the 
scattering properties of the solution were also monitored by measuring the extinction at 
350 nm. The same solution was also monitored as a function of time by fluorescence 
spectroscopy, adding pyrene and measuring the I1/I3 ratio. Figure 2-7 shows example UV 
absorbance and fluorescence data for a supersaturated solution of danazol as a function of 
time, in the absence of a polymer.  The UV data shows an initial drop in signal followed 
by a change in slope after about 5-10 min. The fluorescence data shows a relatively 
constant I1/I3 ratio for about 5-10 minutes followed by a rapid increase. The initial 
decrease in the UV signal is attributed to the rapid coalescence of the LLPS nanodroplets 
(DLS data shown in Fig. 2-11 provides evidence of rapid coalescence) which will change 
their absorption and scattering properties,37 thus impacting the UV signal. Small particles 
will absorb UV light to a greater extent than larger particles in the submicron region.37 
Thus if the droplet size is rapidly increasing, the absorbance will decrease as observed in 
this study. This decrease is not thought to be due to crystallization based on the 
fluorescence data (as well as the SHG data presented above). Instead, the crystallization 
induction time is taken as the time when the UV data show a change in slope, 
simultaneous with the increase in the I1/I3 ratio. For the danazol solution at 10 µg/mL, 
which is below the LLPS concentration, the solution is homogeneous and thus the UV 
absorption data did not show the same initial changes (data not shown) and the induction 






contrast, the fluorescence data provided little insight into the crystallization behavior of 
this system since there is no danazol-rich phase, and hence the I1/I3 ratio is minimally 
impacted by crystallization. Thus in the absence of polymer, and for the experimental 
conditions studied, the induction time for danazol crystallization is around 5-10 minutes 
at all three concentrations. The induction times are summarized in Table 2-4 and Figure 
2-12.   
For solutions containing a polymer, the crystallization induction time increased to 
around 1.5 hours for PVP, to approximately 2.5 hours with HPMC and to 4 or more hours 
for HPMC-AS (Table 2-4); the large variations in induction time are quite typical since 
nucleation is a stochastic process.  Figures 2-8, 2-9, and 2-10 show the UV and 
fluorescence kinetic measurements for a representative experiment for each system.  The 
UV data does not show such a dramatic steep initial decrease in signal when the polymers 
are present; it is well known that polymers are effective at stabilizing colloidal 
systems,12,38 thus it is inferred that droplet coalescence is reduced in the presence of the 
polymers resulting in a more stable UV signal prior to crystallization. This is supported 
by dynamic light scattering data, presented in Figure 2-11A which shows much less 
change in the droplet size in the presence of the cellulosic polymers relative to for 
danazol alone. Figure 2-11B shows zeta potential data for the droplets in the absence and 
presence of polymer. Danazol droplets have a negative zeta potential. In the presence of 
polymers, the zeta potential changes, indicating that the polymers are adsorbed at the 
droplet interface. While the negatively charged HPMCAS increased the negative zeta 






Neutral cellulose polymers have been observed to have a similar effect on decreasing the 
negative zeta potential observed for talc particles following adsorption.39  
Changes were also observed in the UV signal at 350 nm, consistent with a change 
of scattering properties upon crystallization and the time of these changes are noted in 
Table 2-4. The sharp decrease in the UV absorbance signal shows a good coincidence 
with the increase in the I1/I3 ratio from the fluorescence measurements, for the systems at 
a danazol concentration of 15 and 20 µg/mL. Interestingly, the final value of the ratio of 
the I1/I3 pyrene peaks did not return to value observed for pyrene in water suggesting the 
presence of some unknown pyrene-drug-polymer complex.  In the absence of danazol, 
the polymers did not affect the I1/I3 of pyrene in water, so this observation cannot be 
explained by the formation of a pyrene-polymer complex.  Control experiments were 
performed using pure crystalline danazol added to aqueous solutions containing pyrene 
and polymers.  The I1/I3 ratio was not initially influenced in any systems but after 24 
hours, systems with polymers showed a slight decrease in the I1/I3 ratio (Figure 2-14).  It 
is likely that the polymer adsorbs to the surface of the crystalline drug, and pyrene 
interacts with the drug and polymer in this region. A similar observation has been made 
for crystalline carbamazepine in the presence of a surfactant.40 
The final UV concentration measured in the presence of polymers was around 2-3 
µg/mL which is greater than the crystalline solubility of danazol (~1 µg/mL) but much 
lower than the LLPS concentration. The 10 µg/mL danazol solutions are either below or 
just at the LLPS concentration in the presence of the polymer and thus the fluorescence 
method ceases to provide meaningful data and induction times are inferred solely on the 






changes as a function of concentration, or when the fluorescence I1/I3 ratio increases, are 
summarized in Figure 2-12; good agreement is seen between the various methods.  
Clearly, the systems containing HPMCAS have the longest induction times, taking 6 
hours to crystallize as compared to around 5 min in the absence of polymer. PVP and 
HPMC also substantially increase induction times to approximately 100 and 150 min 
respectively. In general, the systems above the LLPS concentration have shorter 
induction times than the one phase solutions; this can most clearly be seen in the case of 
solutions containing HPMC; induction times in the absence of the polymers were too 
short to make this distinction.    
  
2.6 Discussion 
As the use of solubility enhancing formulations becomes more widespread, it 
becomes increasingly important to understand the phase behavior of highly 
supersaturated solutions of poorly water soluble drugs. Supersaturation can be generated 
by dissolution of amorphous solid dispersions,10 following dilution of a cosolvent 
formulation,41 by changing the pH environment,42 or upon digestion of a lipid 
formulation.43 It is important to note that supersaturation is fundamentally different from 
solubilization; in a supersaturated solution, the solute concentration (chemical potential) 
is higher than that obtained by dissolving the crystalline material in the same medium and 
a thermodynamic driving force for crystallization exists, whereas in a solubilized 
solution, the equilibrium crystalline solubility is increased leading to higher solution 
concentrations (without an increase in solute chemical potential), but no possibility of 






flux across a membrane while solubilized systems do not enhance flux unless the rate 
limiting step is dissolution.44-45 This has led to a great interest in solubility enhancing 
strategies that generate supersaturated solutions, and the number of commercial products 
that employ this strategy is increasing with recent examples including ASDs of 
telaprevir45 and vemurafenib47. 
When supersaturated solutions are generated, precipitation is often observed. The 
term precipitation is used in a generic sense to define the formation of a new phase 
without defining the structure of the precipitating material. Precipitation is widely 
regarded as an undesirable event and there has been much exploration of precipitation 
inhibitors.6,18,48 Additives can inhibit precipitation by two main mechanisms, either 
decreasing the supersaturation of the system by increasing the equilibrium solubility, or 
by inhibiting nucleation or growth of the crystalline phase. Although precipitation from a 
solubility enhancing formulation is generally considered unfavorable, recent studies have 
shown that precipitation to an amorphous form results in maintenance of supersaturation, 
while precipitation to a crystalline solid results in a rapid depletion of the 
supersaturation.42 Furthermore, it appears that precipitation is inevitable in some 
instances because there is an upper limit to supersaturation that can be achieved for 
hydrophobic drugs, dictated by the spinodal decomposition point; beyond which phase 
separation is spontaneous and inevitable.  For several compounds, the concentration at 
which spontaneous precipitation occurred has been found to be very close to the 
theoretically estimated amorphous solubility.16 In other words, if the amorphous 
solubility is exceeded, precipitation to an amorphous material, via the process of liquid-






The implications of liquid-liquid phase separation on the subsequent 
crystallization behavior of supersaturated solutions are not well understood. The colloidal 
solutions generated following LLPS are supersaturated and crystallization can 
theoretically occur from either the drug-rich or the solution-rich phase. In studies with 
ritonavir, a slowly crystallizing compound, it was also noted that the crystallization 
kinetics were different depending if the colloidal drug-rich droplets were present or 
absent;16 induction times were shorter in the two phase system. The crystallization 
kinetics of a two phase colloidal solution of ritonavir were also highly dependent on the 
type of additives present with different additives either enhancing or delaying 
crystallization.12  It is apparent that ASDs can generate the very high supersaturations 
necessary for LLPS to occur upon dissolution, and colloidal species have been widely 
reported in the solutions that evolve from these formulations.10,13,49-50 Thus it is clearly 
important to understand the phase behavior of different compounds in highly 
supersaturated solutions and the impact of polymeric additives on the phase behavior.  
Danazol is an interesting compound because the initial precipitate, which is clearly non-
crystalline based on the fluorescence and SHG data shown in Figures 2-6 and 2-13, is 
very short lived in the absence of additives. However, the concentration at which a 
precipitate first forms corresponds closely to the predicted amorphous solubility of 
danazol, and this phase persists for around 5-10 min. It is thus possible to rapidly 
generate the amorphous material in situ and, by noting the concentration at which a 
precipitate first forms, obtain an experimental estimate of the amorphous solubility. In 
contrast, in two studies where amorphous danazol was dissolved, the maximum solution 






crystallization of the sample before dissolution was complete.3,35 Thus, using the 
approach of creating amorphous danazol in situ by rapidly increasing the solution 
concentration, we are able to verify that the experimental amorphous solubility of 
danazol is in excellent agreement with the theoretically estimated value, providing 
additional validation of the thermodynamic approach developed by Murdande et al and 
described above (Equations 2-1 and 2-2).24  
The impact of the polymers on the solution phase behavior of danazol is 
interesting from two perspectives. First, in the presence of the cellulosic polymers, the 
LLPS concentration is somewhat decreased. This is different from the example of 
ritonavir where polymeric additives were not found to change the LLPS 
concentration.12,16 Second, there is a huge increase in induction time for crystallization, in 
particular in the presence of HPMCAS, but also for the other two polymers.  The 
reduction in the concentration where LLPS is observed in the presence of the cellulosic 
polymers suggests that the polymers are mixing with the drug-rich phase. This would be 
expected to lead to a reduction in the activity of the drug in the drug-rich phase, similar to 
the effect that absorbed water has (and discussed in detail by Murdande et al.)24 and thus 
reduce the solute concentration where LLPS occurs. Unfortunately, our attempts to 
quantitate the amount of polymer in the drug-rich phase were not very successful due to 
the low amounts of material present. However, preliminary NMR experiments suggest 
that the drug-rich phase contained around 10-20% polymer when formed in the presence 
of HPMC.  For the PVP samples, the amount of polymer was lower than the detection 
limit of the method (around 10%). These results are consistent with the experimental 






Clearly some polymer is present in the droplet phase, at least at the interface since the 
polymers influence the droplet size evolution as well as the droplet charge, as shown in 
Figure 2-11.  The incorporation of the polymer into the drug-rich phase is expected to 
impact the crystallization kinetics via at least two mechanisms. First, the rate of both 
crystal nucleation and crystal growth increases with increasing supersaturation. If LLPS 
occurs at a lower concentration, then the supersaturation in that system will be lower than 
in the system which has a higher LLPS concentration, which will have a correspondingly 
higher supersaturation. Thus for the HPMC and HPMCAS systems, the supersaturation is 
lower than for the PVP and no polymer systems. The lower supersaturation of the 
cellulosic polymer containing systems would contribute to a slower nucleation rate, since 
the nucleation rate is highly dependent on the extent of supersaturation,51 and this would 
explain the longer experimentally observed induction times. Supersaturation is further 
reduced if the equilibrium crystalline solubility is increased by the presence of the 
polymer, which occurs in particular for HPMC (Table 2-2). However, supersaturation 
alone does not explain the observed data; for example, HPMCAS systems have a longer 
induction time than HPMC, even though HPMC systems have a lower supersaturation.  
Second, the incorporation of the polymers into the drug-rich droplet, and/or association of 
the polymer at the droplet interface are also likely to be important in terms of disrupting 
the nucleation process. This is particularly true in the context of heterogeneous nucleation 
which will be favored at the droplet-aqueous interface. Association of an additive at the 
interface would be expected to modify heterogeneous nucleation kinetics. In a study of 
ritonavir crystallization in two phase systems, it was found that additives could either 






particular, additives with bulky functional groups were found to be effective inhibitors, 
while compounds with long hydrocarbon chains were found to promote nucleation. These 
additives were not found to impact the supersaturation of the system.  
There are considerable analytical challenges to be overcome in order to 
differentiate between LLPS and crystallization, since the concentrations involved are so 
low. These difficulties are exacerbated by the evolving properties of the colloidal system 
with time which impacts the UV data in particular, as highlighted in Figure 2-13. Here it 
can be seen that there is a substantial change in the signal both in a region of the spectrum 
where both absorption and scattering occurs, and in a spectral region where the main 
effect is scattering. Both absorbance and scattering are strongly dependent on the size of 
the disperse species, and since this changes with time for the colloidal danazol solutions 
(as shown by the DLS data in Fig 2-11), the UV spectroscopic signals also change. Thus 
at an absorbing wavelength, the colloidal system both scatters and absorbs light, making 
quantitative determination of solution concentration extremely challenging.52 To further 
complicate the analysis, the polymers impact the size evolution of the colloidal species, 
and hence the observed UV signals. Therefore it is challenging to fully characterize the 
time dependent phase behavior of the danazol solutions relying solely on the UV data, 
necessitating the implementation of orthogonal techniques. Indeed, it is quite likely that 
the initial phase transformation to a disordered precipitate would be missed unless being 
specifically sought, in particular when non-specific analytical methods relying on 
changes in solution turbidity are used.  We have found that the use of an environmentally 
sensitive fluorescence probe appears to be a good complementary method to the UV 






disordered colloidal phase or to a crystalline phase. Likewise, SHG analysis, which has 
been shown to be able to detect extremely low amounts of crystalline material in solid 
samples,33-34,52 is a valuable analytical technique to confirm both the initially non-
crystalline nature of the turbid danazol solutions, and the induction time for 
crystallization.   
  
2.7 Conclusions 
Aqueous solutions of danazol were found to undergo liquid-liquid phase 
separation when the solution concentration exceeded the amorphous solubility, leading to 
a two phase colloidal solution consisting of a disordered drug-rich danazol phase, and a 
drug-lean aqueous phase. This system was short lived, and crystallization occurred within 
a few minutes, reducing the solution concentration. The crystallization behavior of the 
danazol solution could be modified by the addition of small amounts of polymers which 
dramatically extended the lifetime of the supersaturated solution.  
However, some polymers reduced the maximum extent of supersaturation that 
could be achieved, both by increasing the equilibrium crystal solubility and by reducing 
the amorphous solubility.  Thus the polymeric additives have both favorable and 
unfavorable effects on solution phase behavior and kinetics. Understanding the complex 
phase behavior of supersaturated aqueous solutions ultimately will provide greater insight 







Table 2-1. Select Physical Properties of Danazol 
Property Value 
Molecular Weight 337.5 g/mol 
Melting Temperature  225.4± 0.4°C 
Tg 78.7±0.3°C 
Aqueous Solubility at 25°C 0.9 ± 0.2 µg/mL 
Heat of Fusion 28.9 ± 0.3 kJ/mol 
Moisture Sorption Correction Factor  (exp [-I(a2)]) 0.935  
Amorphous:Crystalline Solubility ratio at 25°C* 19.6 
*Calculated using equation 1. 
 
 
Table 2-2. Crystalline and estimated amorphous solubility of danazol in the presence and 
absence of polymers at 25°C, n=3, errors equal one standard deviation. Amorphous 
solubility values are estimated from the crystalline solubility in a given medium and an 








Danazol  0.9 ± 0.2 16 ± 4 
Danazol and PVP  1.3 ± 0.4 25 ± 8 
Danazol and HPMC  2.2 ± 0.5 43 ± 9 
Danazol and HPMC-AS  1.1 ± 0.4 22 ± 8 
















via UV Extinction 
(μg/mL) 
 
Danazol  16 13  13 
Danazol and PVP 25 11  11 
Danazol and HPMC 43 9  8 
Danazol and 
HPMCAS 






















10 10 ± 6 N/A N/A 
15 6 ± 1 7 ± 1 10 ± 2 
20 7 ± 3 10 ± 7 9 ± 3 
Danazol:PVP 
10 162 ± 25 N/A N/A 
15 112 ± 21 153 ± 37 120 ± 42 
20 88 ± 18 107 ± 15 102 ± 17 
Danazol:HPMC 
10 285 ± 92 N/A N/A 
15 172 ± 4 111 ± 14 195 ± 21 
20 163 ± 15 177 ± 21 167 ± 38 
Danazol:HPMCAS 
10 516 ± 167 N/A N/A 
15 365 ± 148 315 ± 35 370 ± 92 



































































Danazol Conc (UV Absorbance) (ug/mL)
 
Figure 2-2. UV extinction intensity at 350 nm as a function of danazol concentration 
showing an increase in extinction at concentrations >10µg/mL for solutions containing 
































Figure 2-3.The pyrene emission spectra in different solvents (top) and the resulting peak 
ratios between two characteristic peaks, peak I1 and peak I3 (bottom). 






































Figure 2-4. Pyrene I1/I3 ratios as a function of danazol (DNZ) concentration in the 
presence and absence of 10 µg/mL polymer. 
 
 


































































Figure 2-6. Enhanced Focus SHG images of danazol supersaturated systems. Bright spots 
indicate SHG signal and the area visualized is 2 mm by 2 mm.  Top: 10 µg/mL danazol 
solution at various time points. This concentration is below the expected LLPS 
concentration. From left to right; 1 minute, 5 minutes, 12 minutes after generation of 
supersaturation. Bottom: 50 µg/mL danazol solution at various time points. This 
concentration is above the expected LLPS concentration. From left to right; 2 minutes, 5 












Figure 2-7. UV absorbance apparent concentration (left axis, solid symbols) and pyrene 
emission spectral ratios (right axis, open symbols) for a supersaturated solution of 






































































Figure 2-8. UV absorbance apparent concentration (left axis, solid symbols) and pyrene 
emission spectral ratios (right axis, open symbols) for a supersaturated solution of 
danazol (20 µg/mL) containing 0.01% w/v PVP. 






































































Figure 2-9. UV absorbance apparent concentration (left axis, solid symbols) and pyrene 
emission spectral ratios (right axis, open symbols) for a supersaturated solution of 
danazol (20 µg/mL) containing 0.01% w/v HPMC 































































Figure 2-10. UV absorbance apparent concentration (left axis, solid symbols) and pyrene 
emission spectral ratios (right axis, open symbols) for a supersaturated solution of 
danazol (20 µg/mL) containing 0.01% w/v HPMCAS. 




























































































Figure 2-11. (A) Dynamic Light Scattering Data; Z-Average particle diameter of danazol 
systems with and without polymers as a function of time. (B) Zeta potential values for 
danazol systems at a concentration above the LLPS concentration with and without 
polymers. 
 




















































































































































































Figure 2-12. Crystallization induction times of danazol solutions.  All concentrations 








Figure 2-13. Overlay of UV, Fluorescence, and SHG data for a single supersaturated 
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1) Dahan, A.; Hoffman, A. Rationalizing the selection of oral lipid based drug 
delivery systems by an in vitro dynamic lipolysis model for improved oral 
bioavailability of poorly water soluble drugs. Journal of Controlled Release 2008, 
129 (1), 1-10. 
2) Miller, J. M.; Beig, A.; Carr, R. A.; Spence, J. K.; Dahan, A. A Win-Win Solution 
in Oral Delivery of Lipophilic Drugs: Supersaturation via Amorphous Solid 
Dispersions Increases Apparent Solubility without Sacrifice of Intestinal 
Membrane. Molecular Pharmaceutics 2012, 9, 2009-2016. 
3) Murdande, S. B.; Pikal, M. J.; Shanker, R. M.; Bogner, R. H. Solubililty 
Advantage of Amorphous Pharmaceuticals: II. Application of Quantitative 
Thermodynamic Relationships for Prediction of Solubility Enhancement in 
Structurally Diverse Insoluble Pharmaceuticals. Pharmaceutical Research 2012, 
27, 2704-2714. 
4) Murdande, S. B.; Pikal, M. J.; Shanker, R. M.; Bogner, R. H. Solubility 
Advantage of Amorphous Pharmaceuticals, Part 3: Is Maximum Solubility 
Adavntage Experimentally Attainable and Sustainable? Journal of Pharmaceutical 
Sciences 2011, 100 (10). 
5) Hancock, B. C.; Parks, M. What is the True Solubility Advantage for Amorphous 







6) Hancock, B. C.; Zografi, G. Characteristics and Significane of the Amorphous 
State in Pharmaceutical Systems. Journal of Pharmaceutical Sciences 1997, 86 
(1), 1-12. 
7) Marsac, P. J.; Konno, H.; Taylor, L. S. A comparison of the physical stability of 
amorphous felodipine and nifedipine systems. Pharm. Res. 2006, 23, 2306-2316. 
8) Alonzo, D. E.; G.Zhang; Zhou, D.; Gao, Y.; Taylor, L. S. Understanding the 
Behavior of Amorphous Pharmaceutical Systems during Dissolution. 
Pharmaceutical Research 2010, 27 (4), 608-618. 
9) Alonzo, D. E.; Gao, Y.; Zhou, D.; Mo, H.; Zhang, G.; Taylor, L. S. Dissolution 
and Precipitation Behavior of Amorphous Solid Dispersions. Journal of Pharm. 
Sci. 2011, 100 (8), 3316-3331. 
10) Qian, F.; Wang, J.; Hartly, R.; Tao, J.; Haddadin, R.; Mathias, N.; Hussain, M. 
Solution Behavior of PVP-VA and HPMC-AS-Based Amorphous Solid 
Dispersions and Their Bioavailability Implications. Pharamceutical Research 
2012, 29, 2766-2776. 
11) Ilevbare, G. A.; Liu, H.; Pereira, J.; Edgar, K. J.; Taylor, L. S. Influence of 
Additives on the Properties of Nanodroplets Formed in HIghly Supersaturated 
Aqueous Solutions of Ritonovir. Molecular Pharmaceutics 2013, 10, 3392-3403. 
12) Aisha, A. F. A.; Ismail, Z.; Abu-slah, K. M.; Majid, A. M. S. A. Solid Dispersions 
of alpha-Mangostin Improve Its Aqueous Solubility Through Self-Assembly of 







13) Augustijns, P.; Brewster, M. E. Supersaturating Drug Delivery Systems: Fast is 
Not Necessarily Good Enough. Journal of Pharmaceutical Sciences 2012, 101 (1), 
7-9. 
14) Newman, A.; Knipp, G.; Zografi, G. Assessing the Performance of Amorphous 
Solid Dispersions. Journal of Pharmaceutical Sciences 2012, 101 (4), 1355-1377. 
15) Hoffman, J. D. Thermodynamic driving force in nucleation and growth processes. 
J. Chem. Phys. 1958, 29, 1192-1193. 
16) Ilevbare, G. A.; Taylor, L. S. Liquid-Liquid Phase Spearation in Highly 
Supersaturated Aqueous Solutions of Poorly Water-Soluble Drugs: Implications 
for Solubility Enhancing Formulations. Crystal Growth and Design 2013, 13, 
1497-1509. 
17) Feng, B. Y.; Shelat, A.; Doman, T. N.; Guy, R. K.; Shoichet, B. K. High-
throughput assays for promiscuous inhibitors. Nature Chemical Biology 2005, 1 
(3), 146-148. 
18) Warren, D. B.; Benameur, H.; Porter, C. J. H.; Pouton, C. W. Using polymeric 
precipitation inhibitors to improve the absorption of poorly-water soluble drugs: 
A mechanistic basis for utility. Journal of Drug Targeting 2010, 18 (10), 704-731. 
19) Derdour, L. A method to crystallize substances that oil out. Chem. Eng. Res. Des. 







20) Lafferrere, L.; Hoff, C.; Veesler, S. Study of liquid-liquid demixing from drug 
solution. Journal of Crystal Growth 2004, 269, 550-557. 
21) Veesler, S.; Lafferrere, L.; Garcia, E.; Hoff, C. Phase Transitions in 
Supersaturated Drug Solutions. Organic Process Research and Development. 
2003, 7, 983-989 
22) Tung, H. H.; Paul, E. L.; Midler, M.; McCauley, J. A. Critical Issues in 
Crystallization Practice. in Crystallization of Organic Compounds: An Industrial 
Prospective. John Wiley $ Sons, Inc., Hoboken, NJ, USA. 2008; Ch.5. 
23) Maeda, K.; Aoyama, Y.; Fukui, K.; Hirota, S. Novel Phenomenon of 
cystallization and emulsification of hydrophobic solute in aqueous solution. J. 
Colloid Interface Sci. 2001, 234, 217-222. 
24) Murdande, S. B.; Pikal, M. J.; Shanker, R. M.; Bogner, R. H. Solubility 
Advantage of Amorphous Pharmaceuticals: I. A Thermodynamic Analysis. 
Journal of Pharamceutical Sciences 2010, 99 (3), 1254-1264. 
25) Baird, J. A.; Eerdenburgh, B. V.; Taylor, L. S. A classification system to assess 
the crystallization tendency of organic molecules form undercooled melts. J. 
Pharm. Sci. 2010, 99, 3787-3806. 
26) Qian, K. K.; Wuster, D. E.; Bogner, R. H. Spontaneous Crystalline-to-Amorphous 
Phase Transformation of Organic or Medicinal Compounds in the Presence of 








27) Thomas, J. K.; Kalyanasundaram, K. Environmental Effects on Vibronic Band 
Intensities in Pyrene Monomer Fluorescence and Their Application in Studies of 
Micellar Systems. Journal of American Chemical Society 1977, 99 (7), 2039-
2044. 
28) Kabanov, A. V.; Nazarova, I. R.; Astafieva, I. V.; Batrakova, E. V.; Alakhov, V. 
Y.; Yaroslavov, A. A.; Kabanov, V. A. Micelle Formation and Solubilization of 
Fluorescent Probes in Poly(oxyethylene-b-oxypropylene-b-oxyethylene) 
Solutions. Macromolecules 1995, 28, 2303-2314. 
29) Yekta, A.; Dunhamel, J.; Brochard, P.; Adiwidjaja, H.; Winnik, M. A. A 
Fluorescent Probe Study of Micelle-like Cluster Formation in Aqueous Solutions 
of Hydrophobicially Modified Poly(ethylene oxide). Macromolecules 1993, 26, 
1829-1836. 
30) Galla, H.; Sackmann, E. Lateral Diffusion in the Hydrophobic Region of 
Membranes: Use of Pyrene Excimers as Optical Probes. Biochimica et 
Biophysica Acta 1974, 339, 103-115. 
31) Trusova, V.; Yudintsev, A.; Limanskaya, L.; Gorbenko, G.; Deligeorgiev, T. 
Europium Coordination Complexes as Potential Anticancer Drugs: Their 
Partitioning and Permeation Into Lipid Bilayers as Revealed by Pyrene 
Fluorescence Quenching. Journal of Fluorescence 2013, 23, 193-202. 
32) Haupert, D. J.; Simpson, G. J. Chirality in nonlinear optics. Annual Review of 







33) Wanapun, D.; Kestur, U. S.; Kissick, D. J.; Simpson, G. J.; Taylor, L. S. Selective 
Detection and Quantitation of Organic Molecule Crystallization by Second 
Harmonic Generation Microscopy. Analytical Chemistry 2010, 82, 5425-5432. 
34) Kissick, D. J.; Wanapun, D.; Simpson, G. J. Second Order Nonlinear Optical 
Imaging of Chiral Crsytals (SONICC). Annual Review of Analytical Chemistry 
2011, 4, 419-437. 
35) Ozaki, S.; Kushida, I.; Yamashita, T.; Hasebe, T.; Shirai, O.; Kano, K. Evaluation 
of Drug Supersaturation by Thermodynamic and Kinetic Approaches for the 
Prediction of Oral Absorbability in Amorphous Pharmaceuticals. Journal of 
Pharmaceutical Sciences 2012, 101 (11), 4220-4230. 
36) Raina, S. A.; Zhang, G. G. Z.; Alonzo, D. E.; Wu, J.; Zhu, D.; Catron, N. D.; Gao, 
Y.; Taylor, L. S. Enhancements and Limits in Drug Membrane Transport Using 
Supersaturated Solutions of Poorly Water-Soluble Drugs. Journal of 
Pharmaceutical Sciences 2013. 
37) Eerdenbrugh, B. V.; Alonzo, D. E.; Taylor, L. S. Influence of Particle Size on 
Ultraviolet Spectrum of Particulate-Containing Solutions: Implications for In-Situ 
Concentration Monitoring Using UV/Vis Fiber-Optic Probes. Pharmceutical 
Research 2011, 28, 1643-1652. 
38) Hiemenz, P. C.; Rajagopalan, R. Principles of Colloid and Surface Chemistry; 







39) Wang, J., Somasundaran, P. Mechanisms of ethyl(hydroxyethyl) cellulose–solid 
interaction: Influence of hydrophobic modification. Journal of Colloid and 
Interface Science, 2006, 293(2), 322-32. 
40) Rodriguez-Hornedo, N. Murphy, D.  Surfactant-Facilitated Crystallization of 
Dihyrdate Carbamazepine during Dissolution of Anhydrous Polymorph.  Journal 
of Pharmaceutical Sciences, 2004, 93(2), 449-460. 
41) Yalkowsky, S. H. Solubility and solubilization in aqueous media; Oxford 
University Press: Washington DC, 1999. 
42) Hsieh, Y.-L.; Ilevbare, G. A.; Van Eerdenbrugh, B.; Sanchez-Feliz, M. V.; 
Taylor, L. S. pH-Induced Precipiation Behavior of Weakly Basic Compounds: 
Determination of Extent and Duration of Supersaturation Using Potentiometric 
Titration and Correlation to Solid-State Properties. Pharmaceutical Research 
2012. 
43) Anby, M. U.; Williams, H. D.; McIntosh, M.; Benameur, H.; Edwards, G. A.; 
Pouton, C. W.; Porter, C. J. H. Lipid Digestion as a Trigger for Supersaturation: 
Evaluation of the Impact of Supersaturation Stabilization on the in Vitro and in 
Vivo Performace of Self-Emulsifying Drug Delivery Systems. Molecular 
Pharmaceutics 2012, 9, 2063-2079. 
44) Davis, A. F.; Hadgraft, J. Effect of supersaturation on membrane transport: 1. 








45) Pellett, M. A.; Davis, A. F.; Hadgraft, J. Effect of supersaturation on membrane 
transport: 2. Piroxicam. International Journal of Pharmaceutics 1994, 111, 1-6. 
46) Kwong, A. D.; Kauffman, R. S.; Hurter, P.; Mueller, P. Discovery and 
development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 
chronic hepatitus C virus. Nature Biotechnology 2011, 29 (11), 993-1003. 
47) Shah, N.; Malick, W.; et, a. Improved human bioavailability of vemurafenib, a 
practically insoluble drug, using an amorphous polymer-stabilized solid 
dispersions prepared by a solvent-controlled coprecipiation process. Journal of 
Pharmaceutical Sciences 2013, 102 (3), 967-981. 
48) Brouwers, J.; Brewster, M. E.; Augustijns, P. Supersaturating Drug Delivery 
Systems: The Answer to Solubility-Limited Oral Bioavailability. Journal of 
Pharmaceutical Sciences 2009, 98 (8), 2549-2572. 
49) Law, S.; Schmitt, E. A.; Marsh, K. C.; Everitt, E. A.; Wang, W.; Fort, J. J.; Krill, 
S. L.; Qiu, Y. Ritonavir-PEG 8000 amorphous solid dispersions: In vitro and in 
vivo evaluations. Journal of Pharmaceutical Sciences 2004, 93 (3), 563-570. 
50) Frank, K. J.; Westedt, U.; Rosenblatt, K. M.; Holig, P.; Rosenberg, J.; Magerlein, 
M.; Fricker, G.; Brandl, M. The amorphous solid dispersion of the poorly soluble 
ABT-102 forms nano/microparticulate structures in aqueous medium: impact on 
solubility. International Journal of Nanomedicine 2012, 7, 5757-5768. 







52) Kestur, U. S.; Wanapun, D.; Toth, S. J.; Wegiel, L. A.; Simpson, G. J.; Taylor, L. 
S. Nonlinear Optical Imaging for Sensitive Detection of Crystals in Bulk 








CHAPTER 3. CHARACTERIZATION OF HIGHLY SUPERSATURATED 
DANAZOL SOLUTIONS – IMPACT OF POLYMERS ON MEMBRANE 
TRANSPORT AND PHASE TRANSITIONS 
3.1 Abstract 
Excipients are essential for solubility enhancing formulations. Hence it is 
important to understand how additives impact key solution properties, particularly when 
supersaturated solutions are generated by dissolution of the solubility enhancing 
formulation. Herein, the impact of different concentrations of dissolved polymers on the 
thermodynamic and kinetic properties of supersaturated solutions of danazol were 
investigated. A variety of experimental techniques was used, including nanoparticle 
tracking analysis, fluorescence and ultraviolet spectroscopy and flux measurements. 
Neither the crystalline nor amorphous solubility of danazol was impacted by common 
amorphous solid dispersion polymers, polyvinylpyrrolidone, hydroxypropylmethyl 
cellulose (HPMC) or HPMC-acetate succinate. Consequently, the maximum membrane 
transport rate was limited only by the amorphous solubility, and not by the presence of 
the polymers. The polymers were able to inhibit crystallization to some extent at 
concentrations as low as 1 μg/mL, with the maximum effectiveness being reached at 10 
μg/mL.  Aqueous danazol solutions formed a drug-rich phase with a mean size of 250nm 
when the concentration exceeded the amorphous solubility, and the polymers modified 







solutions is thus complex and the kinetics of phase transformations can be 
substantially modified by polymeric additives present at low concentrations. However, 
fortunately, these additives to not appear to impact the bulk thermodynamic properties of 
the solution, thus enabling supersaturated solutions, which provide enhanced membrane 
transport relative to saturated solutions to be generated. 
 
3.2 Introduction 
 Increasingly, potential drug candidates emerging from discovery programs have 
complex molecular structures and properties.  This in turn has led to an increase in the 
prevalence of drugs with sub-optimal aqueous solubility.1  It is estimated that 75% of 
pipeline drugs can be considered to have low aqueous solubility.2  Consequently, the 
development and understanding of solubility enhancing techniques are pivotal to creating 
effective formulations for these difficult to deliver compounds.  Amorphous solid 
dispersions (ASD) are one such formulation approach which has been shown to increase 
the effective solubility3-6 and bioavailability of poorly-soluble drugs.7-9  Upon dissolution 
of an ASD, the solutions generated are typically supersaturated with respect to the 
crystalline form solubility, and therefore have a thermodynamic driving force for 
crystallization.  Recently, it has been shown that ASDs can undergo a second phase 
separation phenomenon in these highly supersaturated solutions as a precursor to 
crystallization, known as liquid-liquid phase separation (LLPS).9-12  The resulting phase 
transformation creates a colloidal dispersion, with one phase consisting of non-crystalline 
water-saturated drug-rich droplets/particles dispersed within the second phase which 







phases are supersaturated and hence crystallization can subsequently occur.  The 
mechanisms and formulation factors impacting the formation of this drug-rich phase are 
not well understood, although it has been suggested that its presence could be important 
in influencing the bioavailability and absorption of certain drugs.9, 13 It has been 
demonstrated that LLPS of poorly water soluble drugs in aqueous media is a widespread 
phenomenon that can occur following pH change, dissolution of ASDs, dilution of 
organic solvent solutions, and by cooling of a supersaturated solution.12, 14-16  
Furthermore, phase separation to a colloidal drug-rich phase during high-throughput 
screening assays for new drug targets is also commonly observed.17-19  
 In order to study and understand the properties of the drug-rich phase produced by 
LLPS in supersaturated solutions, it is necessary to stabilize the system against both 
coalescence and crystallization, and to understand the impact of additives on these 
processes.  For example, surfactants and polymers have been found to influence both 
coalescence and crystallization kinetics.11, 20, 21  Furthermore, it has also been noted that 
excipients such as surfactants can impact both crystal solubility and the concentration at 
which LLPS is observed,22 and therefore can also change the thermodynamic properties 
of the solution.   Both the thermodynamic properties of the supersaturated solution, as 
well as the kinetics of phase transformations are important considerations when designing 
and evaluating solubility enhancing formulations. 
 In this study, the generation, thermodynamics and stability of solutions containing 
drug-rich droplets of the model compound, danazol, were studied, in the presence and 
absence of three polymers commonly used in amorphous solid dispersion formulations, in 







evaluated were polyvinyl pyrrolidone (PVP), hydroxypropylmethyl cellulose (HPMC), 
and HPMC acetate succinate (HPMC-AS).  Multiple analytical techniques were used to 
evaluate the complex phase behavior and to delineate crystalline precipitation, 
amorphous precipitation (in the form of drug-rich droplets), and free-drug solution 
concentrations.  The major goals of this work were to: (1) investigate the impact of 
polymers on the thermodynamic properties of danazol solutions through measurement of 
crystalline solubility, LLPS onset concentrations, and mass transport rate across a 
membrane (flux measurements) and, (2) investigate the impact of polymers on the 
kinetics of danazol phase transformations using crystallization induction time 
experiments and characterization of the droplets as a function of time. 
 
3.3 Materials 
Danazol was purchased from Euroasia Chemicals (Euroasia Ltd., China), pyrene, 
and polyvinyl pyrrolidone (PVP) K29/32 were purchased from Sigma-Aldrich (St. Louis, 
MO), while hydroxypropylmethyl cellulose (HPMC) 606 grade and 
hydroxypropylmethyl cellulose acetate succinate (HPMC-AS) MF grade were supplied 
by Shin-Etsu (Shin-Etsu Chemical Co., Ltd., Tokyo, Japan).  Methanol, acetonitrile, and 
dichloromethane were purchased from Macron Chemicals (Phillipsburg, NJ).  The 
aqueous medium used in all experiments was 10 mM pH 6.8 phosphate buffer.  Pyrene 








3.4.1 Solubility Measurements. 
The aqueous solubility of danazol was determined using high performance liquid 
chromatography (HPLC).  An excess amount of crystalline danazol was added to 50 mL 
of buffer.  The solutions were agitated and allowed to equilibrate for 48 hours at 25°C.  
The supernatant was then separated from the excess solid in solution via 
ultracentrifugation for 15 min at 40,000 rpm in an Optima L-100 XP ultracentrifuge 
equipped with Swinging Bucket Rotor SW 41 Ti (Beckman Coulter, Inc., Brea, CA).  
The supernatant was diluted and the solution concentration of danazol was determined 
using an Agilent HP 1260 HPLC system (Agilient Technologies, Santa Clara, CA).  A 
ZORBAX Eclipse Plus C18 column (4.6 mm x 100 mm, 5 μm) was used for 
chromatographic separation and danazol was detected via ultraviolet (UV) absorbance at 
288 nm.  A volume of 50 μL was injected into a mobile phase consisting of water, 
acetonitrile, and methanol (40:30:30 by volume) at a rate of 1.0 mL/min.  The total 
analytical time was 15 min.  Standards (0.1 – 100 μg/mL) were prepared in methanol, and 
all samples were analyzed in triplicate.  The standards exhibited good linearity (r2 > 0.999) 
over the concentration range.  The equilibrium solubility of danazol in solutions 
containing 1, 10, 100, 1000 μg/mL of PVP, HPMC, and HPMC-AS was also determined 
using this method. 
The theoretical amorphous solubility was calculated via the method derived and 
outlined by Sousa et al.23  The melting temperature, heat of fusion, glass transition 
temperature, and heat capacity data were determined using differential scanning 







calorimeter (TA Instruments, Newcastle, Delaware).  Modification of the solute activity 
by sorbed moisture was determined from the moisture sorption profile at 25 °C using a 
TA Q5000 dynamic vapor sorption analyzer (TA Instruments, New Castle, DE) as 
described previously.6, 20 
 
3.4.2 LLPS Concentration Determination. 
The concentration at which LLPS was observed for danazol was determined using 
the following methods; UV extinction and fluorescent probe methods as described 
previously,20 assay via ultra-centrifugation and HPLC analysis of the supernatant 
concentration, and nanoparticle tracking analysis (NTA). The samples analyzed by UV 
extinction spectroscopy (SI-Photonics UV spectrometer, Tucson, AZ, with a 1 cm path 
length dip probe, extinction monitored at 450 nm) consisted of 50 mL of buffer stirred at 
300 rpm and maintained at 25°C using a jacketed vessel fed by a Julabo MA water bath 
(Seelbach, Baden-Wurttemberg, Germany).   The aqueous solution concentration of 
danazol was continually increased by using a syringe pump to add small volumes of a 
concentrated stock solution of danazol dissolved in methanol (5 mg/mL). Polymers (1-
1000 μg/mL) were pre-dissolved in the aqueous buffer.  Danazol was added to the 
aqueous buffered solutions at a rate of 1 μg/mL/min.  When no polymers were present in 
the buffer, an aliquot of the danazol stock solution was added to create a starting solution 
concentration of 5 μg/mL of danazol, in order to reach the concentration at which LLPS 
occurred prior to crystallization using the same subsequent rate of addition (1 







Pyrene was used as an environmentally sensitive fluorescent probe to evaluate the 
evolution of different environments in the solution with different danazol concentrations. 
Peaks I and III of the emission spectra were analyzed to determine if LLPS had occurred 
within the solution.  The expectation is that formation of a drug-rich phase will lead to 
mixing of pyrene with this phase, and hence the emission spectrum will reflect a more 
hydrophobic environment. The samples analyzed consisted of 50 mL of buffer with a 
pyrene concentration of 2 μM.  Polymer was pre-dissolved in the buffer (1-1000 μg/mL) 
and danazol concentrations from 0-20 μg/mL were analyzed in 0.5 μg/mL increments.  
Samples were stirred at 300 rpm and maintained at 25°C using a jacketed vessel fed by a 
Julabo MA water bath (Seelbach, Baden-Wurttemberg, Germany).  Solutions were 
prepared via the solvent shift method by adding small aliquots of a methanolic stock 
solution of danazol (5 mg/mL) to the aqueous solutions.  Samples were then withdrawn 
after each subsequent addition of the stock solution and analyzed using a Shimadzu RF-
5301pc Spectrofluorometer (Kyoto, Japan).  The excitation wavelength was 332 nm, and 
the emission spectrum was collected at 0.2 nm intervals from 350-420 nm.  The 
excitation slit width was 15 cm, while the emission slit width was 1.5 cm.   
The concentration in the continuous phase was determined using 
ultracentrifugation to pellet the drug-rich phase, followed by HPLC analysis of the 
supernatant.  Samples consisted of 10 mL of buffer with varying amounts of pre-
dissolved polymer.  An initial solution concentration of 15 μg/mL of danazol was added 
via small aliquots of a methanolic stock solution of danazol.  The samples then 
underwent ultracentrifugation using an Optima L-100 XP ultracentrifuge (Beckman 







were centrifuged at 35,000 rpm for either 30 minutes (polymer concentration < 100 
μg/mL) or 60 minutes (polymer concentration ≥ 100 μg/mL) at 25°C.  The resulting 
supernatant of each sample was diluted at a ratio of 1:1 with a mobile phase of 
water:acetonitrile:methanol (40:30:30 by volume).  HPLC analysis was then performed 
using the method described previously.  The ultracentrifuge method provides the 
concentration of the drug in the continuous aqueous phase once phase separation is 
complete and represents one of the binodal points.25  
NTA was used to determine the concentration at which scattering species could be 
observed using this methodology.  Samples consisted of 10 mL of buffer at 25°C with 
varying amounts of pre-dissolved polymer.  Danazol was added using small aliquots of 
the methanolic stock (5 mg/mL) to create varying final danazol concentrations (0-15 
μg/mL).  1 mL samples of each solution were withdrawn and analyzed using a NanoSight 
LM10 from Malvern Instruments (Westborough, MA) equipped with nanoparticle 
tracking analysis software.  The LM10 was equipped with a 75 mW green (532 nm) laser 
and a temperature controlled flow through cell stage.  Samples were analyzed for 60 
seconds and camera settings were held constant throughout all experiments (screen gain = 
2.0, camera level=7).  The detection threshold upon analysis was also held constant (20) 
for all experiments along with camera gain (5.0).  The onset of LLPS was determined by 
analyzing the observed light scattering particle concentration as a function of added 








3.4.3 Flux Measurements. 
A side-by-side diffusion cell apparatus (PermaGear, Inc. Hellertown, 
Pennsylvania) was used to determine the flux of danazol solutions as a function of added 
concentration, in the presence and absence of different amounts of dissolved polymer.  A 
regenerated cellulose membrane with a molecular weight cut off (MWCO) of 6-8 KDa 
was used to separate the receiver and donor chambers.  Each chamber had a maximum 
capacity of 34 mL and was filled with buffer with pre-dissolved polymer (1-1000 μg/mL) 
in both chambers.  The orifice surface area was 7.065 cm2.  The temperature for all 
experiments was maintained by a recirculating water bath at 25°C.  Supersaturation was 
generated by adding aliquots of a methanolic stock solution of danazol (5 mg/mL) to the 
donor compartment.   
 A UV dip probe (2 cm path length) connected to a SI-Photonics UV spectrometer 
was used to determine the apparent drug concentration in the solution for the receiver 
chamber by monitoring the absorption peak at 288 nm as a function of time.  
Concentration versus time plots were generated for the receiver chamber and the slope of 
the line was estimated using linear regression.  The flux across a membrane can be 
estimated from the slope of the concentration versus time plots, assuming sink conditions 
in the receiver chamber and constant concentration in the donor chamber.25  The flux can 















The flux (J) is determined from the change in mass per unit time (dM/dt).  This in turn is 
dependent on the diffusion coefficient (D), the membrane cross-sectional area (S), the 
solute thermodynamic activity (a), the activity coefficient of the solute in the membrane 
(γm), and the thickness of the membrane (h).  S, D, γm , h are constants using the 
experimental setup described above.  The activity of the drug is given by the following 
equation: 
𝑎 = 𝐶𝛾 
Equation 3-2 
 The activity (a) is determined by the activity coefficient (γ) and the concentration 
(C).  Thus, the flux as determined from the slope of M versus t, is directly proportional to 
the activity of the drug in solution.  Flux data can be therefore used to assess the free-
drug solution concentration of danazol in the donor chamber and determine if polymers 
impact that danazol activity. 
 
3.4.4 Induction Time Experiments. 
The crystallization induction time was determined by UV spectroscopy as 
described in previously.20, 26  Samples consisted of 50 mL of buffer containing pre-
dissolved polymer (1-1000 μg/mL).  An initial danazol concentration of 15 μg/mL was 
created via addition of a small aliquot of a methanolic stock solution of danazol (5 
mg/mL).  The apparent UV concentrations were measured via absorbance at 288 nm and 
the induction times were determined as the time where an abrupt and sustained decrease 







3.4.5 Characterization of the Drug-Rich Droplets formed via LLPS. 
The size and zeta-potential of the drug-rich colloidal droplets formed during 
LLPS were analyzed using dynamic light scattering (DLS).  Each sample consisted of 10 
mL of buffer with pre-dissolved polymer (1-1000 μg/mL).  The solution was stirred (200 
rpm) and the temperature was held constant at 25°C by placing a scintillation vial inside a 
jacketed vessel connected to a water circulator.  Supersaturated solutions of danazol were 
prepared as described above.  0.5 mL of each solution was withdrawn and analyzed using 
a Nano-Zetasizer (Nano-ZS) from Malvern Instruments (Westborough, MA) equipped 
with dispersion technology software.  A backscatter detector was used, and the scattered 
light was detected at an angle of 173°.  Particle size analysis data were obtained using 12 
mm square polystyrene disposable cuvettes, and zeta potential data were obtained using 
disposable capillary cells.   
The size of the drug-rich droplets was also analyzed using nanoparticle tracking 
analysis (NTA).  Solution samples were prepared as for the for DLS analysis and were 
analyzed using the same NTA parameters described above.  Particle size distributions and 
mean particle size was obtained for all systems studied. 
 
3.5 Results 
3.5.1 Danazol Crystalline Solubility 
The impact of polymers, present at different concentrations, on the solubility of 
crystalline danazol is summarized in Table 3-1. It is apparent that relatively minor 
increases in solution concentration are observed even for the highest polymer 







the amorphous solubility, and a value of 7.8 μg/mL was obtained.  This is lower than the 
previously reported estimated value of 16 μg/mL 20  This can be rationalized by the more 
rigorous calculation method used in the current study. Use of heat capacity data has been 
found to result in predictions of the amorphous solubility more in accordance with 
experimental values.23 
The concentration where LLPS occurs has been found to correlate with the 
amorphous solubility for several compounds.12, 20, 23, 25  Methods previously used for 
determining the onset concentration at which LLPS occurs involve measuring a change in 
the solution properties as the concentration of drug is continually increased. These 
methods have included UV extinction, where the formation of a new phase leads to 
scattering at a non-absorbing wavelength, and using environmentally sensitive 
fluorescence probes that mix with the newly formed drug-rich phase, and then show a 
change in emission spectrum (i.e. they register a more hydrophobic environment) relative 
to when dissolved in a single phase aqueous solution.11, 20, 25, 27  Herein, we have explored 
two additional methods, ultracentrifugation to separate the two phase and determine the 
concentration of the supernatant, and nanoparticle tracking analysis to directly detect at 
what concentration the drug-rich droplets can be detected.   
Nanoparticle tracking analysis tracks and analyzes individual particles/droplets 
within a dilute solution.  NTA was used to analyze different concentrations of danazol for 
the presence of scattering centers beyond the background noise.  Figures 3-1(a-c) show 
frames captured from video whereby the light scattered from individual droplets/particles 
is tracked as a function of time. Figure 3-1(a) shows that at a low concentration of 3 







centers while increasing the concentration to 11 μg/mL shows an increase in the number 
of droplets present in solution.   
The images were processed to determine the particle concentration as a function 
of danazol concentration, and data is summarized in Figure 3-2. Here is can be clearly 
seen that, for danazol solutions in buffer, the particle count is very low at concentrations 
up to 8 μg/mL, and increases steeply at higher concentrations.  
Results obtained with the various techniques for danazol solutions in the presence 
and absence of polymers are summarized in Table 3-2. In general, it can be seen that 
there is good agreement between the various techniques. LLPS is observed at 
concentrations of approximately 7-9 μg/mL danazol and no trend is discernable with 
polymer type or concentration.  If the polymers are substantially incorporated into the 
danazol drug-rich phase and thus reduce the thermodynamic activity of danazol in the 
system, it would be anticipated that the concentration where LLPS is observed would be 
reduced. This does not appear to be the case for these systems, but in order to confirm 
that the activity of the drug is unchanged in the presence of polymers, flux measurements 
were conducted.   
 
3.5.2 Flux Measurements 
The relationship between flux and added danazol concentration was determined for 
danazol in the absence of a polymer, and results are summarized in Figure 3-3. The flux 
increases linearly with added concentration until a concentration of 8 μg/mL. Above this 
concentration, the flux is constant within experimental error.  It has been shown 







correlates to the concentration at which LLPS occurs,25 because the system has reached 
the maximum free-drug solution concentration. Addition of more compound beyond this 
concentration, leads to the formation of more of the drug-rich phase, which does not 
contribute to the observed flux.  From the flux data, the measured LLPS concentration for 
danazol in the absence of a polymer is 8 µg/mL. 
Corresponding flux measurements were then obtained for solutions containing 
different amounts of polymer, in order to determine if the presence of the polymer 
reduced the maximum free drug concentration.  Figure 3-4 shows a summary of the 
maximum flux values obtained for various danazol-polymer solutions. If the polymer was 
substantially mixing with the drug-rich phase, depressing the danazol concentration at 
which it forms, it would be expected that the flux would decrease in the presence of the 
polymers. Within experimental error, it is apparent that the polymer do not reduce flux 
across the concentration range studied, and thus the polymer does not impact that free 
drug concentration. This can also be seen from Fig. 3-3, where the maximum flux from 
danazol solutions containing 10 μg/mL of polymer overlap the maximum flux seen for 
danazol alone.  
 
3.5.3 Kinetic Fluorescence Experiments 
 Previously, it was reported that the concentration at which LLPS was observed, as 
determined using a fluorescent probe, decreased in the presence of dissolved polymer for 
danazol solutions containing PVP, HPMC, and HPMC-AS (10 μg/mL polymer 
concentration).20  However, in this study, no difference was observed for danazol alone, 







droplet formation in systems without polymer was slower than in solutions containing a 
polymers, which could lead to an overestimation of the concentration at which LLPS was 
observed experimentally, for solutions analyzed immediately after generation of a 
supersaturated solution. In other words, there is a finite time for the nucleation of 
danazol-rich droplets. To investigate this, danazol solutions of different concentrations 
were analyzed over short time periods, using the fluorescent probe method.  Figure 3-5 
shows the pyrene I1/I3 ratio vs danazol concentration at different analysis times; 15 
seconds (the original method),20 1 minute, and after 5 minutes; these times are all before 
the samples start crystallizing ~10-15 min.  The formation of drug-rich droplets is 
indicated by a drop in the pyrene I1/I3 peak ratio.  Clearly, at 15 seconds, the formation of 
drug-rich droplets is picked up at a higher danazol concentration (between 10 and 14 
μg/mL; 13 μg/mL was the value previously reported),20 relative to when the analysis was 
conducted after 1 and 5 minutes, where a danazol-rich phase was detected at around 8 
μg/mL.  This result is interesting in that we have analyzed >20 compounds using this 
approach, and have never observed any time dependent effects of this nature previously. 
Additional experiments with pre-dissolved PVP revealed similar results, while 
solutions containing either HPMC and HPMC-AS showed no kinetic effects and showed 
changes in the pyrene I1/I3 ratio around 7-8 μg/mL of danazol, regardless of the time of 
acquisition.   
 
3.5.4 Induction Time Experiments. 
In order to explore the kinetic properties of the colloidal solutions, and the impact 







containing 15 µg/mL of danazol. Based on the NTA information shown in Figure 3-2 
these solutions contain >3 x 109 droplets per mL. Figure 3-6 shows examples of how the 
polymers impact induction times, prolonging the duration of supersaturation in all cases, 
albeit to different extents. PVP is the least effective polymer, while HPMCAS is highly 
effective at preventing crystallization.  
 The impact of polymer concentration on induction times was also assessed with 
results summarized in Figure 3-7.  Danazol, in the absence of polymer crystallizes within 
10-15 minutes.  In the presence of all three polymers, crystallization was inhibited for a 
significant amount of time ranging from 30 minutes to 6 hours.  At a polymer 
concentration of 1 μg/mL, the polymers have equal impact on crystallization inhibition, 
and only marginally extend induction times. However, at polymer concentrations of 10 
μg/mL and above, a clear differentiation between polymers is apparent, with HPMCAS 
being much more effective than PVP and HPMC. Increasing the polymer concentration 
from 10 to 1000 μg/mL did not extend induction times any further.  
 
3.5.5 Zeta-potential of the Drug-rich Droplets. 
To better understand the concentration dependent interactions of polymer with the 
droplets, zeta-potential measurements were conducted. Zeta-potential is related to the 
surface charge and characteristics of the particles being measured.28  Figure 3-8 
summarizes the zeta-potential values measured for the various danazol-polymer systems 
studied.  
 The zeta-potential of danazol droplets in the absence of polymer was found to be 







potential, consistent with the polymers interacting with the surface and reducing the 
negative charge.  The extent of the increase in zeta potential was concentration dependent 
for PVP,  with less concentration dependence observed for HPMC  The addition of 
HPMC-AS, a negatively charged polymer at the pH employed, decreased the zeta-
potential, with the extent of the decrease being dependent on the concentration of the 
polymer.  
 
3.5.6 Particle Size Analysis on Drug-rich Droplet Phase. 
Both DLS and NTA size analysis was performed on danazol nanodroplets in order 
to evaluate the impact of polymer type and amount on droplet size.  The size analysis 
data is summarized in Figure 3-9. 
The mean particle diameter (z-diameter), as determined from DLS analysis, 
suggested that the droplet size decreased from around 350 nm with no/low polymer 
concentrations to around 150 nm with the highest polymer concentrations, with a similar 
trend being observed for all the polymers studied.  However, the NTA data did not show 
any obvious trends in mean droplet size as a function of polymer concentration, with the 
mean droplet size being determined as ~200-250 nm.  Particle size analysis results on a 
sample with the same particle size distribution are known to sometimes vary when using 
DLS versus NTA.  DLS is highly biased towards the presence of a few larger particles 
within a single sample as compared to NTA.  This bias skews the distribution and 
calculated mean particle size towards the larger particles.29  Therefore, it appears that in 
the presence of a polymer, the formation of some larger droplets, probably through 







particles, a few large particles do not have such a major contribution to the mean particle 
size, since they are statistically less likely to be analyzed.  
 
3.6 Discussion 
 When considering solubility enhancing formulations, an important distinction 
should be noted between supersaturation and solubilization. Solubilization increases the 
drug concentration in solution by increasing the equilibrium solubility, and therefore does 
not increase the solute chemical potential. These systems will not precipitate unless 
dilution of the solubilizing component occurs.  In a supersaturated solution, the solute 
concentration is higher than the concentration that can be achieved by dissolving the 
crystalline material.  Supersaturating drug delivery systems, such as amorphous solid 
dispersions (ASDs), are thus designed to increase aqueous drug concentrations beyond 
that achievable with formulations containing crystalline drug.  This can lead to highly 
supersaturated solutions which are inherently meta- or unstable, because the chemical 
potential of the solute is increased relative to the reference crystal form, thus there is a 
thermodynamic driving force for crystallization.  However, supersaturated solutions are 
regarded favorably for drug delivery, since they have improved mass transport across 
membranes because of the increase in the amount of free drug molecules as compared to 
solubilized systems, where the overall concentration is increased, but not the membrane 
transport rate.30-32 
Two potential phase transitions can occur in supersaturated solutions depending 
on the degree of supersaturation, and the properties of the solute, namely LLPS followed 







certain supersaturation is exceeded, whereas crystallization can theoretically occur once 
the concentration exceeds the threshold concentration for primary nucleation. The 
potential phase transitions are summarized in Figure 3-10. Differentiating these 
transitions is important, since crystallization will deplete the supersaturation until 
ultimately, the equilibrium solubility is reached. In contrast, LLPS, while leading to a 
new phase, will result in a system that is still supersaturated. This motivates our interest 
in the properties of the colloidal solutions resulting from LLPS. LLPS can be understood 
at a more fundamental level by referring to the phase diagram shown in Figures 3-11.  
For a system that exhibit a miscibility gap,  as shown by the free energy of mixing 
versus composition diagram in Figure 3-11,39 there is an upper limit of concentration 
(supersaturation for samples that are crystalline at the temperature of analysis) of the drug 
in the aqueous phase that can be achieved (and likewise, an upper limit of water than can 
be present in the drug-rich phase), and when this concentration is reached, the system 
becomes unstable and will undergo spinodal decomposition, where phase separation is 
spontaneous and unavoidable.12, 25, 39  For spinodal decomposition, the activation energy 
for formation of a new phase is zero, so demixing is spontaneous. For a solution of drug 
and water, the resultant two phase system consists of a drug-rich phase and a water-rich 
phase, with compositions of xab and xba. These binodal points (XAB and XBA) indicate the 
boundary concentrations at which two phases can coexist. Concentrations between the 
binodal and spinodal points can undergo phase separation so long as the activation energy 
of forming the new phase is overcome. If the melting point of the drug is above the 
experimental temperature, these two phases exist in metastable equilibrium, and 







and spinodal points can be experimentally estimated if crystallization is sufficiently slow 
to enable the measurements to be made.12, 37, 40   
This phase diagrams can also help with a potential explanation for the data shown 
in Figure 5.  From a theoretical perspective, if the difference between the binodal and 
spinodal points is large enough, and the activation energy for formation of the new phase 
is high, then supersaturation with respect to the binodal composition (i.e. the amorphous 
solubility, point XAB) might be observed, with phase separation being observed at a 
higher concentration than the amorphous solubility. For most systems studied to date, 
little supersaturation has been observed with respect to the co-existence concentration,12, 
23 whereby phase separation is observed immediately this concentration is exceeded.  
However, in the case of danazol, we speculate that the difference seen in Figure 3-5, 
where the concentration at which LLPS occurs shows some time dependency, is due to a 
higher energy barrier for formation of the new phase, as compared to other systems that 
have been studied. This allows the amorphous solubility to be exceeded during the 
experiments where supersaturation is generated very rapidly.  The addition of polymer 
seemingly lowers this activation barrier, yielding lower experimental LLPS 
concentrations than for the drug alone at short time frames.  The polymer is most likely 
interacting with the droplets, lowering the surface tension needed to form the new 
interface necessary for LLPS.  The measured zeta-potential of droplets provides support 
for this supposition since the polymers clearly interact with the droplet surface (Figure 3-
8).    
One of the primary goals of this study was to evaluate the impact of polymers 







solutions as well as the kinetics of subsequent phase transformations.  Excipients that 
influence the crystalline solubility or the concentration at which LLPS is observed impact 
the solute thermodynamic activity, which in turn can impact mass transport across a 
membrane.  For example a second component that mixes with the drug-rich phase will 
decrease the amorphous solubility, and thus lower the maximum achievable 
supersaturation. Additives that increase crystalline solubility through complexation or 
micellar solubilization, can “consume” the supersaturation, reducing the amount of free 
drug and the rate of transport across a membrane.22  For the danazol-polymer systems 
studied herein, there are no significant changes to the crystalline solubility (Table 3-1).  
Furthermore, the experimentally determined amorphous solubility (based on the HPLC 
data, Table 3-2) in the presence of polymer was independent of the amount of polymer 
added and also showed good correlation with the theoretically estimated amorphous 
solubility of danazol which was 7.8 µg/mL.  Most definitively, the flux values for the 
systems were the same regardless of polymer type or amount, whereby the maximum 
achievable flux was the same as that for drug alone. Flux values are highly dependent on 
the thermodynamic activity of the solute, rather than on concentration per se, and hence 
this data supports the supposition that the polymers do not impact the ability of danazol 
to undergo membrane transport.30   These data thus confirm that significant amounts of 
polymer do not mix with the danazol-rich phase (if it did, the danazol activity would be 
reduced), and hence there is no change in the amorphous solubility.  In other words, the 
polymers evaluated do not solubilize the drug, and do not spontaneously mix with the 
amorphous drug-rich droplets formed via LLPS water, and thus allow highly 







resveratrol, where cellulose polymers were found to result in a considerable solubilization, 
reducing the extent of supersaturation achieved in the systems.  
  Although the thermodynamics properties of danazol solutions appear to be 
unaltered by the presence of polymers, up to a concentration of 1 mg/mL, the polymers 
have a dramatic effect on crystallization kinetics, as observed previously for numerous 
drug-polymer systems.26, 41-44  To expand on previous studies with danazol,20 the impact 
of polymer concentration on the induction times was evaluated for two phase solutions, 
i.e. solutions that had undergone LLPS. Interestingly, for all polymers studied, the largest 
gain in crystallization inhibition was achieved upon increasing the concentration from 1 
to 10 μg/mL, with fairly minimal increases in induction times upon increasing the 
polymer concentration to 1 mg/mL. This highlights the extremely small quantities of 
polymers needed to achieve crystallization inhibition, even in the presence of a drug-rich 
phase. Although there was evidence from the zeta potential measurements that all three 
polymers interacted with the surface of the danazol droplets, HPMC-AS was clearly the 
most effective crystallization inhibitor, while PVP was least effective. Furthermore, even 
though the zeta potential continued to decrease with increasing polymer concentration for 
HPMC-AS containing solutions, suggesting that more polymer was present at the droplet 
surface at higher polymer concentrations, this did not translate into increased 
crystallization inhibition.    
 
3.7 Conclusions 
 Supersaturated danazol solutions were found to undergo LLPS in the presence 







a mean size of around 200-250 nm.  The onset concentration of LLPS was found to be in 
good agreement with the estimated amorphous solubility.  Common amorphous solid 
dispersion polymers did not alter either the crystalline or amorphous solubility of danazol, 
and hence did not compromise the improved membrane transport rates afforded by 
maximally supersaturated solutions. However, the dissolved polymers did dramatically 
improve the stability of supersaturated solutions to crystallization, with polymer 
concentrations as low as 1 μg/mL showing inhibitory effects. Characterizing the solution 
phase behavior of supersaturated solutions of poorly water soluble drugs in the presence 











Table 3-1. Crystalline Solubility (μg/mL) of Danazol in the Presence and Absence of 
Polymers at 25°C, n=3, Errors Equal One Standard Deviation 
Amount of Polymer PVP HPMC HPMC-AS 
0 μg/mL 0.9 ± 0.1 
1 μg/mL 0.8 ± 0.2 0.9 ± 0.3 1.0 ± 0.2 
10 μg/mL 1.3 ± 0.4 2.2 ± 0.5 1.1 ± 0.4 
100 μg/mL 1.1 ± 0.4 1.7 ± 0.8 1.4 ± 0.6  











Table 3-2. LLPS Concentrations (µg/mL) via multiple analytical techniques.  Error shows 
one standard deviation for the UV Extinction and HPLC data (n=3).  Fluorescent Probe 
and NTA data were also performed in triplicate, whereby the concentration increment 
was 1 μg/mL. The error for these systems was less than the concentration increment. 









1 µg/mL 8.2 ± 0.4 8 8.2 ± 0.6 8 
10 µg/mL 8.3 ± 0.5 8 8.9 ± 0.2 7 
100 µg/mL 7.8 ± 0.5 8 9.1 ± 0.5 8 
500 µg/mL 8.1 ± 0.6 7 8.8 ± 0.4 8 






1 µg/mL 8.7 ± 1.2 8 8.6 ± 0.7 8 
10 µg/mL 8.1 ± 0.6 8 8.3 ± 0.8 7 
100 µg/mL 8.0 ± 0.3 8 8.3 ± 0.5 8 
500 µg/mL 7.7 ± 0.4 7 8.1 ± 0.8 7 







 1 µg/mL 8.5 ± 0.3 9 8.1 ± 0.4 8 
10 µg/mL 7.6 ± 0.9 8 8.0 ± 0.3 8 
100 µg/mL 7.7 ± 0.8 8 8.2 ± 0.4 7 
500 µg/mL 8.0 ± 0.5 8 8.4 ± 0.6 7 
1000 µg/mL 8.1 ± 0.2 7 8.2 ± 0.3 7 










Figure 3-1. Nanoparticle Tracking Analysis images taken from danazol solutions below 
8μg/mL (a), at 8μg/mL (b), and above 8μg/mL (c) the measured LLPS concentration. 
 
 
Figure 3-2. The numbers of particles tracked per mL of solution as a function of danazol 
concentration obtained from NTA. 


































Figure 3-3. Danazol flux versus the concentration of danazol in the donor chamber of the 
diffusion cell. The flux of solutions containing 10 μg/mL of polymer is also shown, as is 
the flux of a suspension containing crystalline danazol, (solubility of 0.9 μg/mL). 
 






























Figure 3-4. Maximum flux values from supersaturated danazol solutions (15 μg/mL) with 





































































Figure 3-5. Pyrene I1/I3 peak ratio as a function of danazol concentration whereby the 
solutions were evaluated at different time points following the addition of danazol to the 
solution. 






































Figure 3-6. UV Absorbance data used to determine the crystallization induction time of 
supersaturated danazol solutions (added danazol concentration of 15 µg/mL) in the 
presence and absence of 10 µg/mL polymer. 





















































Figure 3-7. Average crystallization induction times of supersaturated danazol solutions 
(15 µg/mL) with varying amounts of pre-dissolved polymer. 
 

































Figure 3-8. The zeta-potential of the drug-rich droplets formed via LLPS in danazol-
polymer systems. 
 






























Figure 3-9. The mean size of the drug-rich danazol droplets as determined from DLS (left) 













Figure 3-11. Free energy of mixing diagram depicting a miscibility gap which can result 
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CHAPTER 4. DISSOLUTION AND PHASE BEHAVIOR OF DANAZOL 
AMORPHOUS SOLID DISPERSIONS 
4.1 Abstract 
 Amorphous solid dispersions are currently being widely investigated for the 
ability increase the apparent solubility of poorly soluble drugs.  The dissolution of 
amorphous solid dispersions results in supersaturated solutions which can result in 
multiple phase transitions.  The purpose of this chapter was to investigate the dissolution 
profiles of amorphous solid dispersions with a model drug, danazol, with regards to 
supersaturation and precipitation. Solution concentration vs time profiles were generated 
in parallel with a fluoresecent probe technique to identify the nature of the precipitation 
(liquid-liquid phase separation or crystallization).   Dispersions instantaneously exhibited 
liquid-liquid phase separation upon surpassing the amorphous solubility and subsequently 
undergo crystallization after a period of time (1-8 hours) depending on the polymer used 
in the dispersion.  A side-by-side diffusion cell was used to assess the extent of 
supersaturation and the maximum free-drug concentration achieved from the dissolution 
of amorphous solid dispersions.  Supersaturation equivalent to the amorphous solubility 
was achieved for multiple drug-polymer systems, resulting in a maintained 
supersaturation during dissolution until crystallization.  Overall, the dissolution profiles 
of were impacted by the creation of a second drug-rich droplet phase through liquid-









 Amorphous solid dispersions (ASDs) are of great interest as a formulation 
strategy because upon dissolution, they can increase the effective solubility and 
consequently, in many instances, the bioavailability of poorly soluble drug molecules.1-5 
The increase in effective solubility is due to the thermodynamically higher energy state of 
the amorphous form relative to the crystalline form.6  The formulation of robust ASDs 
can be challenging due to the risk for transformation to the crystalline form.7  Polymers 
are added to ASDs to stabilize against crystallization both during storage8 and 
dissolution.9-12  The inhibition of crystallization during dissolution enables a 
supersaturated solution to be generated under non-sink dissolution conditions.10, 12  
Furthermore, there is mounting evidence that a second phase transition can occur in 
highly supersaturated drug solutions prior to crystallization known as liquid-liquid phase 
separation (LLPS).13, 14  
 LLPS occurs in solutions when the addition of a drug into an aqueous solution 
surpasses a boundary concentration above which the drug is no longer miscible with the 
aqueous phase.15 The LLPS boundary concentration can also be defined as the 
amorphous solubility.2, 13, 16-18  The amorphous solubility has been described previously 
and is the maximum increase in apparent solubility upon dissolution of an amorphous 
form relative to the crystalline form when no crystallization occurs.2-5  The amorphous 
solubility can be estimated from the thermodynamic properties of the crystalline and 
amorphous drug, and LLPS determination experiments have shown that the estimated 
amorphous solubility is generally in good agreement with the experimentally observed 








highly supersaturated system where crystallization is inhibited.  The presence of a 
polymer can thus inhibit crystallization, creating the potential to enter a solution 
concentration regime where LLPS can occur; this has been demonstrated for 
supersaturated solutions of nifedipine where the LLPS concentration cannot be achieved 
in the absence of an effective crystallization inhibitor.19, 20 However, the tendency of 
ASDs formulated with different polymers and at different drug loading to undergo LLPS 
upon dissolution has not been evaluated to date. 
 In the current study, we examined the dissolution behavior of ASDs containing 
the model drug, danazol.  The solution behavior of danazol has been extensively studied 
with regards to supersaturation and precipitation.18, 21, 22   Methods to detect both LLPS 
and crystallization in danazol-polymer solution systems were previously developed and 
employed in the current study to evaluate the dissolution of ASDs formulated using three 
model polymers; polyvinyl pyrrolidone (PVP), hydroxypropylmethyl cellulose (HPMC), 
and HPMC acetate succinate (HPMC-AS).  Using these methods, the tendency of the 
various formulations to lead to LLPS upon dissolution was evaluated and correlated to 
the level of supersaturation generated as well as the expected amorphous solubility. 
 
4.3 Materials 
Danazol was purchased from Euroasia Chemicals (Euroasia Ltd., China), pyrene 
and polyvinylpyrrolidone (PVP) K29/32 were purchased from Sigma-Aldrich (St. Louis, 
MO), while hydroxypropylmethyl cellulose (HPMC) 606 grade and 
hydroxypropylmethyl cellulose acetate succinate (HPMC-AS) MF grade were supplied 








dichloromethane were purchased from Macron Chemicals (Phillipsburg, New Jersey). 
The aqueous medium used in all experiments was 10 mM pH 6.8 phosphate buffer.  
Pyrene was added to solutions at a concentration of 2 µM for fluorescence measurements.     
 
4.4 Methods 
4.4.1 Preparation of Amorphous Solid Dispersions 
Amorphous solid dispersions (ASDs) of polymer-danazol systems consisting of 
90:10, 70:30, and 50:50 polymer-drug ratios were prepared via spin-coating.  Stock 
solutions of danazol and polymer (PVP, HPMC, and HPMC-AS) were prepared by 
dissolving a total weight of 1 g of polymer-drug in 10 mL of ethanol and 
dichloromethane (1:1 w/w).  A few drops of each stock solution were dropped onto the 
center of a 22 mm by 22 mm No 1. glass cover slip and prepared on a KW-4A two-stage 
spin coater (Chemat Technology, Northridge, CA) by rotating at 500 and 1000 rpm for 10 
and 30 s, respectively.  The process was repeated on the same cover slip sample to build 
layers of the ASD and achieve the desired ASD weight, adequate for dissolution 
experiments.  The amount of drug added to the system was optimized to create theoretical 
maximum solution concentrations between 20-30 μg/mL for all experiments, which is 
above the expected LLPS onset concentration of 8 μg/mL.  Polarized light microscopy 
was used to determine if there was any crystallinity in the resultant ASD films.  All ASDs 
of 90:10 and 70:30 polymer-drug were completely void of any crystalline domains.  The 
50:50 ASDs contained some crystalline domains approximately equivalent to 10% of the 









4.4.2 Parallel UV Spectroscopy and Fluorescence Spectroscopy during Dissolution of 
Danazol ASDs   
The phase behavior of the solutions generated during dissolution of the ASDs was 
monitored using ultraviolet (UV) and fluorescence spectroscopy. For the fluorescence 
spectroscopy, the fluorescence emission spectrum of an environmentally sensitive probe, 
pyrene, was monitored, after adding pyrene to the solution at a concentration of 2 μM.  
ASD films were added to 50 mL of aqueous buffer solution (10 mM phosphate buffer, 
pH 6.8) and the solution was stirred using a magnetic stirrer at 300 RPM. UV spectra 
were obtained from this solution using an in situ fiber optic dip probe with a path length 
of 1 cm coupled to a SI Photonics UV/vis spectrophotometer (Tucson, Arizona).  
Calibration standards of danazol, prepared in methanol (1-100 μg/mL), resulting in a 
linear standard curve (r2 > 0.999) were used to estimate the concentration evolution 
during the dissolution measurements.  UV signal intensity was processed at two 
wavelengths: the maximum absorbance wavelength of danazol (288 nm) and at 350 nm, 
where no absorption is observed.  UV spectra were obtained every 60 s.  Fluorescence 
spectroscopy was also obtained on the same samples.  2 mL aliquots were extracted and 
analyzed at various time points using a Shimadzu RF-5301pc Spectrofluorometer (Kyoto, 
Japan).  The excitation wavelength was 332 nm, and the emission spectrum was collected 
at 0.2 nm intervals from 350 to 420 nm. The excitation slit width was 10 nm, while the 









4.4.3 Flux Measurements via Diffusion Cell Apparatus 
A side-by-side diffusion cell (PermeGear, Inc. Hellertown, Pennsylvania) was 
used to evaluate the relationship between flux rate, donor solution concentration, and 
LLPS using a method developed previously.17   A regenerated cellulose membrane with a 
MWCO of 6–8 KDa was used to separate the donor and receiver chambers. Both the 
donor and receiver compartments hold a maximum of 200 mL and are separated by a 
circular opening with a diameter of 30 mm.  Both compartments were filled with 200 mL 
of buffer and the ASD samples were placed inside a Tissue-Tek biopsy cassette (Sakura 
Finetek USA, Inc., Torrance, California) with 1 mm pores to prevent fragments of the 
ASD from interfering with the UV dip probe (Figure 4-1).  A fiber optic dip probe with a 
path length of 2 cm coupled to a SI Photonics UV/vis spectrophotometer was submerged 
in the receiver side, while a second dip probe with a path length of 1 cm was submerged 
in the donor side.  UV spectra were obtained every 15 s. for 60 minutes for both sides.   
Concentration versus time profiles for the receiver compartment were generated 
and analyzed to determine the flux of the drug from the donor compartment to the 
receiver compartment.   The flux (J) is determined from the change in mass per unit time 
(dM/dt) and can be obtained from the slope of the concentration versus time profile using 
linear regression.  The relationship between flux and the properties of the drug and the 
















The flux is dependent on the diffusion coefficient (D), the membrane cross-
sectional area (S), the solute thermodynamic activity (a), the activity coefficient of the 
solute in the membrane (γm), and the thickness of the membrane (h).  Furthermore, the 






where Ci is the experimental free drug concentration and CS is the crystalline equilibrium 
solubility.17  The activity estimated as the ratio of the free drug concentration to the 
crystalline equilibrium solubility can also be defined as the supersaturation (Si).  A 
solution with a free drug concentration below the crystalline solubility, and therefore no 
crystallization, has a supersaturation <1.  In contrast, a solution with a free drug 
concentration greater than the crystalline solubility has a supersaturation >1, and a 
thermodynamic driving force for crystallization.  Substituting Equation 4-2 into Equation 
4-1 shows that the supersaturation is directly proportional to the flux: 





 For this study, S, D, γm , and h, are constants using the experimental setup 
described above.  A linear standard curve (r2 > 0.997) was created by determining the 








solubilities, in the donor cell.  The flux of the drug upon dissolution of the ASDs was 
then determined and used to calculate the maximum supersaturation achieved by 
dissolution of the different ASD formulations. This value was compared with both the 
UV absorbance data and the amorphous solubility of the drug. 
 
4.4.4 Nanoparticle Tracking Analysis   
Nanoparticle tracking analysis was used to characterize the precipitate formed 
upon dissolution of the ASD films.  1 mL samples of each solution were withdrawn at the 
desired time point and analyzed using a NanoSight LM10 from Malvern Instruments 
(Westborough, MA) equipped with nanoparticle tracking analysis software.  The LM10 
was equipped with a 75 mW green (532 nm) laser and a temperature controlled flow 
through cell stage.  Samples were analyzed at 25°C for 30 seconds and camera settings 
were held constant throughout all experiments (screen gain = 2.0, camera level=7).  The 
detection threshold upon analysis was also held constant (5) for all experiments along 
with camera gain (10.0).  
 
4.5 Results and Discussion 
4.5.1 Dissolution Behavior of Danazol ASDs 
Supersaturated solutions of poorly water soluble drugs, such as those that can 
result from the dissolution of ASDs under non-sink conditions, have been shown to 
undergo different types of phase transitions, which are often collectively termed 
precipitation.15, 21, 23  Formation of a new phase (i.e. precipitation) is normally regarded as 








precipitation is an ambiguous term which doesn’t discriminate between the formation of 
crystalline and amorphous phases.  Formation of a disordered, drug-rich (amorphous) 
phase by the process of LLPS, which yields a turbid solution, results in a two phase 
system which is supersaturated relative to the crystalline form.  Furthermore, it has been 
suggested that the drug-rich phase, which is in metastable equilibrium with the bulk 
aqueous solution, can act as a drug reservoir, replenishing drug that it absorbed and 
maintaining supersaturation at a constant value during absorption as long as the two 
phases are present and crystallization is avoided.17  In contrast, crystallization will lead to 
depletion of supersaturation. Consequently, in order to evaluate the dissolution behavior 
of ASDs and understand their in vivo advantage, it is essential to evaluate their solution 
thermodynamics and phase behavior.  
 Although the dissolution of ASDs has be extensively studied9-12, 25, the 
occurrence of LLPS during the dissolution process is not typically investigated, although 
several studies have noted the generation of colloidal species during the dissolution 
process.10, 13, 26  Ilevbare demonstrated that the formation of these colloidal species during 
the dissolution of an ASD could be rationalized based on understanding the LLPS 
phenomenon.13  In other words, when the ASD dissolves to a concentration higher than 
the amorphous solubility, a new drug-rich phase is evolved. This was demonstrated by 
dissolving a high polymer loading ASD of ritonavir formulated with PVP. However, 
there are several outstanding questions about the link between ASD dissolution and LLPS. 
These include understanding if LLPS leading to the formation of a drug-rich phase only 
occurs when a certain polymer is used to formulate the dispersion, and if the 








undergo LLPS.  In an attempt to address these questions, we applied several orthogonal 
techniques, previously applied to study LLPS in supersaturated solutions generated by 
antisolvent addition, to evaluate the non-sink dissolution behavior of danazol ASDs 
formulated with different polymers and drug loadings.  
The dissolution profiles of ASDs formulated with HPMCAS, HPMC or PVP with 
polymer-drug ratios of 90:10 are shown in Figure 4-2.   Figure 4-2 shows the apparent 
concentration as a function of time for the various dispersions, obtained using UV 
spectroscopy.  Also shown in the plot are fluorescence data, obtained by monitoring the 
emission spectrum of the environmentally sensitive fluorescence probe, pyrene. 
Monitoring the solution concentration reveals that the dissolution is rapid from the ASD, 
and the concentration quickly exceeds the crystalline solubility (0.9 μg/mL), forming a 
supersaturated solution, and then exceeds the amorphous solubility (8 μg/mL). Above the 
amorphous solubility, the UV determined concentration values are not reliable due to the 
expected presence of nanospecies that both absorb and scatter light.27 The ratio of the 
intensities of the first and the third peaks (I1/I3) of the pyrene emission spectrum provide 
information about the local environment of the probe.28  When this ratio is high (~1.9), 
the probe is in a hydrophilic, aqueous environment. This is the value of the I1/I3 ratio at 
the beginning of the experiment.  Once the dissolved danazol concentration reaches a 
certain value, it can be seen that the I1/I3 ratio decreases. This is consistent with the 
preferential interaction of the probe with a newly formed disordered drug-rich phase. 
Hence the probe is in a more hydrophobic average environment and a decrease in the I1/I3 
ratio is observed. The supersaturation generated by the ASD dissolution does persist 








ASD. In the case of the PVP dispersion (Fig 4-2a), after approximately 75 min, a 
decrease in UV absorption is observed, indicating that crystallization has commenced and 
the supersaturation is being depleted due to the formation and growth of crystalline 
danazol particles. Concomitantly, the I1/I3 ratio increases, indicating that the disordered 
drug-rich phase is lost as crystals form. For the HPMC and HPMCAS dispersions, 
corresponding changes in concentration and pyrene I1/I3 ratio were observed at 300 and 
360 minutes respectively as shown in Fig 4-2b and 4-2c. 
All of the 70:30 dispersions and the 50:50 PVP:danazol dispersions showed 
similar dissolution profiles, whereby the amorphous solubility was exceeded, and LLPS 
was detected based on the response of the pyrene probe. Differences in the duration of 
supersaturation were observed, as for this 90:10 dispersions, and these will be discussed 
in more detail below. However, dispersions formulated with HPMC and HPMC-AS at the 
50:50 ratio resulted in different dissolution profiles.  Figure 4-3 shows an example of 
each of the 50:50 systems.  Both the HPMC and HPMC-AS systems have a much slower 
initial dissolution and lack the characteristic drop in apparent solution concentration 
indicative of crystallization.  The fluorescence data for the 50:50 dispersions with HPMC 
(Fig. 4-3b) showed a decrease in the pyrene I1/I3 ratio when the solution concentration 
exceeds 8 μg/mL.  In contrast, 50:50 dispersions with HPMC-AS (Fig. 4-3c) do not reach 
the amorphous solubility and only a small decrease in the I1/I3 ratio is observed which 
probably can be attributed to the interaction of the probe with undissolved dispersion; this 
is most noticeable only at long time periods. 
The phase behavior of the various ASDs following dissolution, in terms of the 








summarized in Figure 4-4. The data for the solutions generated from ASD dissolution is 
also compared to phase behavior of danazol supersaturated solutions produced by 
antisolvent addition,22 in order to understand how predictive these simple screening 
experiments are with regard to ASD performance.   
The crystallization induction times for solutions resulting from ASD dissolution 
are similar to the solutions generated by anti-solvent addition, which contain the 
corresponding polymer, pre-dissolved, with the exception of the 50:50 HPMC and 
HPMC-AS dispersions which do not show desupersaturation over the duration of the 
experiments. It can be seen that all systems containing PVP had the shortest induction 
times, whereas the HPMC-AS systems have the longest induction times.  Hence in the 
case of danazol ASDs, the solution screening experiments predict the stability of the 
ASDs during dissolution quite well. The concentration at which LLPS occurs was also 
estimated from the ASD dissolution data by evaluating the apparent solution 
concentration at the time point when the pyrene I1/I3 ratio showed a dramatic decrease. It 
should be noted that time resolution of the fluorescence measurements is not as high as 
the UV measurements since the former were obtained using manual sampling. With this 
caveat in mind, it can be seen that fluorescence measurements indicate that LLPS has 
occurred for all dispersions bar the 50:50 HPMC-AS dispersions, when the concentration 
exceeds 6-10 μg/mL. This concentration range is in good agreement with the estimated 
amorphous solubility (8 μg/mL), as well as the results obtained for solutions generated by 









4.5.2 Characterization of the Drug-Rich Droplets Formed upon Dissolution. 
The dissolution of the danazol ASDs resulted in supersaturated drug solutions and 
the results obtained with the fluorescence probe, pyrene, suggested that LLPS occurred, 
leading to the formation of a drug-rich phase.  NTA was employed to study the size 
characteristics of the new phase and this information is summarized in Table 4-1 for 
solutions produced by both anti-solvent addition and ASD dissolution.  
 The average sizes observed for the drug-rich phase generated by dissolution from 
the ASD are similar to those obtained following creation of the drug-rich phase by anti-
solvent addition.22 The concentrations shown are determined based on the number of 
“particles” tracked by the instrument and the sample volume analyzed.  The 
concentration of scattering species is slightly higher for solutions evolved from ASD 
dissolution relative to the anti-solvent addition samples, and this can be readily accounted 
for by a difference in the mass of the drug added (15 μg/mL for anti-solvent addition vs 
20-30 μg/mL for the ASD samples).  Figure 4-5 shows single frames taken from the 
video capture of the NTA scattering data, showing the light scattered by the drug rich 
phase produced upon the dissolution of 90:10 polymer-drug ASDs as compared to a 
solution which was supersaturated using anti-solvent addition.  Samples were analyzed at 
a time point corresponding to a maximum in apparent solution concentration profile, and 
therefore provide a snapshot of the size and amount of the drug-rich phase formed via 
LLPS, prior to the onset of crystallization.  The clear presence of a scattering phase of 
submicron dimensions in highly supersaturated solutions provides additional support for 
our conjecture that these systems can undergo an amorphous precipitation (LLPS) 








further by exploring the mass transport properties of the solutions derived from ASD 
dissolution.  
 
4.5.3 Comparison of Maximum Free-Drug Concentration for Different ASD 
formulations  
In order to fully understand the thermodynamics and ultimate impact LLPS, the 
free-drug concentration, or the maximum achievable supersaturation resulting from ASD 
dissolution must be determined.  UV absorption data provides a good starting point for 
measuring the apparent solution concentration, in particular during the early stages of 
dissolution but the presence of nano-sized drug droplets (such as those formed during 
LLPS) can impact the observed concentrations.  Nano-sized particles have been shown to 
both scatter and absorb ultra-violet light, thus leading to an overestimate of molecularly 
dissolved drug based on the UV absorption data.27  Filtering may not be particularly 
useful since some or all of the drug-rich phase may pass through the filter, and the 
filtration process may induce crystallization.29  The free drug concentration, in other 
words the amount of molecularly dissolved drug, is important since it directly dictates the 
supersaturation in the system, which not only provides the thermodynamic driving force 
for crystallization, but also leads to enhanced membrane transport. When LLPS occurs, 
the free drug concentration reaches a maximum, and thus all the ASDs which showed 
LLPS should show the same flux. Therefore, in order to assess relative supersaturation 
achieved by dissolving the various dispersions, the flux of the drug molecule across a 
membrane was measured to determine the free-drug concentration.  As described above 








concentration or more precisely, the solute thermodynamic activity (i.e. supersaturation), 
rather than total concentration.  To perform these experiments, the dissolution of danazol 
ASDs was performed in the donor compartment, creating a supersaturated solution, and 
the concentration evolution in both the donor and receiver cells was monitored as a 
function of time. The flux was determined from the slope of the concentration versus 
time plot in the receiver cell once the concentration in the donor cell reached a maximum 
and prior to crystallization, as shown in Figure 4-6.  
At steady state, the flux is directly proportional to the free drug concentration in 
the donor compartment (Equation 4-3).  The supersaturation can then be calculated and 
evaluated from the flux data upon dissolution.  Figure 4-7 provides a summary of the 
maximum supersaturation observed for the various ASDs and comparable anti-solvent 
experiments, calculated from the flux data shown in Table 4-2.   
All of the ASDs with the exception of the 50:50 HPMC-AS:danazol system 
dissolved to produce the same maximum supersaturation, which, within experimental 
error, had a free drug concentration equivalent to the amorphous solubility, 8 μg/mL. 
This was despite the fact that the concentration registered in the donor compartment was 
higher based on the UV absorption data, and in terms of the amount added. All of these 
dispersions underwent LLPS, giving rise to two phase solutions. As discussed previously, 
the amorphous solubility represents the maximum achievable supersaturation and free 
drug concentration. This has been shown previously for solutions created by anti-solvent 
addition,22 but is confirmed here for supersaturated solutions generated by ASD 
dissolution. Thus, when ASDs undergo LLPS, the maximum in membrane transport rate 








HPMC-AS:danazol dispersion, shows a lower maximum flux than the other systems, 
consistent with a lower overall supersaturation (see Figure 4-3c, which shows the 
dissolution profile and Figure 4-7 which shows the lower supersaturation achieved by this 
system). These results thus clearly demonstrate the potential benefits of formulating an 
ASD system such that LLPS occurs on dissolution, since this process, which leads to a 
maximally supersaturated solution, correlates with the maximum in transport rate. Clearly 
in the case of danazol, quite high drug loadings can be achieved such that LLPS is still 
observed upon dissolution; up to 30% drug loading for all of the polymers investigated. 
However, the even higher drug loading systems (50% drug loading) show much slower 
dissolution rates, and even if they do exceed threshold concentration for LLPS, this was 
only observed at long time frames, and hence these formulations might not be expected to 
perform comparably in terms of membrane transport in vivo. 
 
4.6 Conclusions 
The data outlined above provides strong evidence that for these specific drug-
polymer system, LLPS occurs prior to crystallization which reaches a maximum 
supersaturation regardless of how it is created (anti-solvent vs ASD dissolution).  The 
presence of LLPS during dissolution is a critical result in the understanding of ASD 
dissolution.  LLPS occurs at the amorphous solubility limit or can otherwise be 
considered the miscibility limit of the drug in an aqueous system. These results reveal 
that above a critical concentration, additional drug that dissolves from the amorphous 
formulation will phase separate into drug-rich droplets, effectively creating a maximum 








upon ASD dissolution does not always result in a loss of supersaturation, but rather could 
maintain supersaturation through the formation of the drug-rich droplets formed during 










Table 4-1. Nanoparticle Tracking Analysis of solutions generated by surpassing the 
amorphous solubility prior to crystallization. 
System 




DNZ 15 μg/mL* 267 ± 67 3.2 ± 0.6 
PVP:DNZ 
100:15 μg/mL* 223 ± 64 2.9 ± 0.2 
90:10 ASD 256 ± 75 4.1 ± 0.8 
HPMC:DNZ 
100:15 μg/mL* 233 ± 74 3.0 ± 0.5 
90:10 ASD 284 ± 81 4.5 ± 0.7 
HPMC-AS:DNZ 
100:15 μg/mL* 205 ± 63 2.9 ± 0.6 
90:10 ASD 246 ± 54 4.4 ± 0.5 
* Pre-dissolved polymer and supersaturation created using anti-solvent method from 
previous study.22 The added danazol concentration was 15 μg/mL and the polymer 









Table 4-2. Flux and free drug concentration data from ASD dissolution and 
supersaturated danazol solutions. 
System Flux (μg/min) 
Free Drug Concentration 
(μg/mL) 
DNZ 
Crystalline 0.006 ± 0.001 1.0 ± 0.1 
15 μg/mL* 0.115 ± 0.009 8.1 ± 1.2 
PVP:DNZ 
90:10 ASD 0.103 ± 0.006 7.3 ± 1.0 
50:50 ASD 0.099  ± 0.008 7.1 ± 1.1 
100:15 μg/mL* 0.100 ± 0.008 7.2 ± 1.1 
HPMC:DNZ 
90:10 ASD 0.124 ± 0.009 8.7 ± 1.2 
50:50 ASD 0.129  ± 0.016 9.1 ± 1.6 
100:15 μg/mL* 0.110 ± 0.004 7.8 ± 0.9 
HPMC-
AS:DNZ 
90:10 ASD 0.117 ± 0.010 8.2 ± 1.2 
50:50 ASD 0.073  ± 0.003 5.4 ± 0.8 
100:15 μg/mL* 0.116 ± 0.009 8.2 ± 1.2 












Figure 4-1. Schematic of diffusion cell apparatus setup.  The donor cell and receiver cell 















Figure 4-2. Dissolution profiles of 90:10 polymer-drug ASDs with PVP (a), HPMC (b), 
and HPMC-AS (c).  The apparent solution concentration was measured using UV 
absorbance (left axis and black squares) while the presence of LLPS was monitored using 
pyrene as a fluorescent probe (right axis and open blue circles). 
























































































































































































































Figure 4-3. Dissolution profiles of 50:50 polymer-drug ASDs with PVP(a), HPMC (b), 
and HPMC-AS (c).  The apparent solution concentration was measured using UV 
absorbance (left axis and black squares) while the presence of LLPS was monitored using 
pyrene as a fluorescent probe (right axis and open blue circles). 
 
 











































































































































































































































Figure 4-4. Comparison of crystallization induction times (left) and onset LLPS 
concentrations (right) for ASDs dissolution and supersaturated danazol solutions created 
by anti-solvent addition (15 ug/mL of added danazol) with pre-dissolved polymer. Data 





Figure 4-5. NTA images of a supersaturated danazol solution (15 ug/mL DNZ) via anti-
solvent method (left) and supersaturated danazol solution via dissolution of PVP-DNZ 

























































































Figure 4-6. Example of determination of the flux during the dissolution of an ASD (90:10 
HPMC:DNZ).  Using UV dip probes, the donor concentration is plotted on the left y-axis 
in blue and the receiver concentration on the right axis in red.  Black vertical lines 
indicate the time over which the flux was determined using the slope of the receiver 
concentration, dotted black line.  (R2 = 0.999, slope = 0.00454 µg/mL/min, and flux = 
0.908 µg/min). 
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Figure 4-7. Maximum supersaturation in solution during the dissolution of danazol ASDs 
and supersaturated danazol solutions via anti-solvent from ref 22 (added concentration of 
danazol = 15 µg/mL).   
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CHAPTER 5. SUPERSATURATION IN THE PRESENCE OF CRYSTAL SEEDS 
DURING THE DISSOLUTION OF AMORPHOUS SOLID DISPERSIONS 
5.1 Abstract 
The supersaturation profiles of solutions created from the dissolution of amorphous 
solid dispersions (ASDs) were examined in this chapter.  Previously, supersaturation was 
observed from the dissolution of a model drug-polymer ASD (danazol-HPMC) with 
presence of crystalline seeds within the dispersion prior to dissolution.  In this study, the 
degree of supersaturation and the crystallization behavior of several drug systems in the 
presence and absence of crystalline drug introduced in multiple ways was measured using 
UV spectroscopy and a side-by-side diffusion.  A plateau supersaturation was observed 
for all systems, but the plateau value varied depending on how crystalline material was 
introduced into the system.  Furthermore the relationship between dissolution rate, 
nucleation induction time, and crystal growth was evaluated with respect to these systems.  
Ultimately, supersaturation was achieved and maintained upon dissolution of an ASD in 
the presence of crystalline drug and the degree of supersaturation was dependent on the 











 Amorphous solid dispersions (ASD) are of great interest for the formulation of 
poorly water soluble drugs because of their ability to dissolve and generate supersaturated 
solutions resulting in enhanced uptake from the GI tract, and ultimately, increased 
bioavailability.1-10  The solutions resulting from ASD dissolution under non-sink 
conditions are supersaturated with respect to the crystalline drug and thus have a 
tendency to crystallize; crystallization must be inhibited for a sufficient period of time in 
order to utilize the increases in apparent concentration.9-13 In the absence of rapid 
crystallization, the upper limit of achievable supersaturation is dictated by the amorphous 
solubility, and the dissolution of ASDs can lead to liquid-liquid phase separation, leading 
to the formation of a colloidal, drug-rich phase in metastable equilibrium with the bulk 
aqueous solution.8, 14-19 
 Understanding the different phase transformations is critical to understanding the 
likely in vivo performance of supersaturated solutions.  Precipitation is generally 
regarded as a negative consequence of generating a supersaturated solution20-23 and much 
effort is being directed towards employing additives for solution crystallization 
inhibition.11-15, 18, 24-27  Formulations are being developed to maintain supersaturation 
upon dissolution by selection of a polymer which both stabilizes the amorphous drug in 
the solid state (i.e. in the solid dispersion) and is able to inhibit crystallization from 
solution.   
One area of research that has received little attention, is the impact of trace 
crystallinity on the ability of ASDs to dissolve and generate supersaturated solutions. 








evolving during processing,28 or may form during storage.29 To date, most research on the 
impact of crystals on the duration of supersaturation has focused on adding native 
crystals to supersaturated solutions and monitoring desupersaturation profiles.11, 30  In 
these studies, it was noted that addition of crystalline material resulted in rapid 
desupersaturation which could be hindered by the addition of polymers, but not 
completely prevented. In a previous study, it was noted that, somewhat surprisingly, the 
dissolution of an ASD consisting of a 50:50 ratio of danazol and hydroxypropylmethyl 
cellulose (HPMC) yielded a supersaturated solution that persisted for 24 hours, despite 
the ASD containing up to 10% crystalline material, formed during ASD preparation.8 The 
goal of the current study was to evaluate the dissolution behavior of ASDs in the 
presence of crystalline material in terms of the supersaturation behavior. The crystalline 
material was either formed in the ASD during the production process, or was added 
separately in the form of crystal seeds. Crystal growth rate measurements in the presence 
and absence of polymers were used to aid in interpretation of the results. 
 
5.3 Materials 
Danazol was purchased from Euroasia Chemicals (Euroasia Ltd., China), and 
hydroxypropylmethyl cellulose (HPMC) 606 grade was supplied by Shin-Etsu (Shin-Etsu 
Chemical Co., Ltd., Tokyo, Japan).  Methanol, acetonitrile, and dichloromethane were 
purchased from Macron Chemicals (Phillipsburg, New Jersey). The aqueous medium 










5.4.1 Preparation of Danazol Systems 
Amorphous solid dispersions (ASDs) of polymer-danazol systems consisting of 
90:10 and 50:50 polymer-drug ratios were prepared via spin-coating.  Stock solutions of 
danazol and HPMC were prepared by dissolving a total weight of 1 g of polymer-drug in 
10 mL of ethanol and dichloromethane (1:1 w/w).  A few drops of each stock solution 
were dropped onto the center of a 22 mm by 22 mm No 1. glass cover slip and prepared 
on a KW-4A two-stage spin coater (Chemat Technology, Northridge, CA) by rotating at 
500 and 1000 rpm for 10 and 30 s, respectively.  The process was repeated on the same 
cover slip sample to build layers of the ASD and achieve the desired ASD weight, 
adequate for dissolution experiments.  The amount of drug added to the system was 
optimized to create theoretical maximum solution concentrations between 20-30 μg/mL 
for all experiments, which is above the expected LLPS onset concentration of 8 μg/mL, 
and therefore can generate maximally supersaturated solutions under non-sink dissolution 
conditions.   
Samples containing crystalline danazol were produced by adding 1 mg of 
crystalline danazol to 10 mL of deionized water and drying. Polymer-coated crystalline 
danazol was produced by adding 1 mg of crystalline danazol to 10 mL of deionized water 
containing 100 μg/mL of pre-dissolved HPMC.  The polymer-coated crystalline danazol 
was prepared in order to investigate the impact of polymer adsorption/coating of 
crystalline danazol on its ability to grow in a supersaturated danazol solution.  A few 
drops of the suspensions containing crystalline drug were placed on a glass cover slip and 








containing Drierite (97% anhydrous calcium sulfate and 3% cobalt (II) chloride) for 12 
hours.  Samples were then placed in a vacuum oven at room temperature for 12 hours to 
evaporate off any residual solvent.   
 
5.4.2 Polarized Light Microscopy   
Polarized light microscopy (PLM) was used to analyze the prepared ASD films to 
assess the extent of crystallization using the approach developed by Van Eerdenburgh et 
al,31, 32 and to characterize the amorphous or crystalline nature of any precipitates formed 
upon dissolution of the films.  The films were assessed by direct evaluation of the ASD 
films formed on the coverslips, while the dissolution media was analyzed by collecting a 
small aliquot of the solution at the desired time point and placing 2-3 drops of the sample 
solution onto a quartz slide containing a depression.  All samples were imaged using a 
Nikon Eclipse E600 Pol microscope with a 10X objective and the NIS-Elements software 
package (Version 2.3; Nikon Company, Tokyo, Japan).   
 
5.4.3 Flux Measurements   
A side-by-side diffusion cell (PermeGear, Inc. Hellertown, Pennsylvania) was 
used to determine the extent of supersaturation generated during ASD dissolution by 
determining danazol flux. Both the impact of crystal seeds present within the ASD matrix 
of an ASD as well as the effect of pure crystalline drug added separately during ASD 
dissolution were investigated.  A regenerated cellulose membrane with a MWCO of 6–8 
KDa was used to separate the donor and receiver chambers. Both the donor and receiver 








diameter of 30 mm.  A temperature of 25°C was maintained using a Julabo MA water 
bath connected to the jacketed vessels of the side-by-side diffusion cell.  Both 
compartments were filled with 200 mL of buffer and all samples were placed inside a 
Tissue-Tek biopsy cassette (Sakura Finetek USA, Inc., Torrance, California) with 1 mm 
pores to prevent fragments of the ASD from interfering with the UV dip probe (Figure 5-
1).  A fiber optic dip probe with a path length of 2 cm coupled to a UV/Vis 
spectrophotometer (SI Photonics Inc., Tucson, Arizona) was used on the receiver side, 
while a second dip probe with a path length of 1 cm was used on the donor side.  UV 
spectra were obtained every 30 s. for 240 min. for both sides.  Measurements were 
obtained at two wavelengths; the maximum UV absorbance wavelength of 288 nm for 
danazol and at a wavelength of 350 nm where danazol shows no absorption; scattering 
due to a new phase can be monitored at 350 nm.   
Concentration versus time profiles for the receiver compartment were generated 
to determine the flux of the drug from the donor compartment to the receiver 
compartment, as described in previous studies.8, 19, 33  Concentration versus time profiles 
for the donor compartment were also generated.  
 
5.4.4 Seeded Desupersaturation Experiments   
The desupersaturation profile of supersaturated danazol solutions following 
seeding was evaluated in order to evaluate bulk crystal growth rates in buffer and in the 
presence of pre-dissolved polymer. Samples consisted 50 mL of aqueous buffer, stirred at 
300 RPM and held at 25°C using a jacketed beaker fed by a Julabo MA water bath.  The 








(extinction of solution) were collected every 30 s. for 240 min.  Supersaturation was 
created using an anti-solvent method.  A small aliquot of danazol dissolved in methanol 
was added to buffer to create specific supersaturations, in order to study the relationship 
between supersaturation and crystal growth rates, using similar supersaturation values to 
those obtained during ASD dissolution.  The crystalline samples were again prepared on 
glass coverslips and placed inside biopsy cassettes to prevent large fragments from 
interfering with the UV dip probe.  Crystalline danazol was added one minute after 




5.5.1 Characterization of the ASDs and Crystalline Samples   
Polarized light microscopy revealed no crystalline material present in ASDs with a 90:10 
polymer:drug ratio.  However, small crystals were present in the 50:50 ASDs.  Figure 5-2 
shows representative polarized light microscope images.  The crystals present in the 
50:50 ASD samples are relatively small in size and cover approximately 10% of the 
surface area of the sample on the glass cover slip.  The crystalline samples and polymer-
coated crystalline samples showed uniform coverage on the coverslip. 
 
5.5.2 Dissolution Behavior of ASDs with Crystal Seeds Present   
The properties of the solutions generated by ASD dissolution, with respect to 








apparatus.  The dissolution profiles (non-sink dissolution conditions) of a variety of ASD 
samples are shown in Figure 5-3. 
 The 90:10 ASDs all showed a fast initial dissolution rate, however the maximum 
concentration reached varied depending if crystalline material was present. The 90:10 
ASD without crystalline material dissolved to reach the highest apparent concentration, 
which was just above the amorphous solubility of 8 μg/mL. Adding some of the partially 
crystallized 50:50 ASD resulted in a somewhat slower dissolution rate after about 45 min, 
but the maximum apparent solution concentration was similar to that obtained for the 
90:10 ASD.  In contrast, samples which contained native crystalline drug (both with and 
without a polymer coating) impacted the dissolution of the 90:10 ASD, resulting in a 
much lower plateau concentration, ~4-5 ug/mL, i.e. only approximately half of that 
reached for the other 90:10 samples. The partially crystallized 50:50 dispersion had a 
much slower dissolution rate and reached a maximum concentration of around 4 μg/mL 
at 240 min. 
 The free drug concentration at the plateau of the profiles observed in Figure 5-3 
was determined using flux measurements in order to determine the extent of 
supersaturation in the different solutions.  Previously it has been shown that the 
supersaturation of the solution in the donor compartment can be determined based on the 
flux across a membrane and knowledge of the crystalline solubility.8, 33  Figure 5-4 shows 
the maximum supersaturation obtained by dissolving each system and the relationship to 
the crystalline and amorphous solubilities of danazol. 
The extent of supersaturation achieved upon the dissolution of the 90:10 spiked with the 








the amorphous solubility.  These systems may have surpassed the amorphous solubility, 
as shown previously,8 and have reached the maximum free-drug solution and the overall 
supersaturation by undergoing liquid-liquid phase separation.  The remaining systems 
(90:10 ASD + crystalline danazol, 90:10 ASD + 50:50 physical mixture of HPMC and 
crystalline danazol, and 50:50 ASD) all has similar plateau supersaturation values (Si ~ 
5.5).  Control experiments with crystalline danazol led to a supersaturation value of 1.0 ± 
0.1 after 4 hours, as expected. 
 
5.5.3 Seeded Desupersaturation   
During the dissolution of ASDs, supersaturated solutions were generated and 
maintained for at least 4 hours even in presence of crystalline seeds of danazol.  Seeded 
and unseeded experiments were therefore carried out at two supersaturation levels (8 
µg/mL and 5 µg/mL), corresponding to the plateau levels obtained in the ASD 
experiments, with pre-dissolved HPMC (100 µg/mL) in the solution.  Figure 5-5 shows 
the apparent solution concentration over 4 hours with and without seeding. 
Supersaturated danazol solutions in absence of any polymer crystallized rapidly 
and the apparent solution concentration decreased to the crystalline solubility within 10-
20 minutes, both in the presence and absence of seeds (as shown in Chapter 2).  In the 
presence of pre-dissolved polymer, unseeded danazol solutions at either supersaturation 
show very little desupersaturation over a 4 hr period.  At the higher initial supersaturation 
(8 µg/mL), the addition of crystalline seeds results in an initial rapid desupersaturation 








supersaturation, addition of seeds results in very slow desupersaturation over the time 
frame of the experiment, and a minimal decrease in solution concentration.  
 
5.6 Discussion 
 The solution concentration-time profile, and hence the subsequent supersaturation, 
following dissolution of an ASD will depend on the interplay between the dissolution rate 
of the amorphous formulation and kinetics of crystallization.  Davey and Cardew 
investigated and modeled the solvent-mediated phase transformation of a metastable 
polymorph to the stable form and their approach can be used to better understand the 
behavior of the systems under evaluation in our study.34  They pointed out that the 
supersaturation-time profile of a metastable system undergoing transformation to a stable 
form is dependent on the solubility difference between the two forms, the dissolution rate 
of the metastable polymorph and the crystal growth rate of the stable polymorph.34  This 
approach results in a model whereby the supersaturation profile over time can be 
predicted based on these two rates. Following this same logic, for an amorphous solid 
dispersion, the maximum supersaturation will be dictated by the ratio of the amorphous 
and crystalline solubility values, while the supersaturation time profile will depend on the 
rate of dissolution of the amorphous solid dispersion, the lag time for nucleation of the 
crystalline phase and the growth rate of the crystals.    
 The dissolution rate of the metastable phase and growth rate of the stable phase 
will increase and decrease the supersaturation respectively.  Thus, it has been shown that 
a plateau supersaturation can be achieved for some duration of time while the dissolution 








ultimately decreasing towards the equilibrium concentration when the metastable form 
has dissolved completely.34  The supersaturation at which this plateau occurs will depend 
on the relationship between dissolution rate and crystal growth rate.  During ASD 
dissolution, if the crystal growth rate is much greater than the dissolution rate, the plateau 
supersaturation will be low.  This scenario would be expected to occur in an ASD system 
where crystals are present and the polymer is a poor inhibitor of crystal growth at the 
supersaturation generated by the dissolving amorphous form. Hence the advantage of 
using an amorphous formulation is lost because the crystal growth rate is too high.  
However, as the growth rate decreases (by adding an effective crystal growth inhibitor), 
then a higher supersaturation plateau can be achieved.  When the dissolution rate is much 
greater than the growth rate, the supersaturation can reach the maximum free-drug 
concentration which is dictated by the amorphous solubility, above which the system 
with spontaneously form a drug-rich phase via liquid-liquid phase separation (LLPS).14, 16  
This drug-rich phase will enable the supersaturation to be maintained at the maximum 
value since it will act as a reservoir to replace drug removed by crystallization.19  Given 
sufficient time, the solution concentration of all systems will decrease towards the 
equilibrium concentration. 
 The supersaturation profiles of the HPMC-danazol ASD systems studied herein 
were greatly influenced by the presence of crystalline seeds.  The dissolution of the 
different systems (Figure 5-3) resulted in different plateau supersaturation depending on 
the presence or absence of crystalline material, as well as how the crystalline material 
was generated.  In the absence of crystal seeds, the plateau supersaturation upon 








maximum free-drug concentration.  This system has a high dissolution rate and previous 
work has shown that the crystallization induction time is greater than 3 hours in the 
presence of HPMC.33  Hence only the dissolution rate dictates the time until the 
maximum supersatuation is achieved, while the maximum supersaturation observed is 
determined by the amorphous solubility.  When crystal seeds evolved from within the 
solid dispersion matrix (50:50 ASD) were added to the 90:10 ASD, the maximum 
supersaturation was again achieved, suggesting that the added crystals grew more slowly 
than the dissolution of the amorphous material.  In contrast, native danazol crystals 
appeared to grow faster, leading to a plateau supersaturation value approximately half 
that observed for the crystal free dispersion, although the system was still supersaturated 
with respect to the crystalline solubility. This system has reached a pseudo-equilibrium 
between the dissolution of the ASD and the growth of drug crystals.   
 By removing the dissolution step, and instantaneously generating a supersaturated 
solution, the ability of different types of crystalline material to induce desupersaturation 
can be evaluated. Interestingly, the crystals evolved from the ASD were much less 
effective at inducing desupersaturation at a supersaturation equivalent to the maximum 
achievable supersaturation relative to with native crystals or polymer-coated native 
crystals (Figure 5-4).  These experiments confirm the importance of the growth rate in 
determining the overall supersaturation profile. Furthermore, the driving force for crystal 
growth also needs to be considered since clearly at a lower supersaturation, all types of 
crystal seeds were relatively ineffective at inducing desupersaturation – in other words, in 
the presence of a pre-dissolved polymer, crystal growth was effectively inhibited over the 








supersaturation can persist in the presence of crystalline seeds, albeit at a lower level than 
the amorphous solubility. The observation that polymers are more effective crystal 
growth inhibitors has been noted previously.11, 15 The growth rate data correlate very well 
with the ASD dissolution data and help to explain the levels of supersaturation observed 
in the seeded dissolution studies.  
Figure 5-6 shows desupersaturation profiles in the presence of crystalline seeds 
with and without the presence of polymer.  The addition of polymer dramatically 
decrease the crystal growth rate while the system without polymer has a fast growth rate 
and the solution rapidly reaches the equilibrium solubility.  The dissolution of ASDs 
above in the presence and absence of crystalline seeds is similar to the supersaturation 
profile shown here.  The ability to maintain supersaturation is thus reliant on ability of the 
polymer to inhibit crystal growth.  Furthermore, when trying to evaluate the impact of 
residual crystallinity on the performance of an ASD, it may be important to produce the 
crystalline material in the presence of the polymer, since the ASD evolved crystals may 
have a different impact of crystallization relative to native crystals.  
 
5.7 Conclusions 
 The ability to produce sustained supersaturation following ASD dissolution is 
dependent on the interplay between dissolution and crystallization kinetics. Adding 
crystal seeds to the ASD and monitoring the dissolution profile enables the effectiveness 
of a given polymer at inhibiting crystal growth at relevant supersaturations to be 
evaluated. Surprisingly, the crystal seed history influences the concentration-time profiles 








to test the impact of residual crystallinity. In order to successfully formulate ASDs to 
yield maximum supersaturation, the interplay between dissolution rate and crystallization 











Figure 5-1. Schematic of diffusion cell apparatus setup.  The donor cell and receiver cell 
both hold a maximum of 200 mL. 
 
 
Figure 5-2. Polarized light microscopy images of danazol systems prepared on glass 
coverslips; 50:50 HPMC-danazol ASD (left), pure crystalline danazol (center), and 









Figure 5-3. Dissolution Profiles of HPMC-danazol ASDs.  There were five drug systems 
investigated; 90:10 ASDs (black squares), 50:50 ASDs (blue triangles), 90:10 ASDs + 
50:50 ASDs (red circles), 90:10 ASDs + crystalline danazol (purple triangles), and 90:10 
ASDs + polymer-coated crystalline danazol (green diamonds). 
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Figure 5-4. Maximum observed supersaturation of solutions following dissolution of 
different ASDs systems containing some crystalline drug.  The crystalline solubility of 
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Figure 5-5.  Apparent UV concentrations of supersaturated danazol solutions in the 
presence and absence of crystal seeds.  All solutions above have pre-dissolved HPMC 
polymer (100 µg/mL HPMC). 
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Figure 5-6.  Desupersaturation profiles of supersaturated danazol solutions in the 
presence and absence of polymer and crystal seeds.  The polymer concentration was 100 
µg/mL for systems indicated to include polymer. 
  




































1) Dahan, A.; Hoffman, A., Rationalizing the selection of oral lipid based drug 
delivery systems by an in vitro dynamic lipolysis model for improved oral 
bioavailability of poorly water soluble drugs. Journal of controlled release : 
official journal of the Controlled Release Society 2008, 129 (1), 1-10. 
2) Miller, J. M.; Beig, A.; Carr, R. A.; Spence, J. K.; Dahan, A., A win-win solution 
in oral delivery of lipophilic drugs: supersaturation via amorphous solid 
dispersions increases apparent solubility without sacrifice of intestinal membrane 
permeability. Molecular pharmaceutics 2012, 9 (7), 2009-16. 
3) Murdande, S. B.; Pikal, M. J.; Shanker, R. M.; Bogner, R. H., Solubility 
advantage of amorphous pharmaceuticals: II. Application of quantitative 
thermodynamic relationships for prediction of solubility enhancement in 
structurally diverse insoluble pharmaceuticals. Pharmaceutical research 2010, 27 
(12), 2704-14. 
4) Murdande, S. B.; Pikal, M. J.; Shanker, R. M.; Bogner, R. H., Solubility 
advantage of amorphous pharmaceuticals, part 3: Is maximum solubility 
advantage experimentally attainable and sustainable? Journal of pharmaceutical 
sciences 2011. 
5) Hancock, B. C.; Parks, M., What is the True Solubility Advantage for Amorphous 








6) Zografi, G.; Hancock, B. C., Characteristics and Significance of the Amorphous 
State in Pharmaceutical Systems. Journal of pharmaceutical sciences 1997, 86 
(1), 1-12. 
7) Marsac, P. J.; Konno, H.; Taylor, L. S., A comparison of the physical stability of 
amorphous felodipine and nifedipine systems. Pharmaceutical research 2006, 23 
(10), 2306-16. 
8) Jackson, M. J.; Taylor, L. S., Dissolution and Phase Behavior of Danazol 
Amorphous Solid Dispersions. In Preparation for Submission 2015. 
9) Alonzo, D. E.; Gao, Y.; Zhou, D.; Mo, H.; Zhang, G. G.; Taylor, L. S., 
Dissolution and precipitation behavior of amorphous solid dispersions. Journal of 
pharmaceutical sciences 2011, 100 (8), 3316-31. 
10) Alonzo, D. E.; Zhang, G. G.; Zhou, D.; Gao, Y.; Taylor, L. S., Understanding the 
behavior of amorphous pharmaceutical systems during dissolution. 
Pharmaceutical research 2010, 27 (4), 608-18. 
11) Ilevbare, G. A.; Liu, H.; Edgar, K. J.; Taylor, L. S., Maintaining Supersaturation 
in Aqueous Drug Solutions: Impact of Different Polymers on Induction Times. 
Crystal Growth & Design 2013, 13 (2), 740-751. 
12) Hsieh, Y. L.; Box, K.; Taylor, L. S., Assessing the impact of polymers on the pH-
induced precipitation behavior of poorly water soluble compounds using 
synchrotron wide angle X-ray scattering. Journal of pharmaceutical sciences 









13) Konno, H.; Handa, T.; Alonzo, D. E.; Taylor, L. S., Effect of polymer type on the 
dissolution profile of amorphous solid dispersions containing felodipine. 
European journal of pharmaceutics and biopharmaceutics : official journal of 
Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 2008, 70 (2), 
493-9. 
14) Jackson, M. J.; Toth, S. J.; Kestur, U. S.; Huang, J.; Qian, F.; Hussain, M. A.; 
Simpson, G. J.; Taylor, L. S., Impact of polymers on the precipitation behavior of 
highly supersaturated aqueous danazol solutions. Molecular pharmaceutics 2014, 
11 (9), 3027-38. 
15) Ilevbare, G. A.; Liu, H.; Pereira, J.; Edgar, K. J.; Taylor, L. S., Influence of 
additives on the properties of nanodroplets formed in highly supersaturated 
aqueous solutions of ritonavir. Molecular pharmaceutics 2013, 10 (9), 3392-403. 
16) Ilevbare, G. A.; Taylor, L. S., Liquid–Liquid Phase Separation in Highly 
Supersaturated Aqueous Solutions of Poorly Water-Soluble Drugs: Implications 
for Solubility Enhancing Formulations. Crystal Growth & Design 2013, 13 (4), 
1497-1509. 
17) Raina, S. A.; Alonzo, D. E.; Zhang, G. G.; Gao, Y.; Taylor, L. S., Using 
Environment-Sensitive Fluorescent Probes to Characterize Liquid-Liquid Phase 
Separation in Supersaturated Solutions of Poorly Water Soluble Compounds. 










18) Raina, S. A.; Eerdenbrugh, B. V.; Alonzo, D. E.; Mo, H.; Zhang, G. G.; Gao, Y.; 
Taylor, L. S., Trends in the precipitation and crystallization behavior of 
supersaturated aqueous solutions of poorly water-soluble drugs assessed using 
synchrotron radiation. Journal of pharmaceutical sciences 2015, 104 (6), 1981-
92. 
19) Raina, S. A.; Zhang, G. G.; Alonzo, D. E.; Wu, J.; Zhu, D.; Catron, N. D.; Gao, 
Y.; Taylor, L. S., Enhancements and limits in drug membrane transport using 
supersaturated solutions of poorly water soluble drugs. Journal of pharmaceutical 
sciences 2014, 103 (9), 2736-48. 
20) Derdour, L., A method to crystallize substances that oil out. Chemical 
Engineering Research and Design 2010, 88 (9), 1174-1181. 
21) Warren, D. B.; Benameur, H.; Porter, C. J.; Pouton, C. W., Using polymeric 
precipitation inhibitors to improve the absorption of poorly water-soluble drugs: 
A mechanistic basis for utility. Journal of Drug Targeting 2010, 18 (10), 704-731. 
22) Feng, B. Y.; Shelat, A.; Doman, T. N.; Guy, R. K.; Shoichet, B. K., High-
throughput assays for promiscuous inhibitors. Nature chemical biology 2005, 1 
(3), 146-8. 
23) McGovern, S. L.; Helfand, B. T.; Feng, B.; Shoichet, B. K., A Specific 
Mechanism of Nonspecific Inhibition. Journal of Medicinal Chemistry 2003, 46, 
4265-4272. 
24) Chen, J.; Ormes, J. D.; Higgins, J. D.; Taylor, L. S., Impact of surfactants on the 
crystallization of aqueous suspensions of celecoxib amorphous solid dispersion 








25) Hsieh, Y. L.; Ilevbare, G. A.; Van Eerdenbrugh, B.; Box, K. J.; Sanchez-Felix, M. 
V.; Taylor, L. S., pH-Induced precipitation behavior of weakly basic compounds: 
determination of extent and duration of supersaturation using potentiometric 
titration and correlation to solid state properties. Pharmaceutical research 2012, 
29 (10), 2738-53. 
26) Raina, S. A. Phase Behavior of Supersaturated Solutions of Poorly Soluble Small 
Molecules. Purdue University, 2014. 
27) Raina, S. A.; Zhang, G. G.; Alonzo, D. E.; Wu, J.; Zhu, D.; Catron, N. D.; Gao, 
Y.; Taylor, L. S., Impact of Solubilizing Additives on Supersaturation and 
Membrane Transport of Drugs. Pharmaceutical research 2015. 
28) Kestur, U. S.; Wanapun, D.; Toth, S. J.; Wegiel, L. A.; Simpson, G. J.; Taylor, L. 
S., Nonlinear optical imaging for sensitive detection of crystals in bulk 
amorphous powders. Journal of pharmaceutical sciences 2012, 101 (11), 4201-
13. 
29) Wegiel, L. A.; Mauer, L. J.; Edgar, K. J.; Taylor, L. S., Crystallization of 
amorphous solid dispersions of resveratrol during preparation and storage-Impact 
of different polymers. Journal of pharmaceutical sciences 2013, 102 (1), 171-84. 
30) Alonzo, D. E.; Raina, S.; Zhou, D.; Gao, Y.; Zhang, G. G. Z.; Taylor, L. S., 
Characterizing the Impact of Hydroxypropylmethyl Cellulose on the Growth and 
Nucleation Kinetics of Felodipine from Supersaturated Solutions. Crystal Growth 









31) Van Eerdenbrugh, B.; Lo, M.; Kjoller, K.; Marcott, C.; Taylor, L. S., Nanoscale 
mid-infrared evaluation of the miscibility behavior of blends of dextran or 
maltodextrin with poly(vinylpyrrolidone). Molecular pharmaceutics 2012, 9 (5), 
1459-69. 
32) Van Eerdenbrugh, B.; Lo, M.; Kjoller, K.; Marcott, C.; Taylor, L. S., Nanoscale 
mid-infrared imaging of phase separation in a drug-polymer blend. Journal of 
pharmaceutical sciences 2012, 101 (6), 2066-73. 
33) Jackson, M. J.; Taylor, L. S., Characterization of Highly Supersaturated Danazol 
Solutions – Impact of Polymers on Membrane Transport and Phase Transitions. 
Submitted for Publication 2015. 
34) Cardew, P. T.; Davey, R. J., The Kinetics of Solvent-Mediated Phase 
Transformations. Proceedings of the Royal Society of London. Series A, 








CHAPTER 6. SUMMARY OF RESEARCH AND FUTURE WORK 
RECOMMENDATIONS 
The focus of this thesis was to investigate phase behavior in the supersaturated 
solutions formed during the dissolution of amorphous solid dispersions, specifically for a 
poorly water soluble model drug, danazol.  The following is a chapter by chapter 
summary of the important results observed followed by recommendations for future 
studies. 
 
6.1 Influence of Polymers on the Supersaturation Behavior of Danazol 
In chapter 2, the phase behavior of supersaturated danazol solutions was 
investigated in the presence and absence of polymers.  Upon surpassing a threshold 
concentration (amorphous solubility), these systems undergo liquid-liquid phase 
separation (LLPS), creating a disordered drug-rich droplet phase and a drug-lean aqueous 
phase.  LLPS was observed prior to crystallization in supersaturated danazol solutions by 
using multiple analytical techniques; UV spectroscopy, the use of a fluorescence probe, 
and second harmonic generation.  The addition of polymers (PVP, HPMC, and HPMC-
AS) inhibited crystallization and prolonged the presence of LLPS in systems above the 
amorphous solubility, to varying degrees.  This study serves as a fundamental basis of the 
thermodynamic properties of danazol in an aqueous solution.  Additionally, the 








differentiate between LLPS and crystallization, was vital to studying the complex 
phase behavior within supersaturated drug solutions in later studies.   
 
6.2 Characterization of the Drug-Rich Droplet Phase formed via Liquid-Liquid Phase 
Separation 
The drug-rich droplets formed during LLPS, and the effect of polymers on the 
solution properties, were investigated and characterized in chapter 3.  The onset 
concertation of LLPS was found to correlate with the estimated amorphous solubility and 
the mean droplet size was found to be in range of 200-250 nm.  The addition of polymers 
did not influence the onset concentration of LLPS but it was shown to have an effect on 
the kinetics of both crystallization and LLPS.  The polymers provided crystallization 
inhibition within the solution, allowing for prolonged stability of the two-phase colloidal 
system prior to crystallization.  The ability to evaluate the colloidal solutions formed 
upon supersaturation is pivotal to be able to study the behavior of solutions generated 
from solubility enhancing formulations, such as amorphous solid dispersions.  
 
6.3 Dissolution Behavior of Danazol Amorphous Solid Dispersions 
In Chapter 4, the application of methods and techniques developed in chapters 2 
and 3 for the characterization of the dissolution of amorphous solid dispersions (ASDs) 
of danazol and three polymers (PVP, HPMC, HPMC-AS) is described.  The non-sink 
dissolution behavior was also evaluated using a side-by-side diffusion cell to determine 
the free-drug solution concentration and overall effect of LLPS on passive membrane 








During dissolution, the ASDs studied in this chapter undergo LLPS upon 
surpassing the amorphous solubility of danazol.  The two-phase system persists for 
prolonged periods of time before ultimately crystal nucleation and growth occurred, 
depleting the supersaturation.  These results are significant because it reveals that there is 
an upper limit for the miscibility of a drug in solution, regardless of how the 
supersaturation is generated (anti-solvent or ASD dissolution).  This miscibility is crucial 
for understanding the mechanics behind ASD formulations and the overall upper-limit of 
supersaturation for a given drug molecule.  The addition of a polymer which can inhibit 
the kinetics of crystallization without influencing the thermodynamics (solubility) of the 
drug allows for stabilization of the drug-rich droplet phase, which behaves as a reservoir 
for maintaining the supersaturation of the aqueous phase. 
 
6.4 Influence of Crystal Seeds on Supersaturation via Dissolution of Amorphous Solid 
Dispersions 
In chapter 4, the dissolution of ASDs resulted in supersaturated solutions that 
undergo LLPS.  This result was significant in itself, however, some of the ASD systems 
which generated supersaturated solutions showed the presence of crystal nuclei formed 
during the preparation.  The purpose of chapter 5 was to investigate the presence of 
crystal seeds during the dissolution of danazol ASDs and the impact they have on 
supersaturation.  Side-by-side diffusion experiments and desupersaturation experiments 
were executed to determine the relationship between the dissolution rate, delay in crystal 








The dissolution of ASDs in the presence of crystals still yielded supersaturated 
solutions, albeit at different levels.  Dissolution of systems with no crystals or with 
crystals formed within the matrix of the solid dispersion created supersaturated solutions 
equal to the maximum solution concentration (amorphous solubility) as seen in chapters 
2-4.  However, the introduction of crystalline material (both native and polymer-coated) 
resulted in lower solution concentrations, although solutions were still supersaturated.  It 
is suggested that the ability of the polymer to decrease the crystal growth rate along with 
a high dissolution rate of the ASD results in a pseudo-equilibrium between the 
dissolution of the ASD and growth of crystalline drug; creating a supersaturation plateau 
of possibly several hours before crystal growth dominates and the concentration drops 
towards the crystalline equilibrium.  The significance of creating prolonged 
supersaturated solutions in the presence of crystalline drug cannot be overstated.  It is 
hypothesized that the ability to formulate and control drug supersaturation could depend 
on the interplay between polymer selection, dissolution rate, and the presence of 
crystalline material in the dispersion. 
 
6.5 Future Work Recommendations 
The observations surrounding the phase behavior of ASDs upon dissolution creates 
some intriguing ideas to formulate future studies around.  The following is a brief list of 
avenues for which more investigation is suggested pertaining to these systems. 
 The influence of polymers plays a key role in influencing the kinetics of these 
systems.  Understanding drug-polymer interactions within the solution is crucial 








polymers influence these systems during dissolution.  Additionally, only a few 
polymers were studied within the scope of this thesis research and the ability to 
screen many polymers is vital because currently there are very few models to 
predict drug-polymer interactions both in the solid-state and in solution. 
 Danazol was chosen as a model drug to study because it is poorly soluble in water 
and previously had some interesting precipitation results.  The methods developed 
within the scope of this thesis can and should be applied to multiple drug systems.  
Studying similar drugs to danazol, such as other steroid derivatives like estradiol 
and mevastatin, would produce interesting insight into the role chemical 
properties have on the thermodynamics of ASD formulations.   
 In chapter 2, second harmonic generation (SHG) was used to qualitatively 
determine the crystallinity in solution of supersaturated danazol systems.  This 
tool is unique in its ability to detect only crystalline material in complex samples.  
Analyzing the solution behavior during dissolution of ASDs with SHG would 
enable the creation of crystal growth profiles in solution.  Furthermore, proof-of-
concept experiments have shown promise in detecting crystalline material in 
turbid media, something which cannot be done accurately with current techniques 
(UV spectroscopy, dynamic light scattering, etc.).  Thus, a natural progression 
would be to study similar drug-polymer systems using SHG in biorelevant media 
which cannot be studied using current spectroscopy methods. The ability to 
determine if crystalline material is present or not in turbid media, such as FaSSIF, 
FeSSIF, or Ensure Plus (a dissolution media for a fed meal), would be pivotal in 








 Lastly, LLPS formed in highly supersaturated drug solutions influences the 
amount of free-drug available for uptake.  The drug-rich droplet phase formed 
during LLPS was investigated in chapter 3, but further work is necessary to fully 
understand the consequences of such a phase transformation in solution.  
Additionally, the impact LLPS can have on passive membrane transport was 
explored in chapters 3 and 4, but it would be interesting to investigate the impact 
of LLPS on transport across complex membranes, as it would provide valuable 
information which would more closely mimic a situation occurring during 
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